MDSAP Audit Approach
MDSAP Audit Approach
MDSAP Audit Approach
MDSAP AU
Policy Title: MDSAP AUDIT
P0002.007
APPROACH
Revision Date:
2022-04-15
AUDIT APPROACH
Table of Contents
FOREWORD 5
OVERVIEW 6
TASK 1 – SUBMISSION FOR DEVICE MARKETING AUTHORIZATION AND FACILITY REGISTRATION ............................................................... 39
TASK 2 – EVIDENCE OF MARKETING CLEARANCE OR APPROVAL ......................................................................................................... 45
TASK 3 – NOTIFICATION OF CHANGES TO MARKETED DEVICES OR TO THE QMS ................................................................................... 47
TASK 1 – PROCEDURES FOR MEASUREMENT, ANALYSIS, AND IMPROVEMENT OF QMS EFFECTIVENESS AND PRODUCT CONFORMITY............. 55
TASK 2 – SOURCES OF QUALITY DATA ........................................................................................................................................... 57
TASK 3 – INVESTIGATION OF NONCONFORMITY.............................................................................................................................. 59
TASK 4 – INVESTIGATION OF POTENTIAL NONCONFORMITY .............................................................................................................. 61
TASK 5 – CORRECTION, CORRECTIVE ACTION, AND PREVENTIVE ACTION ............................................................................................. 62
TASK 6 – ASSESSMENT OF DESIGN CHANGE RESULTING FROM CORRECTIVE OR PREVENTIVE ACTION ........................................................ 63
TASK 7 – ASSESSMENT OF PROCESS CHANGE RESULTING FROM CORRECTIVE OR PREVENTIVE ACTION....................................................... 64
TASK 8 – IDENTIFICATION AND CONTROL OF NONCONFORMING PRODUCT .......................................................................................... 66
TASK 9 – ACTION REGARDING NONCONFORMING PRODUCT DETECTED AFTER DELIVERY ....................................................................... 67
TASK 10 – INTERNAL AUDIT ....................................................................................................................................................... 68
TASK 11 – INFORMATION SUPPLIED FOR MANAGEMENT REVIEW ...................................................................................................... 70
TASK 12 – EVALUATION OF INFORMATION FROM POST-PRODUCTION PHASE, INCLUDING COMPLAINTS.................................................... 71
TASK 13 – COMMUNICATIONS WITH EXTERNAL PARTIES INVOLVED ON COMPLAINTS ............................................................................ 76
TASK 14 – EVALUATION OF COMPLAINTS FOR ADVERSE EVENT REPORTING ......................................................................................... 77
TASK 15 – EVALUATION OF QUALITY PROBLEMS FOR ADVISORY NOTICES ........................................................................................... 78
TASK 16 – TOP MANAGEMENT COMMITMENT TO MEASUREMENT, ANALYSIS, AND IMPROVEMENT PROCESS ............................................ 80
CHAPTER 4 - MEDICAL DEVICE ADVERSE EVENTS AND ADVISORY NOTICES REPORTING .................................................. 81
TASK 1 – NOTIFICATION OF ADVERSE EVENTS ................................................................................................................................ 81
MDSAP AU P0002.007 2|Page
Table of Contents
TASK 2 – NOTIFICATION OF ADVISORY NOTICES .............................................................................................................................. 89
TASK 1 – IDENTIFICATION OF DEVICES SUBJECT TO DESIGN AND DEVELOPMENT PROCEDURES; TECHNICAL DOCUMENTATION .......................... 95
TASK 2 – SELECTION OF A COMPLETED DESIGN AND DEVELOPMENT PROJECT ....................................................................................... 97
TASK 3 – DESIGN AND DEVELOPMENT PLANNING ............................................................................................................................ 98
TASK 4 – IMPLEMENTATION OF THE DESIGN AND DEVELOPMENT PROCESS ........................................................................................... 99
TASK 5 – DESIGN AND DEVELOPMENT INPUT ...............................................................................................................................101
TASK 6 – COMPLETENESS, COHERENCE, AND UNAMBIGUITY OF DESIGN AND DEVELOPMENT INPUT .........................................................103
TASK 7 – DESIGN AND DEVELOPMENT OUTPUT AND DESIGN VERIFICATION .........................................................................................104
TASK 8 – RISK MANAGEMENT ACTIVITIES APPLIED THROUGHOUT THE DESIGN AND DEVELOPMENT PROJECT .............................................107
TASK 9 – DESIGN VERIFICATION OR DESIGN VALIDATION TO CONFIRM EFFECTIVENESS OF RISK CONTROL MEASURES ...................................109
TASK 10 – DESIGN VALIDATION.................................................................................................................................................110
TASK 11 – CLINICAL EVALUATION AND/OR EVALUATION OF MEDICAL DEVICE SAFETY AND PERFORMANCE ................................................111
TASK 12 – SOFTWARE DESIGN AND DEVELOPMENT .......................................................................................................................112
TASK 13 – DESIGN AND DEVELOPMENT CHANGE ..........................................................................................................................114
TASK 14 – DESIGN REVIEW ......................................................................................................................................................116
TASK 15 – IMPACT REVIEW OF DESIGN AND DEVELOPMENT CHANGES ON PREVIOUSLY MADE AND DISTRIBUTED DEVICES .............................118
TASK 16 – DESIGN TRANSFER ...................................................................................................................................................118
TASK 17 – TOP MANAGEMENT COMMITMENT TO DESIGN AND DEVELOPMENT PROCESS .......................................................................120
TASK 1 – PLANNING ACTIVITIES REGARDING PURCHASED PRODUCTS AND OUTSOURCED PROCESSES ........................................................162
TASK 2 – SELECTION OF SUPPLIER FILE TO AUDIT ...........................................................................................................................163
TASK 3 – PROCEDURE FOR THE CONTROL OF PURCHASED PRODUCTS AND OUTSOURCED PROCESSES........................................................164
TASK 4 – EXTENT OF CONTROLS APPLIED TO THE SUPPLIER AND THE PURCHASED PRODUCT; CRITERIA FOR SELECTION, EVALUATION, AND RE-
EVALUATION OF THE SUPPLIER ................................................................................................................................................... 165
TASK 5 – SELECTION OF SUPPLIER BASED ON ABILITY OF THE SUPPLIER TO SATISFY THE SPECIFIED PURCHASE REQUIREMENTS ........................166
TASK 6 – RECORDS OF SUPPLIER EVALUATION ..............................................................................................................................169
TASK 7 – EFFECTIVE CONTROLS OVER SUPPLIER AND PRODUCTS .......................................................................................................171
TASK 8 – VERIFICATION OF THE ADEQUACY OF PURCHASING INFORMATION, SPECIFIED PURCHASE REQUIREMENTS, AND WRITTEN AGREEMENT TO
NOTIFY CHANGES, BEFORE THEIR COMMUNICATION TO THE SUPPLIER ................................................................................................ 172
TASK 9 – DOCUMENTED PURCHASING INFORMATION AND SPECIFIED PURCHASE REQUIREMENTS ............................................................173
TASK 10 – VERIFICATION OF PURCHASED PRODUCTS .....................................................................................................................175
TASK 11 – PURCHASING CONTROL ACTIVITIES AS SOURCE OF QUALITY DATA FOR THE MEASUREMENT, ANALYSIS, AND IMPROVEMENT PROCESS
...........................................................................................................................................................................................177
TASK 12 – TOP MANAGEMENT COMMITMENT TO THE PURCHASING PROCESS .....................................................................................178
ANNEX 1 – AUDIT OF PRODUCT/PROCESS RELATED TECHNOLOGIES AND TECHNICAL DOCUMENTATION ..................... 179
ANNEX 3 - MEDICAL DEVICE ADVERSE EVENTS AND ADVISORY NOTICES REPORTING PROCESS QUICK REFERENCE ...... 192
Foreword
The intention of the Medical Device Single Audit Program (MDSAP) is to allow competent auditors
from MDSAP recognized Auditing Organizations (AOs) to conduct a single audit of a medical device
organization’s quality management system that will satisfy the requirements of the medical device
Regulatory Authorities (RAs) participating in the MDSAP program.
Audits performed under the MDSAP program will be process-based, focusing on several defined
processes, a defined method for linking those processes, and built on a foundation of requirements for
risk management.
This document contains specific instructions for performing audits under the MDSAP program. It
incorporates an audit sequence, instructions for auditing each specific process and identifies links that
highlight the interactions between the processes.
red
A box emphasizes the interrelationships of specific processes and the relevant risk
management activities; if viewing a color version of the document or are in gray boxes if viewing the
black and white version. “Blue” font emphasizes the integration of risk management.
This revision of the document combines the formerly separate MDSAP Audit Model and Process
Companion documents into a single document containing additional detail regarding each audited
process; as well as guidance for assessing the conformity of each process. In electronic form, the
navigation bar facilitates quick access to relevant Tasks. The user may create their own bookmarks to
quickly navigate to various sections.
Overview
The design of the Medical Device Single Audit Program (MDSAP) audit process is to ensure a single
audit will provide efficient yet thorough coverage of regulatory requirements. These requirements
include; Medical devices – Quality management systems – Requirements for regulatory purposes (ISO
13485:2016), the Quality Management System requirements of the Conformity Assessment Procedures
of the Australian Therapeutic Goods (Medical Devices) Regulations (TG(MD)R Sch3), the Brazilian Good
Manufacturing Practices (RDC ANVISA 665/2022), the Canadian Medical Devices Regulations, the
Japanese Ordinance on Standards for Manufacturing Control and Quality Control of Medical Devices
and In Vitro Diagnostic Reagents (MHLW Ministerial Ordinance No. 169), the Quality System
Regulation (21 CFR Part 820), and specific requirements of the medical device regulatory authorities
participating in the MDSAP program.
Audit Sequence
The design and development of the MDSAP audit sequence allows a logical, focused and efficient
conduct of an audit. The MDSAP audit sequence follows a process approach and has four primary
processes - Management process, Measurement, Analysis and Improvement process, Design and
Development process and a Production and Service Controls process with links to the supporting
process for Purchasing.
The definition of each process includes a purpose and an outcome that are indicators of process
performance. Each participating Regulatory Authority expects that risk management to be the
foundation for the five processes that are the requirements of a quality management system for
medical device organizations.
The MDSAP audit process has two additional supporting processes: Device Marketing Authorization
and Facility Registration and Medical Device Adverse Events and Advisory Notices Reporting. These
processes are necessary to fulfill specific requirements of the participating MDSAP regulatory
authorities.
The flowchart shown in Figure 1 illustrates the MDSAP audit sequence and interrelationships. The
design of the MDSAP audit approach requires the audit of the primary MDSAP processes in the
following sequence: (1) Management (2) Measurement, Analysis and Improvement (3) Design and
Development, and (4) Production and Service Controls processes. The audit of the Purchasing process
is in conjunction with the Measurement, Analysis and Improvement process, the Design and
Development process, and the Production and Service Controls process.
The design and implementation of a medical device organization’s quality management system is a
strategic decision of the medical device organization. Through this system, it can meet the
requirements of the participating regulatory jurisdictions in a way that is appropriate for the size of the
medical device organization, the processes employed and the products supplied. The medical device
organization’s quality management system does not need to implement certain processes (e.g. Design
and Development) if regulation permits the exclusion or non-application of the process. Auditing
Organizations are not required to audit such processes. However, if the medical device organization
chooses to outsource any processes related to the design and/or manufacture of medical devices for
which the medical device organization has responsibility, these processes remain the responsibility of
the medical device organization. The medical device organization’s quality management system must
implement controls for monitoring and maintaining the quality of product from suppliers and
outsourced processes.
The participating MDSAP jurisdictions intended to promote a single program of audits that takes into
account all of their requirements for quality management systems. Hence, including the regulatory
requirements of all MDSAP participating jurisdictions is a default requirement for a medical device
organization’s participation in the program. Marketing Authorization holders may have previously
used an alternative source of evidence to demonstrate compliance with the regulatory requirements of
a jurisdiction. The supply of a product into the jurisdiction of a participating MDSAP Regulatory
Authority requires the auditor to include the relevant regulatory requirements in the scope of an audit.
However, in addition to the exclusions and non-applications permitted by ISO13485, the medical
device organization may exclude the requirements of markets where the medical device organization
does not intend to supply product. The audit scope and audit criteria must take into account any
justified exclusions or non- applications. When a medical device organization claims an exclusion from
the requirements of a target market, the auditor should use caution when applying the guidance
provided in the MDSAP processes. Some requirements may not be applicable.
Medical devices regulated for use in pre-market clinical studies under special access programs,
humanitarian use exemptions, and investigational device programs are outside of the scope of a
typical MDSAP audit. The manufacture and distribution of a device supplied under a special access-
type program may be subject to parts of the regulatory requirements included in the MDSAP. Auditing
organizations are encouraged to contact the pertinent MDSAP-participating Regulatory Authority for
any questions or clarifications.
Audit Approach
Risk Management
Processes
Figure 1
Device Marketing
Management Authorization and
Facility Registration
Device Marketing
Design and
Authorization and
Development Facility Registration
Production and
Service Provision
Purchasing
Note: Whist there is a prescribed audit sequence for the MDSAP processes, auditors may audit tasks
within a given process in any sequence to allow for an efficient and effective audit.
The audit sequence should be followed as designed, however under certain circumstances, including
the number and qualification of the auditors assigned to an audit, the inequal amount of information
associated with specific client processes and the type of activity being conducted, the rigorous
application of the audit sequence might prevent the efficient use of audit time and create problems
with audit planning. In these cases, judicious exceptions to the audit sequence are allowed as long as
there is sufficient justification and the core elements of the MDSAP Audit Approach, including linkages
between processes are defined and risk-based sample selections, are respected.
• Auditing Measurement, Analysis and Improvement and Management at the same time to
better allocate audit time for a multi-auditor activity.
• Starting the audit of a follow-on MDSAP process, such as Production or Design, when enough
information had been gathered by the review of core elements in Measurement, Analysis and
Improvement and Management and supporting processes, Device Marketing Authorization
and Facility Registration and Medical Device Adverse Events and Advisory Notices Reporting,
but prior to the full completion of these processes.
• Allowing an expert, such an expert in specific sterilization techniques, to commence the review
of these specific client processes and areas.
In all cases of these adjustments, proper attention should be paid to intra-audit communication so
that these decisions are re-evaluated as necessary as additional information is gathered throughout
the audit, and appropriate actions taken if this information alters the viability of these changes.
Audit specific adjustments to the MDSAP audit sequence should be documented in the audit report
along with appropriate justification.
An audit of the medical device organization’s quality management system processes is to assess the
extent to which the medical device organization is applying risk management principles when defining
its activities. Implementing the risk-based approach to controls is an integral aspect of a medical
device organization’s quality management system and it is the responsibility of top management to
provide the necessary commitment and resources for this effort. Effective implementation of the risk-
based approach usually starts in conjunction with the design and development process, proceeds
through product realization, including the selection of suppliers, considers feedback from post-market
monitoring and continues until the time the product is decommissioned. Risk-based decisions occur
throughout the various quality management system processes, and each medical device organization
must implement the risk-based approach as well as risk management in product realization with a
determination of how much residual risk is acceptable to ensure medical devices meet requirements
for safety and performance and regulatory requirements.
Many audit tasks require verification of the availability and control of MDSAP regulator specific
documentation and records. These tasks have a Clause and Regulation reference to ISO 13485:2016
clause 4.2.1, as the quality management system documentation is to include documentation specified
by applicable regulatory requirements (regulations, administrative practices and policies) [4.2.1(e)].
Where a regulatory requirement relates to the documentation required by other, more specific, clauses
of ISO 13485:2016 the auditing organization is to reference the more specific clause when recording
findings of nonconformity (refer to MDSAP AU P0037 - Guidelines on the use of
GHTF/SG3/N19:2012 for MDSAP purposes). To be consistent with ISO 13485:2016 the audit team is
MDSAP AU P0002.007 10 | P a g e
Overview
also reminded to apply the concept that “when a requirement is required to be documented, it is also
required to be established, implemented and maintained.” 1
The medical device organization needs to demonstrate its ability to provide medical devices that
consistently meet customer and regulatory requirements. During the audit, it is important that the
auditors are mindful of any instances where the medical device organization demonstrates failure to
fulfill any of the requirements in ISO 13485:2016, or portion of the requirements listed in the audit
activities and tasks, and that these nonconformities are recorded in appropriate detail. Particular
attention should be paid to the potential interrelationship of the nonconformities observed. For
example, audit findings in both purchasing controls and acceptance activities may indicate a significant
nonconformity because control over suppliers, and the products they supply, depends on an effective
mix of both these activities, and deficiencies in one or the other may affect the quality of the finished
device.
Whenever a MDSAP Audit Task requires an auditor to verify the identification and documentation of a
requirement in QMS documentation, this verification should be performed as part of the pre-audit
preparation and documentation review, as practical, to minimize on-site audit time and to increase the
auditor’s familiarity with the medical device organization’s QMS.
Terminology
The term “device” is used throughout the MDSAP processes. For the purpose of applying the MDSAP
processes, and to accommodate nuances in the regulatory systems of the participating Regulatory
Authorities, the use of the term “device” is to refer to any product that is capable of functioning as a
medical device, whether or not it is packaged, labeled, or sterilized. In some jurisdictions, such a
product is defined as a “finished device”. In other jurisdictions, a finished device is one that is intended
to be used as a medical device and is at a stage where the product is ready to be placed on the
market, or put into service, by the medical device organization whose name appears on the labelling.
The term medical device organization in this document is intended to be a reference to the definition
in ISO 9000:2016- Cl 3.2.1 and as used in ISO 13485:2016. A “manufacturer” is a specific kind of a
medical device organization that is variously defined in the regulations of the participating regulatory
authorities.
1
ISO 13485:2016 – Clause 0.2
MDSAP AU P0002.007 11 | P a g e
Overview
Critical Suppliers:
For the purposes of MDSAP, “critical suppliers” include, but are not limited to;
- those entities that supply the organization with finished devices, i.e. a device, or accessory to any
device, that is suitable for use or capable of functioning, whether or not it is packaged, labeled,
or sterilized;
- suppliers of products, including services, that impact design outputs that are essential for the
proper functioning of the device; and
- suppliers of products and services that require process validation.
Annexes
Annex 1 contains country specific information as to the expectations for the audit of product / process
related technologies (other than sterilization – See Annex 2) and the audit of technical documentation
as part of the execution of the Audit Tasks.
Annex 2 contains information as to the expectation for the audit of requirements for sterile medical
devices.
2 GHTF/SG3/N17:2008 - Quality Management System – Medical Devices – Guidance on the Control of Products and Services
Obtained from Suppliers
MDSAP AU P0002.007 12 | P a g e
Overview
Annex 3 contains a table showing a summary of timeframes for reporting advisory notices and
individual adverse event reports in the participating MDSAP jurisdictions.
Annex4 contains country specific guidance on expectations for various types of written agreements
for regulatory purposes.
Annex 5 contains tables showing comparisons between Japan’s new and old QMS ordinance. See
footnote 3 in Management.
Annex 6 contains a table for acceptable exclusions from a manufacturer’s scope of certification.
Note: Not all MDSAP participating regulatory authorities require, or make use of, certification
documents that relate to a medical device organization’s QMS. The terms “certification” and
“recertification” appear within this document to maintain consistency with the terminology used within
ISO/IEC 17021-1:2015 Conformity assessment – Requirements for bodies providing audit and
certification of management systems.
The audit cycle of a quality management system for sterile medical device should include a
comprehensive assessment of the control of the device sterility, generally during the
initial/recertification audit. The surveillance audit, in the absence of changes significantly affecting the
control of sterility, may be limited to the verification of the appropriate implementation of the
validated process parameters; control and monitoring activities; and final product release. While some
auditing activities can be conducted remotely (e.g. review of the sterilization process validation report),
remote activities alone cannot effectively ensure the comprehensive control of the device sterilization
processes. The outcome of such remote review activities must serve as input to the on-site audit and
be incorporated or attached to the MDSAP audit report. The off-site assessment of the controls of the
MDSAP AU P0002.007 13 | P a g e
Overview
product sterility should not prevent the on-site audit team from following audit trails, including audit
trails necessitating the review of documents that had previously been assessed remotely.
During the course of the audit cycle, all product families and significant processes should be assessed
when possible.
The selection of samples during audits in order to obtain evidence of conformity or nonconformity
with MDSAP audit criteria can be either statistically based or judgement based. Judgement based
sampling using audit trails from one task or process to inform the selection of samples in other tasks
or processes is preferred. Where possible, auditors should select samples of records representing all
participating MDSAP jurisdictions applicable to the audit.
A Stage 1 audit shall be conducted in accordance with Clause 9.3.1.2 of ISO/IEC 17021-1:2015 and all
applicable MDSAP Audit Process tasks and regulatory requirements.
From an MDSAP perspective, the primary purposes of a Stage 1 audit are (1) to determine if QMS
documentation required by ISO 13485:2016 - Clauses 4.2.1 and other applicable MDSAP
documentation requirements have been adequately defined, and documented; (2) to assess the
medical device organization’s preparedness for a Stage 2 audit; (3) to provide a focus for planning a
Stage 2 audit; and, (4) to collect information regarding the scope of the quality management system
and other aspects of the medical device organization.
Portions of a Stage 1 audit (e.g. documentation review) may be performed at a site other than the
site(s) of the medical device organization seeking initial certification.
The outcome of the Stage 1 audit will assist the MDSAP recognized Auditing Organization in its
determination of the readiness of the medical device organization to undergo a Stage 2 audit. The
Auditing Organization shall determine how best to accomplish tasks of Stage 1 and Stage 2 with
regards to off-site documentation and record review and on-site verifications. Hence portions of a
Stage 1 audit (e.g. documentation review) may be performed at a site other than the site(s) of the
medical device organization seeking initial certification. In practice it is intended that the Auditing
Organization may combine elements of Stage 1 and Stage 2 to allow for a single on-site visit for the
initial audit or re-audit of the medical device organization.
MDSAP AU P0002.007 14 | P a g e
Overview
A Stage 2 audit shall be conducted in accordance with Clause 9.3.1.3 of ISO/IEC 17021-1:2015 and
using all applicable MDSAP Audit Process tasks.
The purpose of a Stage 2 audit is to determine if all applicable requirements of ISO 13485:2016 and
the relevant regulatory requirements from participating regulatory authorities have been implemented.
Stage 2 audit objectives shall specifically include an evaluation of:
- the effectiveness of the medical device organization’s QMS incorporating the applicable
regulatory requirements;
- product/process related technologies (e.g. injection molding, sterilization);
- adequate product technical documentation in relation to relevant regulatory requirements; and,
- the medical device organization’s ability to comply with these requirements.
As part of achieving these objectives, the auditor is to verify that the medical device organization
maintains sufficient and reliable objective evidence to demonstrate its devices meet essential
principles of safety, performance, and effectiveness and any other regulatory requirement identified in
the audit tasks. This verification is to ensure that documentation and records required by the national
regulations of the participating Regulatory Authorities are present, current, and complete. The auditor
should expect that the documentation and records are maintained to demonstrate continued
compliance with regulatory requirements during the post-market phase of the device life-cycle.
A Stage 2 audit shall be performed at all sites that will be recorded on the certificate. (Hence, any sites
which are relevant to the medical device organization’s quality management system but audited off-
site, should not be recorded on the certificate.)
Surveillance Audits
(1st and 2nd Surveillance Audits):
A Surveillance Audit shall be conducted in accordance with Clause 9.6.2.2 of ISO/IEC 17021-1:2015 and
clause 9.6.2 of IMDRF/MDSAP WG/N3:2016 and using applicable MDSAP Audit Process tasks.
The purpose of a series of surveillance audits is to assure that all applicable requirements of ISO
13485:2016 and the relevant regulatory requirements from participating regulatory authorities are
audited during the cycle of a three year audit program for the medical device organization.
Surveillance audit objectives during the audit cycle shall specifically include evaluation of:
- the effectiveness of the medical device organization’s QMS incorporating the applicable
regulatory requirements.
- the medical device organization’s ability to comply with these requirements; and
- new or changed product/process related technologies; and,
MDSAP AU P0002.007 15 | P a g e
Overview
In addition, surveillance audits shall include a review of issues related to medical device safety and
effectiveness since the last audit such as complaints, problem reports, vigilance reports, and
recalls/field corrections/advisory notices.
These objectives allow the MDSAP recognized Auditing Organization to maintain confidence that the
QMS continues to meet requirements between re-audits (re-certification audits). The auditor should
again expect that the documentation and records are maintained to demonstrate continued
compliance with regulatory requirements during the post-market phase of the device life-cycle.
Surveillance audits do not require a Stage 1 audit unless significant changes have occurred since the
last audit. For example, where there are QMS changes associated with new legislation, or legislative
changes, or if otherwise deemed necessary by the Auditing Organization.
Each individual surveillance audit in the cycle need not cover all MDSAP requirements. However, as a
minimum, each surveillance audit must address the following (as applicable):
a) A review of changes to the medical device organization, their QMS, or their products, since
the previous audit
b) The MDSAP Audit Process tasks as listed in the table in Appendix 1 of MDSAP AU P0008 –
Audit Time Determination Procedure.
Note: Where there are indicators of existing or potential nonconformities in the data, or other
information observed during a surveillance audit that suggest that such nonconformities have
not been adequately addressed by the medical device organization’s QMS, an audit of the
Design and Development Process and/or the Production and Service Controls Process should
focus on those indicators of existing or potential nonconformities.
Note: If the first surveillance audit includes the Design and Development Process, the second
surveillance should include the Production and Service Controls Process (or vice-versa) unless
further indicators of existing or potential nonconformities dictate otherwise.
c) Confirmation that the medical device organization has arrangements in place to maintain
the currency of the technical documentation for all devices (see Annex 1).
MDSAP AU P0002.007 16 | P a g e
Overview
Guidance on the selection of samples of data for the audit of the processes in a) and b) above is
provided within the relevant tasks of those MDSAP Audit Processes. The selection should be limited to
the data that is relevant to the processes in a) and b) above.
The purpose of a re-audit is to confirm the continued relevance, applicability and suitability of the
medical device organization’s QMS (as a whole), to satisfy all applicable requirements of ISO
13485:2016 and the relevant regulatory requirements from participating regulatory authorities, with
respect to the scope of certification. Recertification audit objectives shall specifically include
evaluation of:
- the effectiveness of the medical device organization’s QMS incorporating the applicable
regulatory requirements
- product/process related technologies (e.g. injection molding, sterilization)
- adequate product technical documentation in relation to relevant regulatory requirements
- the medical device organization’s continued fulfillment of these requirements.
Re-audits do not require a Stage 1 audit unless significant changes have occurred since the last audit.
For example, where there are QMS changes associated with new legislation or legislative changes, or if
otherwise deemed necessary by the Auditing Organization. If there have been significant changes to
the QMS, Auditing Organizations shall review the documentation that implements those changes in
accordance with Clause 9.6.3.1.3 of 17021-1:2015. Re-audits may be shorter than initial audits through
selective and focused sampling.
As part of achieving the objectives for a Re-Audit, an auditor shall verify the requirements of ISO/IEC
17021-1:2015 Clause 9.6.3.2.1, and the following, where applicable:
- A review of the MDSAP audit reports for the current audit cycle. That is, those prepared since
the initial audit or previous re-audit
- A review of changes to the medical device organization, QMS, or products since the previous
surveillance audit
- A follow-up of corrections and/or corrective actions stemming from the findings of the previous
MDSAP audit, of any kind
- A review of the effectiveness and suitability of the medical device organization’s QMS over the
current audit cycle
- All applicable MDSAP Audit Process tasks.
MDSAP AU P0002.007 17 | P a g e
Overview
The audit of the processes and the sampling should focus on the following (based on risk):
During a recertification audit, the Auditing Organization shall audit all sites that are recorded on the
certificate. (Hence any sites which are relevant to the medical device organization’s quality
management system but audited off-site, should not be recorded on the certificate)
Special Audits
Special audits are extraordinary audits in that they are not part of the planned audit cycle. These
audits should only be used when necessary and should focus on specific elements of the medical
device organization’s QMS.
Special audits may include audits conducted in response to an application for the extension to the
scope of an existing certification, to determine whether or not the extension can be granted or as
short-notice audits conducted to investigate potentially significant complaints, or if specific
information provides reasons to suspect serious non-conformities of the devices, or for other reasons.
Short-notice audits may be conducted at the request, and under the direction, of the MDSAP
participating regulatory authorities or at the discretion of the Auditing Organization.
Special audits should be conducted in accordance with the applicable requirements of ISO/IEC 17021-
1:2015 Clause 9.6.4 as well as any additional requirements of the MDSAP recognized Auditing
Organization and/or the MDSAP participating regulatory authorities (where applicable).
- The need to extend the scope of the audit or certification of the medical device organization to
include new or modified products between regularly programmed audits
- A shortfall in oversight by the MDSAP recognized Auditing Organization. For example, due to
insufficient audit time, inappropriate audit team constitution, etc.
- To follow up on specific post-market issues. For example, for potentially significant complaint.
- To follow up on significant findings from a previous MDSAP audit
- At the request of an MDSAP participating regulatory authority (based on a specific assignment)
- To conduct supplier audits as dictated by regulatory authority or Auditing Organization policy.
MDSAP AU P0002.007 18 | P a g e
Overview
An Auditing Organization that performs a special audit at the request of the recognizing Regulatory
Authority(s) shall submit the audit report to the recognizing Regulatory Authority(s) within 15 days
from the last day of the audit.
Unannounced Audits
Another type of Special Audit is the unannounced audit. The MDSAP participating regulatory
authorities require Auditing Organizations to conduct unannounced audits in circumstances where
high grade non-conformities have been detected. See IMDRF/MDSAP WG/N3 Final: 2016 (2nd Ed) for
criteria.
MDSAP AU P0002.007 19 | P a g e
Chapter 1 - Management
Chapter 1 - Management
The intent of the Management Process is to provide adequate resources for device design,
manufacturing, quality assurance, distribution, installation, and servicing activities; to assure the quality
management system is functioning properly and effectively; and to monitor the quality management
system and make necessary adjustments. A quality management system that has been implemented
effectively and is monitored to identify and address existing and potential problems is more likely to
produce medical devices that function as intended.
The management representative is responsible for ensuring that the requirements of the quality
management system have been effectively defined, documented, implemented, and maintained. Prior
to the audit of a process, it may be helpful to interview the management representative (or designee)
to obtain an overview of the process and a feel for management’s knowledge and understanding of
the process.
The Management process is the first process to be audited per the MDSAP audit sequence.
Outcomes: As a result of the audit of the Management process, objective evidence will show whether
the medical device organization has:
A) Identified processes needed for the quality management system, their application throughout
the medical device organization, and their sequence and interaction
B) Defined, documented, and implemented procedures and instructions to ensure the
development and maintenance of an effective quality management system
C) Established quality objectives at relevant functions and levels within the medical device
organization consistent with the quality policy and ensured that these are periodically reviewed
for continued suitability
D) Determined the criteria and methods needed to ensure the operation and control of quality
management system processes, including the identification and management of interrelated
processes
E) Committed the appropriate personnel and resources for infrastructure to the quality
management system
F) Assigned responsibility and authority to personnel and established the organizational structure
to ensure processes assuring quality are not compromised
Chapter 1 - Management
Task 1 – QMS Planning, Implementation, Changes and Quality Manual
G) Performed risk management planning and ongoing review of the effectiveness of risk
management activities to ensure that policies, procedures and practices are established for
analyzing, evaluating and controlling risk
H) Ensured the continued effectiveness of the quality management system and its processes
I) Established a quality management system which is capable of producing devices that are safe,
effective and suitable for their intended use.
Verify that changes to the quality management system are managed to maintain the
conformity of the quality management system and of the devices produced.
MHLW/PMDA: MHLW MO169: 5-1, 5-2, 5-3, 5-4, 7-1, 14; [Old 3: 5, 7, 14]
3
The MHLW MO169 was initially established in order to harmonize the Japanese medical device QMS to
ISO13485:2003. The ordinance was revised to be aligned to ISO13485:2016 in 2021 and the transition period is
set as 3 years. “Old” in this context means the clause numbers of the old ordinance which is aligned to
ISO13485:2003. The MDSAP auditors are required to audit against the old ordinance, when the organization
selects it as audit criteria during the transition period.
MDSAP AU P0002.007 21 | P a g e
Chapter 1 - Management
Task 1 – QMS Planning, Implementation, Changes and Quality Manual
Assessing conformity
Quality management system
Medical device organizations are required to establish a quality management system (including quality
system procedures and instructions) that is tailored to the regulatory roles assumed by the medical
device organization and the medical devices they are manufacturing or designing. The medical device
organization’s quality management system must properly implement all applicable requirements of
Medical devices – Quality management systems – Requirements for regulatory purposes (ISO
13485:2016), the Quality Management System requirements of the Conformity Assessment Procedures
of the Australian Therapeutic Goods (Medical Devices) Regulations (TG(MD)R Sch3), Brazilian Good
Manufacturing Practices (RDC ANVISA 665/2022), Japanese QMS Ordinance (MHLW MO 169), the
Quality System Regulation (21 CFR Part 820) and specific requirements of medical device regulatory
authorities participating in the MDSAP program, as well as other necessary controls to assure its
finished devices, the design and manufacturing processes, and all related activities conform to
approved specifications.
4
ISO13485:2016 – Clause 0.2
MDSAP AU P0002.007 22 | P a g e
Chapter 1 - Management
Task 2 – Management Representative
planning at this level shouldn’t be confounded with quality planning as described in clause 7.1 of ISO
13485:2016.
Evidence of quality system planning should at least include documents that identify and record the
inputs and outputs of quality system planning. A procedure for quality system planning may also be
available.
- quality policy
- quality objectives
- quality management system standards (e.g. ISO 13485:2016)
- regulatory requirements
- product-specific requirements (e.g. servicing, installation, etc.)
- risk mitigation strategies (e.g. user training)
- required changes (e.g. identified during audits or management review)
- a description of the QMS processes and their inputs, outputs, sequence, and interactions
- the quality manual and associated procedures
- a gap analysis
- identification or resources needed to implement the QMS
- identification of competences and training needed to implement the QMS
- implementation and action plans.
Quality management system planning should also be used when changes to the quality management
system are contemplated or required in order to ensure the continuing conformity of the QMS.
Links
Measurement, Analysis and Improvement; Design and Development; Purchasing; Production
and Service Controls; Device Marketing Authorization and Facility Registration
During the audit, whenever a change is identified, verify that the medical device organization has
implemented appropriate change controls.
Assessing conformity
Management representative
It is important to confirm that top management has appointed a management representative and that
the responsibilities and authorities of the management representative have been defined,
documented, and implemented. The appointment of the management representative must be
documented.
Confirm appointment
The medical device organization may document the appointment of a management representative in
an organizational chart, Quality Manual, memorandum to file, position description, or other
appropriate manner. The appointment of the management representative may be made by name or
title.
MDSAP AU P0002.007 24 | P a g e
Chapter 1 - Management
Task 3 – Quality Policy and Quality Objectives
Other examples
Additional examples of evidence of the management representative’s responsibilities and authorities
may include:
Training
Where the activities performed personally by the management representative result in a determination
of whether product meets requirements, including regulatory requirements, the management
representative must be competent to perform such activities. In such cases, verify that training and
experience includes the relevant regulatory requirements.
Links
None
Ensure the quality objectives are measurable and consistent with the quality policy.
MDSAP AU P0002.007 25 | P a g e
Chapter 1 - Management
Task 4 – Organizational Structure, Responsibility, Authority, Resources
Assessing conformity
Quality policy
A quality policy is comprised of one or more statements of the medical device organization’s
intentions and direction with respect to meeting agreed requirements. Top management must
establish the quality policy and ensure quality objectives are established that are consistent with the
quality policy. Top management must ensure that the quality policy is understood and communicated
at all levels of the medical device organization. An assessment of whether the medical device
organization’s quality system is satisfying the established quality policy and objectives should be a
topic addressed during management reviews.
Quality objectives
An effective way of determining whether quality objectives have been implemented is to ask for
examples of quality objectives and the status of these objectives. Typically, a quality objective is
expressed as a measurable target or goal. An example of a medical device organization’s quality
objective could be “to have all essential components meet specifications at a defined reliability rate or
better.”
To accomplish this objective, the medical device organization will have to identify, evaluate, and
approve reliable suppliers or bring the manufacturing of that component in-house.
Links
None
MDSAP AU P0002.007 26 | P a g e
Chapter 1 - Management
Task 5 - Extent of Outsourcing
ANVISA: RDC ANVISA 665/2022: Art. 8º, Art. 13, Art. 14, Art. 15; Art. 16, Art. 17
Assessing conformity
Responsibility and authority
Methods for completing this audit task include reviewing the organizational chart(s) and asking
authority and responsibility questions. The responsibilities and authorities of various individuals within
the medical device organization are also typically described within the Quality Manual, position
descriptions, and job postings.
Resources
Top management is responsible for ensuring that resources necessary to maintain an effective quality
management system are provided. Resources include money, equipment, supplies, and personnel.
One method for confirming that adequate resources are made available is to ask the management
representative to provide several examples of recent requests for different types of resources and
describe the outcomes of these requests.
Links
None
MDSAP AU P0002.007 27 | P a g e
Chapter 1 - Management
Task 5 - Extent of Outsourcing
ANVISA: RDC ANVISA 665/2022: Art. 21, Art. 22, Art. 23, Art. 24
Australia (TGA):
The conditions of marketing authorization (ARTG inclusion) require that Australian Sponsors undertake
some regulatory activities including; customer complaint handling (Act s 41FN, Reg 5.8), the
management and communication of technical files /technical documentation (Act s 41FN(3)), adverse
event reporting (Act s 41FN, Reg 5.7), conducting recalls (Part 4-9), ensuring that the name and
address of the Sponsor is provided with the device (Reg 10.2), the storage of devices (Act s 41FN,Reg
5.9), the keeping of complaint and distribution records (Act s 41FN,Reg 5.10), annual reporting for an
initial period of three years, of specified information to the TGA (ACT s41FN, Reg 5.11) for Class AIMD,
Class III and Class IIb devices that are implantable, information about supply of specified IVDs (Act
s41FN, Reg 5.12), ensuring that some devices that would contravene Part 2 of the Poisons standards
are not supplied.
Some Sponsors also provide services for the installation and servicing of a device on behalf of the
Manufacturer and consequently are to be treated as a supplier to the Manufacturer.
The requirement of Regulation 10.2 for “ensuring that the name and address of the Sponsor is
provided with the device in such a way that the user of the device can readily identify the Sponsor” is
only an obligation on the Sponsor. This activity does not need to be included in the Manufacturer’s
QMS documentation however the arrangements for the provision of this information should be
disclosed in the written agreement between the Manufacturer and the Sponsor. In cases where an
activity performed by the Sponsor also includes the provision of information required by Essential
Principle 13 (Labels and IFU), or 13A (patient implant cards and leaflets), the Manufacturer must treat
the Sponsor as supplier for that activity.
The Sponsor does not need to be treated as a supplier if the scope of the Manufacturer’s quality
management system includes the site and activities of the Sponsor. The oversight of activities that are
required by legislation to be conducted by the Sponsors are to be clearly documented in the QMS and
included in plans for internal audit.
MDSAP AU P0002.007 28 | P a g e
Chapter 1 - Management
Task 6 – Personnel Competency and Training
Canada (HC):
Verify that the roles and responsibilities of any regulatory correspondents, importers, distributors, or
providers of a service are clearly documented in the medical device organization’s quality
management system and are qualified as suppliers and controlled, as appropriate.
Assessing conformity
Outsourcing
Most organizations outsource at least some products (including services) that affect the ability of the
medical device to conform to specified requirements. Some organizations outsource the majority of
products. During interview of the management representative, ascertain the extent to which the
medical device organization outsources processes essential for the proper functioning of the finished
medical device. Process performance and product conformity, including the performance of supplied
product, must be included in management review. The medical device organization must ensure
control over outsourced products and processes that affect product conformance with specified
requirements.
Links
Purchasing
During audit of the medical device organization’s purchasing process, ensure that management has
assured the appropriate level of control over suppliers, including an assessment of the relationship
between supplied products and product risk.
ANVISA: RDC ANVISA 665/2022: Art. 8°, Art. 13, Art. 14, Art. 15
MDSAP AU P0002.007 29 | P a g e
Chapter 1 - Management
Task 7 – Risk Management Planning and Review
Brazil (ANVISA):
Confirm that the manufacturer ensures that any consultant who gives advice regarding design,
purchasing, manufacturing, packaging, labeling, storage, installation, or servicing of medical devices
has proper qualification to perform such tasks. Those consultants shall be contracted as a formal
service supplier, according to purchasing controls defined by the manufacturer [RDC ANVISA
665/2022: Art. 16, Art. 17].
Assessing conformity
Training
A review of employee training records can be performed to ensure that employees have been trained
regarding the medical device organization’s quality policy and objectives. In particular, this should be
done for employees involved in key operations that affect product realization and product quality.
During the audit of the Production and Service Controls process, ensure that employees who are
involved in key operations that affect product realization and product quality have been trained in
their specific job tasks, as well as the quality policy and objectives.
When appropriate, review the training records for those employees whose activities have contributed
to process nonconformities.
Links
Production and Service Controls
MDSAP AU P0002.007 30 | P a g e
Chapter 1 - Management
Task 7 – Risk Management Planning and Review
Assessing conformity
Commitment to risk management
Confirm that top management has shown commitment to the risk management process by ensuring
the provision of adequate resources and the assignment of qualified personnel for risk management
activities. Risk-based decisions occur throughout the various quality management system processes.
Top management is responsible for defining and documenting the policy for determining criteria for
risk acceptability. Additionally, ensure top management reviews the suitability of the risk management
process. This review may be part of the management review. Previously unidentified risks discovered
during production and post-production of the medical device may indicate a need to improve the risk
management process. Each medical device organization must decide how much risk is acceptable.
When appropriate, assess the role of top management when risk-based decisions are made that
appear to justify levels of risk that do not meet the medical device organization’s previously
established risk- acceptance criteria.
Risk management usually starts in conjunction with the design and development planning process, at
a point in the development when the results of risk analysis can affect the design process. During
audit of the Design and Development process, evaluate top management’s commitment to risk
management activities. Evidence of commitment to risk management may include the implementation
of new or more stringent controls in response to changes in the likelihood or severity of a hazard
occurring, external controls (e.g. additional supplier-related controls), or design changes to maintain
an acceptable level of product risk.
Links
Design and Development
MDSAP AU P0002.007 31 | P a g e
Chapter 1 - Management
Task 8 – Document and Record Controls
Confirm the medical device organization retains records and at least one obsolete copy
of controlled documents for a period of time at least equivalent to the lifetime of the
device, but not less than two years from the date of product release.
ANVISA: RDC ANVISA 665/2022: Art. 28, Art. 29, Art. 30, Art. 31, Art. 34, Art. 36, Art. 37
Australia (TGA):
Confirm that Quality Management System documentation and records in relation to a device
described in TG(MD)R Sch3 P1 1.9 are retained by the Manufacturer for at least 5 years.
Note that the conditions of marketing authorization (ARTG inclusion) require Australian sponsors of
Class III/AIMD, implantable Class IIb or Class 4 IVDs to keep records of distribution, and records of
information relating to; any malfunction or deterioration in the characteristics or performance of a
device, or any inadequacy in the design, manufacture, labelling, instructions for use or advertising
materials of a device, or any use in accordance with, or contrary to, the use intended by the
manufacturer of a device, that has led to any complaint or problem in relation to the device, for a
period of up to 10 years. (Reg 5.10)
These requirements should be reflected in the written agreement between the Australian Sponsor and
Manufacturer and may also be identified in the Manufacturer’s procedures.
Brazil (ANVISA):
Verify that change records include a description of the change, identification of the affected
documents, the signature of the approving individual(s), the approval date, and when the change
becomes effective [RDC ANVISA 665/2022: Art. 32].
MDSAP AU P0002.007 32 | P a g e
Chapter 1 - Management
Task 8 – Document and Record Controls
Confirm that the manufacturer maintains a master list of the approved and effective documents [RDC
ANVISA 665/2022: Art. 33].
Verify that electronic records and documents have backups [RDC ANVISA 665/2022: Art. 35].
Japan (MHLW):
Confirm that Quality Management System documentation and records in relation to a device are
retained for the following periods (5 years for training records and documentation). [MHLW MO169: 8,
9, 67, 68]. (1) 15 years for ‘specially designated maintenance control required medical devices’ [or one
year plus the shelf life for products when the shelf life or the expiry date (hereinafter simply referred to
as the "shelf life") plus one year exceeds 15 years]. (2) 5 years for the products other than the ‘specially
designated maintenance control required medical devices’ (or one year plus the shelf life for the
products of which the shelf life plus one year exceeds 5 years).
Note: The ‘specially designated maintenance control required medical device’ is defined as below in
PMD Act 2.8:
A medical device designated by the Minister of Health, Labour and Welfare after hearing the opinion
of the Pharmaceutical Affairs and Food Sanitation Council as those whose potential risk to the
diagnosis, treatment or prevention of disease is significant without proper control since this kind of
equipment requires expert knowledge and skill in examination for maintenance and inspection, repair
and other management.
Assessing conformity
Implementation of document and record control procedures
Confirm that the medical device organization has defined, documented, and implemented procedures
for control of quality management system documents and records. Evidence that these controls are
effective can be ascertained through the audit of the other quality management system processes. For
example, evidence that the document controls process is ineffective might be the observation of
obsolete procedures being used or required records being unavailable.
Links
None
MDSAP AU P0002.007 33 | P a g e
Chapter 1 - Management
Task 9 – Management Reviews
21 CFR820.20(c)]
Assessing conformity
Verify implementation of management review procedures
It is important to verify that the medical device organization has documented and implemented
effective management review procedures. Top management must review the suitability, adequacy and
effectiveness of the medical device organization’s quality management system at defined intervals and
with sufficient frequency to ensure that the quality management system satisfies applicable
requirements of Medical devices – Quality management systems – Requirements for regulatory
purposes (ISO 13485:2016), Brazilian Good Manufacturing Practices (RDC ANVISA 665/2022), Japanese
QMS Ordinance (MHLW MO 169), the Quality System Regulation (21 CFR Part 820) and specific
requirements of medical device regulatory authorities participating in the MDSAP program, in addition
to the medical device organization’s own established quality policy and objectives. The dates and
results of the management reviews must be documented. These documentation requirements must
be included in the management review procedure.
Other requirements commonly seen in management review procedures include a fixed agenda of
topics to be discussed (with flexibility for unique agenda items to be added), the necessary attendees
who are to participate in the management review, and how action items resulting from the
management review are to be addressed and input into the Measurement, Analysis and Improvement
process when necessary. Ensure that the quality policy and objectives have been reviewed for
MDSAP AU P0002.007 34 | P a g e
Chapter 1 - Management
Task 10 – Distribution of Devices with Appropriate Marketing Authorization
continued suitability and that any changes to regulatory requirements have been identified. Other
inputs to management review include results of internal and external audits, customer feedback,
process performance and product conformity, status of preventive and corrective actions, follow-up
actions from previous management reviews, changes that could affect the quality management
system, and recommendations for improvement.
During audit of the Measurement, Analysis and Improvement process, confirm when necessary that
action items resulting from Management review are considered for corrective or preventive action.
Links
Measurement, Analysis and Improvement
Assessing conformity
Responsibilities and authorities of personnel
During the audit of the Management process, verify that the medical device organization has identified
and documented the responsibilities of employees and personnel for ensuring proper registration,
listing, licensing, notification and approval information is accurately submitted to regulatory
authorities or authorized representatives (e.g. Australian Sponsor) participating in the MDSAP.
Verify that the medical device organization has identified and documented the responsibilities and
authorities of personnel who are responsible for implementing controls to ensure that devices are only
distributed in participating MDSAP jurisdictions where market authorizations have been obtained.
Verify that these obligations are being carried out by competent personnel.
MDSAP AU P0002.007 35 | P a g e
Chapter 1 - Management
Task 10 – Distribution of Devices with Appropriate Marketing Authorization
- Change control processes that ensure that changes are assessed for their impact on existing
marketing authorizations
- Procedures and/or work instructions that clearly identify the jurisdictions in which products can
be sold
- Separate part numbers for devices, by jurisdictions
- Review of purchase orders to assure the customer requests and receives only product with the
appropriate market clearance
- Review of sales and marketing practices and materials (including internet pages) to assure
product is promoted only for markets where the product maintains appropriate market clearance
- Segregation of finished devices in warehousing and shipping areas, by jurisdictions
- Business rules in software to prevent the acceptance of purchase orders where marketing
authorization is absent
- Specific language in distribution agreements limiting devices that can be distributed in certain
jurisdictions
- Jurisdiction-specific marketing materials (catalogues, websites, etc.)
- The availability of accurate information on marketing authorizations obtained by jurisdiction.
The verification of the effectiveness of these controls should be specific to the device identifier(s) (e.g.
model number) as listed in the marketing authorization(s). A broad sample covering many products
and jurisdictions should be selected, particularly when reviewing distribution records.
MDSAP AU P0002.007 36 | P a g e
Chapter 1 - Management
Task 11 – Top Management Commitment to Quality
In order to prepare for this audit task, audit teams should ensure that they have current lists of market
authorizations held by the medical device organization as well as the names of all authorized
representatives in the MDSAP jurisdictions prior to coming on site.
The appropriate application of registration, listing, licensing, notification and approval processes, and
the accuracy of information for Device Marketing Authorization for submission to Regulatory
Authorities or authorized representatives (e.g. Australian Sponsor) participating in the MDSAP will be
verified under the Device Marketing Authorization and Facility Registration process. A preliminary
review of device marketing authorization and facility registration may be made during the audit of the
Management process, followed by comprehensive coverage for specific medical devices selected for
review under the Design and Development process.
Links
Device Marketing Authorization and Facility Registration
ANVISA: RDC ANVISA 665/2022: Art. 4°, Art. 5°, Art. 6°, Art. 7°
Assessing conformity
Audit the other processes
During the audit of the other MDSAP processes, the audit team will have the opportunity to assess
whether management is appropriately carrying out its responsibilities; whether the quality policy is
understood, implemented, and maintained at all levels of the medical device organization; if the
MDSAP AU P0002.007 37 | P a g e
Chapter 1 - Management
Task 11 – Top Management Commitment to Quality
necessary resources are being provided to maintain an effective quality management system; if the
management representative has the necessary responsibilities and authorities; the adequacy of the
organizational structure; and whether management reviews and quality audits are effective, etc.
Remember that a quality management system that has been implemented effectively, monitored to
identify and address existing and potential problems, and has an integrated risk management process
utilizing risk-based decision-making is more likely to produce medical devices that function as
intended.
Links
None
MDSAP AU P0002.007 38 | P a g e
Chapter 2 - Device Marketing Authorization and Facility Registration
Outcomes: As a result of the audit of the Device Marketing Authorization and Facility Registration
process, objective evidence will show whether the medical device organization has:
Assessing conformity
In some jurisdictions, Device Market Authorization is the responsibility of the importer / Marketing
Authorization Holder / Sponsor. Market Authorization however may only be appropriate if the medical
Chapter 2 - Device Marketing Authorization and Facility Registration
Task 1 – Submission for Device Marketing Authorization and Facility Registration
device organization and importer fulfil obligations that have been placed upon them by the relevant
legislation, including obligations to each other (e.g. communications concerning feedback, adverse
event reporting and the management of advisory notices and recalls).
Prior to an audit, an Auditing Organization shall independently investigate the identity and range of
products, facilities and importers (e.g. Importer, MAH, Sponsor, etc.) that are known to the Regulatory
Authority of each jurisdiction where the medical device organization intends to supply product.
Verify at audit, or prior to audit, that the regulatory requirements to register and/or license device
facilities and submit device listing information have been appropriately applied by the Medical Device
Organization for each Medical Device Organization / Importer arrangement. Note that some
importers / MAHs / Sponsors may have provided information to Regulatory Authorities indicating that
a medical device organization is the “legal manufacturer” even though the medical device organization
inappropriately considers themselves to be an Original Equipment Manufacturer or an Original Device
Manufacturer. A review of labelling for product being supplied to a particular jurisdiction may assist
with determining if appropriate market authorization processes have been applied.
Special attention should be paid to instances where products are being marketed to MDSAP
jurisdictions that marketing authorization has not been granted. This may be evident through audit of
other processes, such as Design and Development.
Australia (TGA):
Manufacturer of a medical device is the person who is responsible for the design, production,
packaging and labeling of the device before it is supplied under the person’s name, whether or not it is
the person, or another person acting on the person’s behalf, who carries out those operations. A
manufacturer of a medical device is also the person who, with a view to supplying the device under a
person’s name, does one or more of the following using ready made products: assembles, packages,
processes, refurbishes, labels the device, or assigns a different intended purpose through the use of
labels, instructions for use, advertising, or technical documentation (TG Act s41BG).
Australian importers (Sponsors) are required to include (register) medical devices from non-Australian
Manufacturers in the Australian Register of Therapeutic Goods (ARTG). Sponsors are required to
register the Manufacturers that they represent and to obtain a Client ID and Location ID for the
manufacturer from the TGA.
MDSAP AU P0002.007 40 | P a g e
Chapter 2 - Device Marketing Authorization and Facility Registration
Task 1 – Submission for Device Marketing Authorization and Facility Registration
To assist the Australian Sponsor, Manufacturers, who are supplying product to the Australian market
and choose to participate in the MDSAP, must undertake the following to demonstrate that they have
met the obligations on Manufacturers [TG Act s41DA(1)] who wish to supply to Australia;
Note: If the manufacturer chooses to participate in the MDSAP for any reason, and product is
supplied to the Australian market, the requirements for QMS in a relevant conformity
assessment procedure must be included with the scope of the audit performed by a
recognized MDSAP auditing organization.
Note: Sponsors are required to provide the Manufacturer with information in relation to the
Manufacturer’s obligations under a conformity assessment procedure and information in
relation to whether the devices comply with the Essential Principles [TG Act 41FN(3)(e)].
Refer to following:
MDSAP AU P0002.007 41 | P a g e
Chapter 2 - Device Marketing Authorization and Facility Registration
Task 1 – Submission for Device Marketing Authorization and Facility Registration
Brazil (ANVISA):
Manufacturer means any person who designs, manufactures, assembles or processes finished devices,
including those who only perform sterilization process, labeling and packaging [RDC ANVISA
665/2022: Art. 3°, section IX].
For a domestic manufacturer, confirm that the establishment has ANVISA’s authorization to
manufacture medical devices (AFE - Autorização de Funcionamento da Empresa). For domestic and
international manufacturers, verify that the products already distributed in the Brazilian market are
registered/notified with ANVISA [Brazilian Federal Law nº 6360/76].
Notification is a simplified market authorization process, applied to all medical device classes I and II.
[ANVISA RDC nº 36/2015, RDC nº 40/2015]. Registration is valid for 10 years, while notification has no
expiry date. Renewal of the registration shall be requested upon time defined at Brazilian Law
6360/1976.
Establishment license
Importer: the importer is considered the legal representative of the international manufacturer in Brazil
and shall be authorized by ANVISA to import, store, and distribute medical devices. In the case of
outsourcing the storage, the importer does not need authorization for this activity.
Canada (HC):
Manufacturer means a person who sells a medical device under their own name, or under a trade-
mark, design, trade name or other name or mark owned or controlled by the person, and who is
responsible for designing, manufacturing, assembling, processing, labeling, packaging, refurbishing or
MDSAP AU P0002.007 42 | P a g e
Chapter 2 - Device Marketing Authorization and Facility Registration
Task 1 – Submission for Device Marketing Authorization and Facility Registration
modifying the device, or for assigning to it a purpose, whether those tasks are performed by that
person or on their behalf [CMDR 1].
No person shall import or sell a Class II, III or IV medical device unless the manufacturer of the device
holds a license in respect of that device or, if the medical device has been subjected to a change
described in section 34, an amended medical device license [CMDR 26].
An application for a medical device license shall be submitted to the Minister by the manufacturer of
the medical device in a format established by the Minister [CMDR 32].
An application for a medical device license shall include a copy of a quality management system
certificate certifying that the quality management system under which the medical device is
manufactured (class II) or designed and manufacturer (class III or IV) satisfies National Standard of
Canada CAN/CSA-ISO 13485:2016. [CMDR 32(2)(f); 32(3)(j); 32(4)(p)].
Japan (MHLW):
“Marketing Authorization Holder” means a person who resides in Japan and is granted a license for
marketing from a prefectural government [PMD Act 23-2.1].
Class 2, class 3, and class 4 medical devices except for the ones specified by the requirement of PMD Act
23-2-23.1.
An” Application for Marketing Approval” shall be submitted to PMDA by the Marketing
Authorization Holder to get authorization for marketing a medical device in Japan. [PMD Act 23-2-
5.1]
An “Application for QMS Audit” shall also be submitted to PMDA by the Marketing Authorization
Holder, when they do not have an effective QMS Certificate for the device. [PMD Act 23-2-5.6, 7]
Class 2 and class 3 medical devices which are specified by the requirement of PMD Act 23-2-23.1
An” Application for Marketing Certification” shall be submitted to a Registered Certification Body
(RCB) by the Marketing Authorization Holder to get authorization for marketing a medical device in
Japan. [PMD Act 23-2-23.1].
An “Application for QMS Audit” shall also be submitted to an RCB by the person, when the person
does not have a valid QMS Certificate for the device. [PMD Act 23-2-23.3, 4].
A “Notification for Marketing” shall be submitted to PMDA by the Marketing Authorization Holder
for marketing a class 1 device in Japan [PMD Act 23-2-12].
MDSAP AU P0002.007 43 | P a g e
Chapter 2 - Device Marketing Authorization and Facility Registration
Task 1 – Submission for Device Marketing Authorization and Facility Registration
A class 1 medical device doesn’t need any QMS Certificate for marketing.
A medical device manufacturing site which conducts one of the designated manufacturing processes
listed below shall be registered:
- Main Designing
- Main assembly
- Sterilization
- Domestic storage before final release.
The site is called “Registered Manufacturing Site”. It has to submit an application to PMDA for
registration by itself [PMD Act 23-2-3.1, 23-2-4].
Establishment means a place of business under one management at one general physical location at
which a device is manufactured, assembled, or otherwise processed.
Owner or operator means the corporation, subsidiary, affiliated company, partnership, or proprietor
directly responsible for the activities of the registering establishment.
Owner or operator must register the establishment and submit listing information to Food and Drug
Administration (FDA) for those devices in commercial distribution, regardless of classification.
The registration and listing requirements must pertain to any person who:
- Initiates or develops specifications for a device that is to be manufactured by a second party for
commercial distribution by the person initiating specifications
- Manufactures for commercial distribution a device either for itself or for another person;
regardless of whether the manufacturer places the device into commercial distribution or returns
the device to the customer
- Repackages or relabels a device
- Acts as an initial importer, except that initial importers may fulfill their listing obligation for any
device for which they did not initiate or develop the specifications for the device or repackage or
relabel the device by submitting the name and address of the manufacturer
- Manufactures components or accessories which are ready to be used for any intended health-
related purpose and are packaged or labeled for commercial distribution for such purpose
MDSAP AU P0002.007 44 | P a g e
Chapter 2 - Device Marketing Authorization and Facility Registration
Task 2 – Evidence of Marketing Clearance or Approval
- Sterilizes or otherwise makes a device for or on behalf of a specification developer or any other
person
- Acts as a complaint file establishment
- Is a device establishment located in a foreign trade zone.
Links
Management
During audit of the Management process, confirm that management is aware of and has made
arrangements for device marketing authorization and facility registration.
Australia (TGA):
Marketing authorization (inclusion in the Australian Register of Therapeutic Goods [ARTG]) is granted
to the Australian Sponsor. The Sponsor cannot apply for marketing authorization until the
Manufacturer has completed a conformity assessment procedure that is relevant for the Class of the
device. Non-Australian Manufacturers will need to assist the Sponsor through the provision of
information to support an application for marketing authorization and to meet the relevant conditions
for on-going supply. A Sponsor is provided with a Certificate of Inclusion in the ARTG to identify the
products that have been granted marketing authorization. Products with marketing authorization may
be identified from the public facing ARTG database.
A Sponsor is not normally permitted to import, supply, export, or manufacture (in Australia) a medical
device unless; the device complies with the essential principles, the Manufacturer has applied a
relevant conformity assessment procedure, and the Sponsor has included the device in the ARTG. An
exemption to allow importation and supply may be approved and granted to the Sponsor by the TGA,
in cases where the TGA is satisfied that the device is to be used under a clinical trial scheme or the
special access or authorized prescriber schemes. An exemption approval may contain conditions in
MDSAP AU P0002.007 45 | P a g e
Chapter 2 - Device Marketing Authorization and Facility Registration
Task 2 – Evidence of Marketing Clearance or Approval
relation to the manufacture of the product. The Manufacturer should verify with the Australian
Sponsor if any such conditions have been applied to the exemption approval.
A Manufacturer must maintain a list of their Australian Sponsors and the products those Sponsors
have included in the Australian Register of Therapeutic Goods.
A Manufacturer’s procedures should ensure that product is not released for supply to the Australian
market unless the Sponsor has been issued with a “Certificate of Inclusion in the Australian Register of
Therapeutic Goods”, that identifies each kind of medical device that has been approved for supply to
the Australian market [TG Act s41FJ], or the Sponsor holds a relevant exemption (TG Act Part 4-7).
As part of an application for marketing authorization a Sponsor commits to certain requirements that
are identified in s41FD - “Matters to be certified”. These matters include establishing a written
agreement with the manufacturer about the provision of information and establishing effective
communication channels for post-market activities. See Annex 4 for further guidance.
Brazil (ANVISA):
In Brazil there are two kinds of marketing clearance, registration and notification:
- Device market clearance shall be requested to ANVISA by the domestic manufacturer or importer
(legal representative) formally established in Brazil. Registration is a comprehensive process for
market authorization, applied to medical devices in classes III and IV. [ANVISA RDC nº 36/2015,
RDC nº 40/2015].
- Notification is a simplified market authorization process, applied to all medical devices classes I
and II. [ANVISA RDC nº 36/2015, RDC nº 40/2015] Registration is valid for 10 years, while
notifications have no expiry date - renewal of the registration shall be requested upon time
defined at Brazilian Law 6360/1976.
Canada (HC):
No person shall import or sell a Class II, III or IV medical device unless the Manufacturer of the device
holds a license in respect of that device or, if the medical device has been subjected to a change
described in section 34 - an amended medical device license [CMDR 26].
Japan (MHLW):
Any person who intends to market a medical device for business in Japan shall have a license for
marketing granted by the prefectural government. This person is called a “Marketing Authorization
Holder” (MAH) and shall reside in Japan [PMD Act 23-2.1]. The person has to submit an Application
for Marketing Approval/Certification (class 2, 3 or 4 medical device) or a Notification for Marketing
(class 1 medical device) to get marketing clearance for the medical device. No person shall market a
MDSAP AU P0002.007 46 | P a g e
Chapter 2 - Device Marketing Authorization and Facility Registration
Task 3 – Notification of Changes to Marketed Devices or to the QMS
medical device in Japan, unless the Marketing Authorization Holder of the device has been granted the
marketing clearance [PMD Act 23-2-5.1, 23-2-23.1, 23-2-12].
Each person who is required to register his establishment pursuant to 807.20 must submit a premarket
notification submission to the Food and Drug Administration at least 90 days before he proposes to
begin the introduction or delivery for introduction into interstate commerce for commercial
distribution of a device intended for human use which meets any of the following criteria:
- The device is being introduced into commercial distribution for the first time; that is, the device is
not of the same type as, or is not substantially equivalent to, (i) a device in commercial
distribution before May 28, 1976, or (ii) a device introduced for commercial distribution after May
28, 1976, that has subsequently been reclassified into class I or II.
- The device is being introduced into commercial distribution for the first time by a person
required to register.
A Premarket approval is required for any FDA class III device that was not on the market (introduced or
delivered for introduction into commerce for commercial distribution) before May 28, 1976, and is not
substantially equivalent to a device on the market before May 28, 1976, or to a device first marketed
on, or after that date, which has been classified into class I or class II.
Links
Management, Design and Development
During the audit of the Management and Design and Development processes, ensure that
management is aware of requirements for device marketing authorization and facility registration,
and that these are considered when designing the device.
Confirm that management obtains marketing authorization in the appropriate jurisdictions prior to
commercial distribution of the device.
MDSAP AU P0002.007 47 | P a g e
Chapter 2 - Device Marketing Authorization and Facility Registration
Task 3 – Notification of Changes to Marketed Devices or to the QMS
The audit team should pay special attention to situations observed in the audit of the
Design and Development process (specifically design changes) that may require
notification to the jurisdictions to which the changed devices are marketed.
Australia (TGA):
The Manufacturer is required to notify their auditing organization body of:
- A proposed change to their QMS, including the name of location of the manufacturer
- A proposed change to critical suppliers or the goods and services they provide
- A proposed change to a validated manufacturing process
- A proposed change to the kinds of medical devices to which the system is to be applied
- For Class III or AIMD, a proposed change to the design, intended performance, intended user,
packaging, storage or transport conditions of a device.
Changes are to be evaluated by the Auditing Organization to determine whether a special audit is
required to verify the continuing integrity of the quality management system, or whether verification
of the change may occur at the next routine audit. The Auditing Organization should also verify the
continuing adequacy of technical documentation as a result of the change (see Annex 1)
If the Manufacturer is a holder of a TGA Conformity Assessment Certificate, then the Manufacturer is
also required to notify the TGA of these changes, prior to implementation. For changes that are not
considered substantial by the Manufacturer or applicant, they should be notified to the TGA at the
time of recertification of an existing conformity assessment certificate, included within the scope of
another conformity assessment application, or made available for the auditor during the next on site
audit; whichever occurs earlier.
Examples of substantial changes that may require notification to the TGA include, but are not limited
to, the following:
- Product design (e.g. materials for medical devices, storage, shelf-life, and packaging)
- Information to be provided with a medical device (e.g. intended purpose of the device in the IFU,
removal of warnings, contraindications, or other information regarding safety etc.)
Refer to:
Note: An entry in the Australian Register of Therapeutic Goods (inclusion) in the name of the
Australian Sponsor is in effect until cancelled.
Brazil (ANVISA):
Changes involving medical devices already approved by ANVISA, shall be submitted for a new
approval [Brazilian Law nº 6360/76 - Art. 13]. Changes/modifications that shall be submitted are those
ones classified as significant change, which affects:
- features of safety and effectiveness, including measures to communicate information (ex. residual
risk)
- identification of the device or its manufacturer or manufacturing site
- indication for use, including its purpose, patient type (adult, pediatric, newborn)or environment
to be used (domestic, hospital, ambulance, etc.)
- device classification
- technical specification of the device, including composition and other
operational/technical/physical features
- manufacturing method.
Examples of modifications that may require a submission include, but are not limited to, the following:
- Sterilization method
- Structural material / composition
- New or additional manufacturer
- Manufacturing method
- Manufacturing site
- Operating parameters or conditions for use
- Patient or user safety features
- Sterile barrier packaging material
- Stability or expiration claims
- Design
MDSAP AU P0002.007 49 | P a g e
Chapter 2 - Device Marketing Authorization and Facility Registration
Task 3 – Notification of Changes to Marketed Devices or to the QMS
Canada (HC):
If the Manufacturer proposes to make one or more changes, the Manufacturer shall submit to the
Minister, in a format established by the Minister, an application for a medical device license
amendment including the information and documents set out in section 32 that are relevant to the
change [CMDR 34].
Every Manufacturer of a licensed medical device shall, annually before November 1 and in a form
authorized by the Minister, furnish the Minister with a statement signed by the Manufacturer or by a
person authorized to sign on the Manufacturer’s behalf describing any change to the information and
documents supplied by the Manufacturer with respect to the device, other than those to be submitted
under section 34 or 43.1 [CMDR 43].
If the holder of a medical device license discontinues the sale of the medical device in Canada, the
licensee shall inform the Minister within 30 days after the discontinuance, and the license shall be
cancelled at the time that the Minister is informed [CMDR 43(3)].
Subject to section 34, if a new or modified quality management system certificate is issued in respect
of a licensed medical device, the Manufacturer of the device shall submit a copy of the certificate to
the Minister within 30 days after it is issued [CMDR 43.1].
Japan (MHLW):
A change to a medical device which is approved/certified by PMDA/a Registered Certification Body
may require the Marketing Authorization Holder to submit a new application, a change application, or
a change notification [PMD Act 23-2-5.1, 23-2-5.11, 23-2-5.12, 23-2-23.1, 23-2-23.6, 23-2-23.7].
Changes that require the application or the notification are those ones which directly impact the safety
and efficacy of the device and/or the substantial identity of the fact approved during marketing
approval / certification.
The Registered Manufacturing Site shall communicate with the Marketing Authorization Holder about
the change when the Registered Manufacturing Site plans such changes, so that the Marketing
MDSAP AU P0002.007 50 | P a g e
Chapter 2 - Device Marketing Authorization and Facility Registration
Task 3 – Notification of Changes to Marketed Devices or to the QMS
Authorization Holder could take any necessary regulatory actions mentioned above [MHLW MO169:
29].
Examples of changes that may require an application or a notification include, but are not limited to,
the following:
- Design
- Composition
- Raw material
- Sterilization method
- Manufacturing method
- Manufacturing site
- Patient or user safety features
- Operating Parameters or conditions for use
- Indication for use
- Shelf life
- Performance Specification.
MDSAP AU P0002.007 51 | P a g e
Chapter 2 - Device Marketing Authorization and Facility Registration
Task 3 – Notification of Changes to Marketed Devices or to the QMS
the device is to be marketed for a new or different indication. Most changes in indications for use
require the submission of a 510(k).
Examples of modifications that may require a 510(k) submission include, but are not limited to, the
following:
- Sterilization method
- Structural material
- Manufacturing method
- Operating parameters or conditions for use
- Patient or user safety features
- Sterile barrier packaging material
- Stability or expiration claims
- Design.
After FDA’s approval of a PMA, an applicant must submit a PMA supplement for review and approval
by FDA before making a change affecting the safety or effectiveness of the device for which the
applicant has an approved PMA. While the burden for determining whether a supplement is required
is primarily on the PMA holder, changes for which an applicant shall submit a PMA supplement
include, but are not limited to, the following types of changes if they affect the safety or effectiveness
of the device:
MDSAP AU P0002.007 52 | P a g e
Chapter 2 - Device Marketing Authorization and Facility Registration
Task 3 – Notification of Changes to Marketed Devices or to the QMS
Links
Design and Development
During the audit of the Design and Development process, the audit team should confirm the
medical device organization has considered regulatory requirements for device marketing
authorization and facility registration; and has complied with these requirements prior to marketing
the changed device in the applicable regulatory jurisdictions.
MDSAP AU P0002.007 53 | P a g e
Chapter 3 - Measurement, Analysis and Improvement
The purpose of a medical device organization’s Measurement, Analysis and Improvement process is to
collect and analyze information, identify and investigate existing and potential causes of product and
quality problems, and take appropriate and effective corrective or preventive action to prevent
recurrence or occurrence. It is essential that a medical device organization verify or validate these
actions, communicate corrective and preventive action activities to responsible people, provide
relevant information for management review, and document these activities. These activities will help
the medical device organization deal effectively with existing or potential product and quality
problems, prevent their recurrence and/or occurrence, and prevent or minimize device failures or other
quality problems.
The management representative is responsible for ensuring that the requirements of the quality
management system have been effectively defined, documented, implemented, and maintained. Prior
to the audit of a process, it may be helpful to interview the management representative (or designee)
to obtain an overview of the process and a feel for management’s knowledge and understanding of
the process.
The Measurement, Analysis and Improvement process is the second primary process to be audited per
the MDSAP audit sequence. When applicable, information regarding device or identified quality
management system nonconformities observed during the audit of the Measurement, Analysis and
Improvement process should be used to make decisions as to design projects or design changes to
assess during audit of the Design and Development process, suppliers to evaluate during audit of the
Purchasing process, and processes to review during audit of the Production and Service Controls
process.
Outcomes: As a result of the audit of the Measurement, Analysis and Improvement process, objective
evidence will show whether the medical device organization has:
Design and Development; Production and Service Controls; Purchasing; Medical Device Adverse
Events and Advisory Notices Reporting; Management
MDSAP AU P0002.007 55 | P a g e
Chapter 3 - Measurement, Analysis and Improvement
Task 1 – Procedures for Measurement, Analysis, and Improvement of QMS Effectiveness and
Product Conformity
ANVISA: RDC ANVISA 665/2022: Art. 88, Art. 120, Art. 121
MHLW/PMDA: MO169: 6, 54, 55-1, 58, 59, 62, 63, 64; [Old: 6, 54, 55, 58, 59, 62, 63, 64]
Brazil (ANVISA):
Verify that the manufacturer has ensured that information about quality problems or nonconforming
products are properly disseminated to those directly involved in the maintenance of product quality
and to prevent occurrence of such problems [RDC ANVISA 665/2022: Art. 120 section VI].
Confirm procedures provide for the submission of relevant information on identified quality problems,
as well as corrective and preventive actions, for management review [21 CFR 820.100(a)(7)].
Assessing conformity
Procedures
Each medical device organization must establish and maintain procedures for analyzing data and
implementing corrective action and preventive action. The procedures must include requirements for:
Information from the organization’s analysis of quality data should be used to inform
the audit team’s decision as to specific complaint records to review in Task 12, and
products and processes to audit during the Design and Development, Production and
Service Controls, and Purchasing processes.
MHLW/PMDA: MO169: 43, 54, 55-1, 58, 59, 61; [Old: 43, 54, 55, 58, 59, 61]
Assessing conformity
Quality data sources
Complaints, records of acceptance activities and concessions, nonconformities identified in internal
audits, service records, acceptability of supplied product and supplier performance, and data
presented in management review are common quality data sources that are useful in identifying
quality problems, among others.
Some sources of quality data that may be useful in identifying potential problems are acceptance
activities, such as component, in-process, or finished device testing; environmental monitoring, and
statistical process control (SPC). Results of acceptance activities may indicate an unfavorable trend
that left unattended may result in product nonconformity.
MDSAP AU P0002.007 57 | P a g e
Chapter 3 - Measurement, Analysis and Improvement
Task 2 – Sources of quality data
During the audit of the Measurement, Analysis and Improvement process, it is recommended that the
auditor(s) review the previous audit report if there is one for the medical device organization. If this
information is available, the audit team should use the information in the report when selecting some
quality data sources to review during the audit. For example, if service records were reviewed during
the previous audit and the medical device organization handled the data appropriately, the audit team
may wish to select a different data source for review during the audit.
However, if the previous audit documented that the data from service records were not being entered
into the Measurement, Analysis and Improvement process appropriately, the audit team should
consider reviewing service records again to determine whether the previous deficiency was effectively
addressed:
- Select some sources of quality data
- Determine if the data from these sources were entered into the medical device organization’s
Measurement, Analysis and Improvement process for analysis and whether the information was
complete, accurate, and entered in a timely fashion
- Be mindful of quality problems that appear in more than one data source. For example, device
nonconformities noted in complaints should be compared with similar nonconformities noted
during the medical device organization’s analysis of data from other data sources such as
product reject reports, or nonconforming product or process reports.
This comparison will help the medical device organization and the audit teams understand the full
extent of the quality problem.
Analysis of data
A medical device organization should use data from a variety of quality data sources to identify the
causes of existing product and quality problems. Not all organizations will have the same sources of
quality data. For example, service records and installation reports are quality data sources that may
not be found at every medical device organization.
As the audit team is conducting the audit, determine what sources of quality data the medical device
organization has identified. The audit team will also determine whether the sources identified by the
medical device organization are appropriate and if the medical device organization is analyzing quality
data from these sources to identify existing product problems as well as existing problems within its
quality system.
Later in the evaluation of the Measurement, Analysis and Improvement process, the audit team will be
sampling raw quality data to determine how the medical device organization analyzed the quality data
and responded to the results of its analysis.
MDSAP AU P0002.007 58 | P a g e
Chapter 3 - Measurement, Analysis and Improvement
Task 3 – Investigation of Nonconformity
A medical device organization should also use data from a variety of quality data sources to identify
the causes of potential product and quality problems. The medical device organization should be
looking for trends or other indications of potential problems before the problems actually occur. The
medical device organization may choose to perform analysis of competing devices, including
reviewing advisory notices related to competing devices, to determine whether similar
nonconformities could occur in the medical device organization’s devices.
Determine whether the medical device organization can identify potential product and quality
problems that may require preventive action.
A medical device organization has the flexibility to use whatever methods of analysis are appropriate
to identify existing and potential causes of nonconforming product or other quality problems.
However, a medical device organization must use appropriate statistical methodology where necessary
to detect recurring quality problems.
A medical device organization must also use appropriate statistical tools when it is necessary to use
statistical methodology. It should not misuse statistics in an effort to minimize the problem or avoid
addressing the problem.
Links
Purchasing
During the audit of the Measurement, Analysis and Improvement process, the audit team may
encounter data involving product nonconformities, including complaints involving finished devices,
where the underlying cause of the quality problem has been traced to supplied product.
During the audit of the Purchasing process, the audit team should consider selecting suppliers to
audit that have corrective action indicators of nonconformities with supplied components or
processes.
MDSAP AU P0002.007 59 | P a g e
Chapter 3 - Measurement, Analysis and Improvement
Task 3 – Investigation of Nonconformity
MHLW/PMDA: MO169: 63
Assessing conformity
Investigations of nonconformities
Organizations must define and implement a process for investigations. The process should consist of
a structured, risk-based approach (in a mature QS) intended to determine the root or underlying
cause(s) of a quality problem. Criteria should be defined to determine when an investigation is
necessary and the extent of the investigation. The investigation should be based on a pre-approved
plan or other defined approach, timelines should be defined, roles and responsibilities should be
assigned, and the course of action should be assessed when the underlying cause cannot be
determined. The results of the investigation must be recorded. The depth of the medical device
organization’s investigation of a process, product, or other quality system nonconformity should be
commensurate with the significance and risk of the nonconformity. The process for determining the
extent of an investigation may be linked to the medical device organization’s risk management system
and the design outputs essential to the proper functioning of the device.
In order for a medical device organization to take a corrective action (i.e., action taken to prevent
recurrence of an existing nonconformity), an investigation must be conducted to determine the cause
of the nonconformity. Often a medical device organization will only make a correction to handle the
immediate problem (e.g. relabeling a lot of mislabeled finished devices). Determining the cause of the
lot of mislabeled finished devices is more difficult and may be overlooked. Where possible, the
medical device organization should identify the underlying cause or causes of the nonconformity so
that appropriate corrective action can be taken.
Selecting records
When selecting records of investigations to review, be mindful of the risk of the nonconformity to the
product or process. Select records of investigations where the nonconformity has a higher risk of
adversely affecting the ability of the finished device to meet its essential design outputs or the
nonconformity affects the safety and efficacy of the product.
MDSAP AU P0002.007 60 | P a g e
Chapter 3 - Measurement, Analysis and Improvement
Task 4 – Investigation of Potential Nonconformity
Links
None
MHLW/PMDA: MO169: 64
Assessing conformity
Investigations of potential nonconformities
The depth of the medical device organization’s investigation into potential process, product, or other
quality system nonconformities should be commensurate with the risk of the nonconformity if it were
to occur. The process for determining the extent of an investigation may be linked to the medical
device organization’s risk management system and outputs essential to the proper functioning of the
device.
Selecting records
When selecting records of investigations to review, be mindful of the risk of the potential
nonconformity to the product or process. Select records of investigations where the potential
nonconformity has a higher risk of adversely affecting the ability of the finished device to meet its
essential design outputs or the potential nonconformity could affect the safety and efficacy of the
product.
MDSAP AU P0002.007 61 | P a g e
Chapter 3 - Measurement, Analysis and Improvement
Task 5 – Correction, Corrective Action, and Preventive Action
Links
None
Ensure corrective action and preventive action is appropriate to the risk of the
nonconformities or potential nonconformities encountered.
ANVISA: RDC ANVISA 665/2022: Art. 18, Art. 19, Art. 20, Art. 116, Art. 120 sections II, II, IV, V
MHLW/PMDA: MO169: 55-1, 57, 60-1, 63, 64; [Old: 55, 57, 60, 63, 64]
Assessing conformity
Determining the extent of actions
Corrective actions taken by a medical device organization can vary depending on the situation.
Corrective actions are intended to correct and also prevent recurrence of not only nonconforming
product but also poor practices, such as inadequate training.
In developing corrective action addressing nonconforming product, the medical device organization
should consider corrections to be taken regarding the affected products, whether distributed or not.
Corrections and corrective actions must be commensurate with the risk associated with the
nonconformity.
The audit team may encounter situations where a quality problem has been identified, but the medical
device organization’s management has decided not to undertake corrective actions. Confirm that the
medical device organization’s decision not to take corrective action has been made using appropriate
risk-based decision making, including a determination that the finished device meets risk acceptability
criteria.
MDSAP AU P0002.007 62 | P a g e
Chapter 3 - Measurement, Analysis and Improvement
Task 6 – Assessment of Design Change resulting from Corrective or Preventive Action
Review how the medical device organization has determined that the actions do not adversely affect
the finished device(s).
Links
Medical Device Adverse Events and Advisory Notices Reporting
Determine whether any of the medical device organization’s corrective actions require reporting to
participating MDSAP authorities.
ANVISA: RDC ANVISA 665/2022: Art. 18, Art. 19, Art. 20, Art. 60
MDSAP AU P0002.007 63 | P a g e
Chapter 3 - Measurement, Analysis and Improvement
Task 7 – Assessment of Process Change resulting from Corrective or Preventive Action
Assessing conformity
Design change
Completing this audit task may involve linkages to other subsystems. Verification and validation are
important elements in assuring that corrective actions and preventive actions that result in design
changes are effective and do not introduce new hazards.
Links
Design and Development
If the corrective action or preventive action involves changing the design, design controls should be
applied to the change where applicable.
When necessary, confirm that design controls were applied to the change according to the medical
device organization’s procedures.
In addition, design changes should be evaluated under the medical device organization’s risk
management process to ensure that changes do not introduce new hazards.
Verify the medical device organization has performed revalidation of processes where
appropriate.
ANVISA: RDC ANVISA 665/2022: Art. 18, Art. 19, Art. 20, Art. 106, Art. 120
MHLW/PMDA: MO169: 5-2, 5-4, 5-6, 6, 26, 41, 45, 46; [Old: 5, 6, 26, 41, 45, 46]
MDSAP AU P0002.007 64 | P a g e
Chapter 3 - Measurement, Analysis and Improvement
Task 7 – Assessment of Process Change resulting from Corrective or Preventive Action
Australia (TGA):
Confirm that the Manufacturer’s procedure for dealing with substantial changes to a critical process
(e.g. sterilization, processing materials of animal origin, processing materials of microbial or
recombinant origin, or processes that incorporate a medicinal substance in a medical device), requires
the Manufacturer to notify the Auditing Organization of their plans before implementing a change to a
critical process. The Auditing Organization is to assess the proposed change before implementation
by the Manufacturer, to determine if the requirements of the relevant conformity assessment
procedure will still be met after the change. [TG(MD)R Sch3 P1 1.5(2)].
If the Manufacturer is also a holder of a TGA Conformity Assessment Certificate, then the Manufacturer
is also required to notify the TGA of these changes, prior to implementation.
Canada (HC):
Verify that the Manufacturer has a process or procedure for identifying a “significant change” to a class
III or IV device. Verify that information about “significant changes” is submitted in a medical device
license amendment application [CMDR 1, 34].
Japan (MHLW):
Confirm that when the Registered Manufacturing Site plans to make a significant change to a
manufacturing processes (e.g. sterilization site change, manufacturing site change), the Registered
Manufacturing Site notifies the Marketing Authorization Holder so as the Marketing Authorization
Holder can take appropriate regulatory actions [MHLW MO169: 29].
Assessing conformity
Process changes
Completing this audit task may involve linkages to other quality management system processes.
Production processes require at least some degree of qualification, verification, or validation. If the
change involves a validated process, review the medical device organization’s evaluation of the
process change to determine if revalidation is needed.
For changes to production processes that are performed by suppliers, the audit team should consider
selecting those suppliers for evaluation during audit of the Purchasing process. In cases where the
medical device organization makes a change to a validated process performed by a supplier, the audit
team should evaluate whether re-validation is required. If re-validation of production processes is
required, confirm the results show the process meets the planned result.
MDSAP AU P0002.007 65 | P a g e
Chapter 3 - Measurement, Analysis and Improvement
Task 8 – Identification and Control of Nonconforming Product
Links
Production and Service Controls, Purchasing
If the corrective action or preventive action involves changing a production process, the audit team
should consider selecting this change for evaluation during audit of Production and Service
Controls.
Confirm that an appropriate disposition was made, justified, and documented and that
any external party responsible for the nonconformity was notified.
ANVISA: RDC ANVISA 665/2022: Art. 117, Art. 118, Art. 120 section VI
Assessing conformity
Nonconforming product
The audit team should review procedures and controls for preventing the unintended distribution of
nonconforming product. The auditor(s) may choose to select a sample of records involving
nonconforming product that was in stock or returned to review how the procedures and controls were
applied to control the nonconforming product.
Confirm the medical device organization has established and maintained procedures that define the
responsibility for review and the authority for the disposition of nonconforming product, as well as the
MDSAP AU P0002.007 66 | P a g e
Chapter 3 - Measurement, Analysis and Improvement
Task 9 – Action Regarding Nonconforming Product Detected After Delivery
execution of the review and disposition process. Disposition of nonconforming product must be
documented.
The audit team may encounter situations where the medical device organization’s management has
decided to authorize the use of nonconforming product under concession. Documentation must
include the justification for use of nonconforming product and the signature of the individual(s)
authorizing the use. Confirm that the medical device organization’s decision to use nonconforming
product under concession has been made using appropriate risk-based decision making, including a
determination that the finished device meets specified requirements. Be mindful of instances where
the use of nonconforming product under concession has led to devices not meeting specifications.
Selecting records
When selecting records of nonconforming products to review, be mindful of the risk of the
nonconformity to the finished device and the patient or user. Select records of nonconforming
products to review where the nonconformity has a higher risk of adversely affecting the ability of the
finished device to meet its essential design outputs or the nonconformity affects the safety and
efficacy of the product.
Links
None
ANVISA: RDC ANVISA 665/2022: Art. 18, Art. 19, Art. 20, Art. 120 section VIII
MDSAP AU P0002.007 67 | P a g e
Chapter 3 - Measurement, Analysis and Improvement
Task 10 – Internal Audit
Assessing conformity
Control and action based on risk
During this audit task, confirm that the medical device organization has determined the control and
actions to be taken on nonconforming products detected after delivery or use, commensurate with the
risk associated with a product failure.
While it may not be necessary for the medical device organization to recall nonconforming product
from distribution as part of its identified actions needed to correct and prevent recurrence of the
problem, confirm that the decision is made using an adequate risk justification.
Links
Medical Device Adverse Events and Advisory Notices Reporting
If the medical device organization has taken field action on products already distributed, confirm
that the appropriate MDSAP regulatory authorities have been notified, as necessary.
Confirm that the internal audits include provisions for auditor training and
independence over the areas being audited, corrections, corrective actions, follow-up
activities, and the verification of corrective actions.
ANVISA: RDC ANVISA 665/2022: Art. 122, Art. 123, Art. 124
Assessing conformity
Internal audits
Internal audits are systematic, independent examinations of a medical device organization’s quality
management system that are performed at defined intervals and at sufficient frequency to determine
whether both quality management system activities and the results of such activities comply with
quality management system procedures. Internal audits should also determine whether these
procedures are implemented effectively and whether they are suitable to achieve quality management
system objectives.
Auditors
Internal audits are to be conducted according to established procedures by appropriately trained
individuals not having direct responsibility for the matters being audited. If possible, interview
auditors and ask how audits are conducted, how long audits typically last, what documents are
typically reviewed, etc.
Requirements
Internal audit procedures typically include requirements for auditor qualifications, requirements for the
frequency of audits, specified functional areas to be audited, and audit plans (or the requirement to
establish audit plans prior to the audit). Procedures should also include requirements for:
- How audit activities and results are to be communicated, addressed, and followed up (including
re-audit, if necessary) and,
- How audit activities are to be documented.
Links
Management
During the audit of the Management process, the audit team should confirm that the output of
internal audits is an input to management review.
MDSAP AU P0002.007 69 | P a g e
Chapter 3 - Measurement, Analysis and Improvement
Task 11 – Information Supplied for Management Review
ANVISA: RDC ANVISA 665/2022: Art. 12, Art. 120 section VII
MHLW/PMDA: MO169: 19
Assessing conformity
Management review
During the performance of this audit task, the auditor(s) may choose to select a recent, significant
corrective or preventive action and determine which records or information regarding the event was
submitted for management review.
Links
Management
During the audit of the Management process, the audit team should have confirmed that the status
of corrective and preventive actions is an input to the management review.
During the audit of the Measurement, Analysis and Improvement process, determine if top
management is aware of higher-risk quality problems, as well as significant corrective and
preventive actions, when necessary.
MDSAP AU P0002.007 70 | P a g e
Chapter 3 - Measurement, Analysis and Improvement
Task 12 – Evaluation of Information from Post-Production Phase, Including Complaints
Select records of complaints for review that represent the highest risk to the user or
have the largest impact on the ability of the device to meet its essential design outputs.
Verify that information from the analysis of production and post-production quality
data was considered for amending the analysis of product risk, as appropriate.
MHLW/PMDA: MO169: 6, 29, 43, 55-1, 55-2, 62; [Old: 6, 29, 43, 55, 62]
Australia (TGA):
Verify that the medical device organization has procedures for a post-marketing system that includes a
systematic review of post-production experience (e.g. from; expert user groups, customer surveys,
customer complaints and warranty claims, service and repair information, literature reviews, post-
production clinical trials, user feedback other than complaints, device tracking and registration
schemes, user reactions during training, adverse event reports). Investigation should take place in a
timely manner to ensure that reporting timeframes for adverse events or the implementation of
advisory notices (recalls) may be met by the Australian Sponsor [TG(MD)R Sch3 P1 1.4(3)(a)].
Note: In Australia the conduct of a recall is the responsibility of the Australian Sponsor in accordance
with the Australian Uniform Recall Procedure for Therapeutic Goods.
MDSAP AU P0002.007 71 | P a g e
Chapter 3 - Measurement, Analysis and Improvement
Task 12 – Evaluation of Information from Post-Production Phase, Including Complaints
Brazil (ANVISA):
Verify that each manufacturer has established and maintains procedures to receive, examine, evaluate,
investigate and document complaints. Such procedures must ensure that:
Canada (HC):
Verify that the Manufacturer maintains records of reported problems related to the performance
characteristics or safety of a device, including any consumer complaints received by the Manufacturer
after the device was first sold in Canada, and all actions taken by the Manufacturer in response to the
problems referred to in the complaints [CMDR Section 57].
Verify that the Manufacturer has established and implemented documented procedures that will
enable it to carry out an effective and timely investigation of the problem reports through the
customer complaints, and to carry out an effective and timely recall of the device [CMDR Section 58].
Verify that the Manufacturer has established and implemented documented procedures for preparing
summary reports with respect to information received or of which they became aware:
During the previous 12 months for class III and IV medical devices. CMDR 61.4(1)]
MDSAP AU P0002.007 72 | P a g e
Chapter 3 - Measurement, Analysis and Improvement
Task 12 – Evaluation of Information from Post-Production Phase, Including Complaints
• Adverse effects;
• Reported problems and complaints;
• Reportable incidents in accordance with section 59(1);
Serious risks of injury to human health that are relevant to the safety of the medical device in
accordance with section 61.2(2). [CMDR 61.4(2)]
Verify that the summary report includes a concise critical analysis of the information required in
section 61.4(2)
[CMDR 61.4(3)]
Verify that the manufacturer has determined, based on the analysis of data, whether what is known
about the benefits and risks associated with the medical device has changed as follows:
• Any of the benefits that may be obtained by patients through the use of the medical device
could be less;
• In respect of any of the risks:
o the risk is more likely to occur; or,
o if the risk occurs, the consequences for the health and safety of patients, users or other
persons could be more serious.
• a new risk has been identified.
Verify that the manufacturer has included the conclusions drawn from the above-mentioned analysis
in the summary report.
[CMDR 61.4(4)&(5)]
Verify that the manufacturer has notified the Minister in writing within 72 hours after concluding that
what is known about the benefits and risks associated with the medical device has changed. [Note:
Refer to the guidance document “Guidance on summary reports and issue-related analyses for
medical devices: Summary reports” for instructions for reporting to the Minister.]
[CMDR 61.4(6)]
MDSAP AU P0002.007 73 | P a g e
Chapter 3 - Measurement, Analysis and Improvement
Task 12 – Evaluation of Information from Post-Production Phase, Including Complaints
Verify that the manufacturer retains records of the summary reports, the information used in the
preparation of the reports, and any associated notification to the Minister for seven years after the day
on which they are created.
[CMDR 61.6]
Japan (MHLW/PMDA):
Confirm that the person operating the Registered Manufacturing Site has determined and
implemented effective arrangement for communicating with the Japanese Marketing Authorization
Holder in relation to customer feedback, including customer complaints, and advisory notices [MHLW
MO169: 29].
Each manufacturer must review and evaluate all complaints to determine whether an investigation is
necessary. When no investigation is made, the manufacturer must maintain a record that includes the
reason no investigation was made and the name of the individual responsible for the decision not to
investigate.
Any complaint of the failure of the device, labeling, or packaging to meet any of its specifications must
be reviewed, evaluated, and investigated, unless such investigation has already been made for a similar
complaint and another investigation is not necessary.
Any complaint that represents an event which must be reported to FDA must be promptly reviewed,
evaluated, and investigated by a designated individual(s) and must be maintained in a separate
portion of the complaint files or otherwise clearly identified. Records of investigation must include a
determination of:
MDSAP AU P0002.007 74 | P a g e
Chapter 3 - Measurement, Analysis and Improvement
Task 12 – Evaluation of Information from Post-Production Phase, Including Complaints
When an investigation is made, a record of the investigation must be maintained by the formally
designated unit. The record of investigation must include:
When the manufacturer’s formally designated unit is located at a site separate from the manufacturing
establishment, the investigated complaint(s) and the record(s) of investigation must be reasonably
accessible to the manufacturing establishment [21 CFR 820.198].
Assessing conformity
Evaluation of post-production data
During the review of quality data sources that serve as inputs to the Measurement, Analysis and
Improvement process, the audit team may choose to review complaints and customer feedback.
Confirm that complaints are handled as required by the MDSAP participating regulatory authorities.
Complaints can be an important source of information regarding quality problems and are often
indicative that distributed devices (or their packaging or labeling) did not meet specified requirements.
Selecting records
One method to analyze complaints and customer feedback is to review the analysis of complaint data
and postmarket surveillance activities and select one or more complaint failure modes, preferably
failure modes associated with higher risk to the patient or user. Once the audit team has selected
complaint failure modes, the auditor(s) can select a sample of complaints from those failure modes
and confirm the complaints are handled appropriately, including investigation and implementation of
corrective action when necessary.
Risk management
Information from post-production sources, including complaints, customer feedback, and postmarket
surveillance can provide important information for the risk management activities for the device. In
particular, previously unidentified risks discovered during the post-production monitoring may
indicate a need for improving the risk management process or may indicate a need for design
MDSAP AU P0002.007 75 | P a g e
Chapter 3 - Measurement, Analysis and Improvement
Task 13 – Communications with External Parties Involved on Complaints
changes. Additionally, on the basis of post-production quality data, the medical device organization
may choose to enact new or more stringent controls to maintain an acceptable level of product risk.
Links
Medical Device Adverse Events and Advisory Notices Reporting; Design and Development;
Production and Service Controls
During the review of complaints and feedback, confirm that individual medical device reports were
made to the appropriate regulatory authorities when necessary.
Assessing conformity
Complaints and nonconformities attributed to supplied product
Confirm that information related to quality problems or nonconforming product, including complaints,
is disseminated to those directly responsible for assuring the quality of product. This includes
instances where investigation reveals the underlying cause of the complaint or nonconforming product
to be related to the supplied product. The medical device organization should notify the supplier of
the quality problem and appropriate corrective action must be taken when necessary. Failure of an
MDSAP AU P0002.007 76 | P a g e
Chapter 3 - Measurement, Analysis and Improvement
Task 14 – Evaluation of Complaints for Adverse Event Reporting
outside medical device organization to provide products that meet specified requirements may
disqualify them as an acceptable or approved supplier.
Links
Purchasing
During the audit of the Measurement, Analysis and Improvement process, if significant
nonconformities are related to the supplied product, the audit team should consider selecting those
suppliers for evaluation during the audit of the medical device organization’s Purchasing process.
Confirm that decisions to not report complaints were made according to established
procedures and a documented rationale.
ANVISA: RDC ANVISA 665/2022: Art. 120 section VIII, RDC ANVISA 67/2009
Assessing conformity
Individual adverse event reports
An output of the activities associated with the Measurement, Analysis and Improvement process, such
as complaint handling, is the evaluation of individual adverse events to determine whether individual
adverse event reports are required to be submitted to the regulatory authorities. During review of
complaint records, assess whether the complaint was evaluated to determine whether the criteria for
MDSAP AU P0002.007 77 | P a g e
Chapter 3 - Measurement, Analysis and Improvement
Task 15 – Evaluation of Quality Problems for Advisory Notices
reporting was met and confirm the appropriate reports and information was provided to the
regulatory authority when appropriate. Ensure the individual adverse event reports contain accurate
information by comparing the submitted reports to the associated complaint and complaint
investigation.
Reportable events are often an important Measurement, Analysis and Improvement process quality
data source since these events are indicative that the finished device has caused death, serious injury,
or has malfunctioned in a manner such that if the malfunction were to recur, the result could be death
or serious injury. Any death, even if the medical device organization attributes it to user error, is
considered to have potentially high risk associated with it. Confirm that reportable events were
evaluated for corrective action when necessary.
Links
None
Select records for review of quality problems that were evaluated for potential issuance
of advisory notices (include records where a decision was made not to issue an advisory
notice as well as records of decision to issue advisory notices) and assess whether the
organization has taken actions appropriately based on risk and documented the
rationale.
ANVISA: RDC ANVISA 665/2022: Art. 120 section VIII, RDC ANVISA 551/2021
MDSAP AU P0002.007 78 | P a g e
Chapter 3 - Measurement, Analysis and Improvement
Task 15 – Evaluation of Quality Problems for Advisory Notices
Assessing conformity
Advisory notices
An output of the activities associated with the Measurement, Analysis and Improvement process,
including complaint handling and the discovery of nonconforming product that has been distributed,
may be the determination of whether an advisory action is necessary. When applicable, select quality
issues that were evaluated for potential advisory actions and assess whether appropriate actions were
taken and the organization’s decisions were justified, based on the risk of the quality problem to
device users. This may include assessing whether the organization appropriately determined the
scope of the quality issue. For example, if the organization determined that a product is distributed in
three MDSAP jurisdictions, but the advisory notice was only issued in one MDSAP jurisdiction, the
audit team should determine whether the organization has an appropriate documented justification
for the scope of the advisory action.
The quality problems that led to an advisory notice is often an important quality data source for the
corrective actions process since these events are indicative that the finished device does not meet
specified requirements and has the potential for unreasonable risk to the user. Confirm that quality
problems that were evaluated by the organization for potential advisory actions were evaluated for
corrective action. If corrective action was taken, evaluate the mechanism by which the medical device
organization assured the action is effective and does not adversely affect the ability of the device to
meet specified requirements. If corrective action was not taken for quality problems associated with a
correction, removal, or advisory notice; or action appears unduly delayed considering the risk of the
quality problem, review the medical device organization’s rationale for not undertaking corrective
action and confirm that the decision is appropriate using a risk-based decision making process.
Links
None
MDSAP AU P0002.007 79 | P a g e
Chapter 3 - Measurement, Analysis and Improvement
Task 16 – Top Management Commitment to Measurement, Analysis, and Improvement
Process
MHLW/PMDA: MO169: 5-3, 11, 54, 62; [Old: 5, 11, 54, 62]
Links
None
MDSAP AU P0002.007 80 | P a g e
Chapter 4 - Medical Device Adverse Events and Advisory Notices Reporting
Outcomes: As a result of the audit of the Medical Device Adverse Events and Advisory Notices
Reporting process, objective evidence will show whether the medical device organization has:
Verify that the complaint process has a mechanism for reviewing each complaint to
determine if a report to a regulatory authority is required.
Confirm that the medical device organization’s processes meet the timeframes required
by each regulatory authority where the product is marketed.
Country-specific requirements
Australia (TGA):
Manufacturers are required to implement a post-marketing system that includes provisions for adverse
event reporting – e.g. Therapeutic Goods (Medical Devices) Regulations 2002 Schedule 3 Part 1 Clause
1.4(3)(c)(i). In view of the written agreement between Manufacturers and the Australian Sponsor [TG
Act 41FD], events must be reported by the Manufacturer to the TGA, or to the Sponsor, in a timely
manner to ensure that a Sponsor can meet their reporting obligations under the Therapeutic Goods
(Medical Devices) Regulation 5.7:
- Verify that the Manufacturer or other person becoming aware of an event that represents a
serious threat to public health provides information as soon as practicable. The Sponsor is to
report the event within 48 hours.
- Verify that the Manufacturer or other person becoming aware of an event that led to the death
or serious deterioration in the state of health of a patient, a user, or other person provides
information as soon as practicable. The Sponsor is to report the event within 10 days.
- Verify that the manufacturer or other person becoming aware of an event that the recurrence of
which might lead to the death or serious deterioration in the state of health of a patient, a user,
or other person provides information as soon as practicable. The Sponsor is to report the event
within 30 days.
Note: An event that leads to a serious threat to human health is a hazard arising from a systematic
failure of the devices or an event or other occurrence that may lead to death or serious injury.
Note: Adverse events may be reported on-line to the TGA, by the Manufacturer or Sponsor, at
https://www.tga.gov.au/reporting-problems.
Note: It is a condition on Australian Sponsors of Class AIMD, Class III and Implantable Class IIb
devices that they provide three consecutive annual reports to the TGA following inclusion of the
device in the ARTG. Annual reports are due 1 October each year. Reports should be for the period 1
July to 30 June. The report is to include:
- ARTG no.
- Product name
- Model no(s)
- Number supplied in Australia
- Number supplied worldwide (Numbers should include devices that are the same but supplied
under a different name in another jurisdiction)
- Number of complaints in Australia
- Number of complaints worldwide
MDSAP AU P0002.007 82 | P a g e
Chapter 4 - Medical Device Adverse Events and Advisory Notices Reporting
Task 1 – Notification of Adverse Events
- Number of adverse events and incident rates in Australia (Rate= No. of events/ No. Supplied x
100 = Rate%)
- Number of adverse events and incident rates worldwide
- A list of the more common complaints and all of the adverse events
- Device Incident Report (DIR) number of those adverse events reported to the TGA
- Regulatory/corrective action/notification by Manufacturer
Note: Australian Sponsors are required to provide Manufacturers with any information that will
assist the Manufacturer to comply with the obligations of a conformity assessment procedure (e.g.
information in relation to adverse events) [TG(MD)R Reg 5.8].
Brazil (ANVISA):
Verify that a post-market surveillance system is established and implemented in the medical device
organization and integrated into the Quality System, with procedures and workflows established to
ensure the correct and the prompt identification of adverse events, the performance of investigations
and use of the results to improve the safety and effectiveness of the device when necessary [RDC
ANVISA 67/2009 – Art. 6º].
For domestic manufacturers (also applies to legal representatives in Brazil) - verify that top
management has designated a professional to be responsible for the post-market surveillance system.
This designation shall be documented [RDC ANVISA 67/2009 – Art. 5º].
Verify that the medical device organization has mechanisms for processing and recording complaints,
conducting investigations, and providing feedback directly to the complainant, or in the case of an
international manufacturer, to their legal representative in Brazil, as necessary [RDC ANVISA 67/2009 –
Art. 6º, Art. 7º, Art. 9º].
Verify that the medical device organization has notified the regulatory authority about problems
associated with their devices, including adverse events (critical or non-critical), any technical defect
that was identified regarding products already marketed, anything that can cause a serious hazard to
public health, or cases of counterfeit [RDC ANVISA 67/2009 – Art. 8º].
For international manufacturer, verify that the legal representative in Brazil is aware about the
occurrence of possibility of death, serious hazard to public health or cases of counterfeit, associated
with their products exported to Brazil [RDC ANVISA 67/2009 – Art. 8º].
Canada (HC):
CMDR 59-61.1, 61.2-61.3
MDSAP AU P0002.007 83 | P a g e
Chapter 4 - Medical Device Adverse Events and Advisory Notices Reporting
Task 1 – Notification of Adverse Events
Verify that the Manufacturer and the importer of a medical device make a preliminary and final
report to the minister concerning any incident occurring inside Canada involving a device sold
(authorized for sale) in Canada that:
• Is related to the failure of the device or deterioration in its effectiveness or any inadequacy in
its labeling or in its directions for use; and
• Has led to death or serious deterioration in the state of health of a patient, user, or other
person, or could do so if it were to recur [CMDR 59(1)].
[Note: the requirement to report incidents occurring outside of Canada no longer applies to class
II-IV devices authorized for sale in Canada. The requirement nonetheless still applies for class I
devices.[CMDR 59(1.1)]]
Verify that the Manufacturer or other person becoming aware of an event that led to the death or
serious deterioration in the state of health of a patient, a user, or other person provides
information in a preliminary report within 10 days after the person becomes aware of the event or
occurrence [CMDR 60 (1)(a)(i)].
Verify that the Manufacturer or other person becoming aware of an event that the recurrence of
which might lead to the death or serious deterioration in the state of health of a patient, a user, or
other person provides information in a preliminary report within 30 days after the person becomes
aware of the event or occurrence [CMDR 60 (1)(a)(ii)].
Verify that Manufacturer has made effective arrangements to submit preliminary reports to the
Minister and that the reports contain [CMDR 60 (2)]:
• the identifier of any medical device that is part of a system, test kit, medical device group,
• medical device family or medical device group family
• if the report is made by:
o the Manufacturer:
the name and address of that Manufacturer and of any known importer, and
the name, title and telephone and facsimile numbers of a representative of the
Manufacturer to contact for any information concerning the incident, or
o the importer of the device:
the name and address of the importer and of the Manufacturer, and
the name, title and telephone and facsimile numbers of a representative of the
importer to contact for any information concerning the incident.
• the date on which the incident came to the attention of the Manufacturer or importer
• the details known in respect of the incident, including the date on which the incident occurred
• and the consequences for the patient, user or other person
• the name, address and telephone number, if known, of the person who reported the incident
to the Manufacturer or importer
• the identity of any other medical devices or accessories involved in the incident, if known
• the Manufacturer’s or importer’s preliminary comments with respect to the incident
MDSAP AU P0002.007 84 | P a g e
Chapter 4 - Medical Device Adverse Events and Advisory Notices Reporting
Task 1 – Notification of Adverse Events
• the course of action, including an investigation, that the Manufacturer or importer proposes to
follow in respect of the incident and a timetable for carrying out any proposed action and for
submitting a final report
• a statement indicating whether a previous report has been made to the Minister with respect
to the device and, if so, the date of the report.
If a preliminary report required by section 60 is submitted to the Minister and/or Importer, verify
that the Manufacturer has submitted a final report to the Minister in writing in accordance with the
timetable established under CMDR 60(2)(h) and the final report contains [CMDR 61(1)(2)]:
• a description of the incident, including the number of persons who have experienced a serious
deterioration in the state of their health or who have died
• a detailed explanation of the cause of the incident and a justification for the actions taken in
respect of the incident
• any actions taken as a result of the investigation, which may include:
o increased post-market surveillance of the device
o corrective and preventive action respecting the design and manufacture of the device,
and
o recall of the device.
Manufacturers and Importers can use the “Mandatory Medical Device Problem Reporting Form
for Industry” to submit preliminary and final incident report.
If the reports required by section 60 and 61 are submitted to the Minister just by the Importer,
verify that the Manufacturer has advised the Minister in writing that the reports the Manufacturer
and importer would have submitted were identical and that the Manufacturer has permitted the
importer to prepare and submit reports to the Minister on the Manufacturer’s behalf [CMDR 61.1].
This notification is to be done using Health Canada form “FRM-0090”.
Verify that the Manufacturer of a medical device submits to the Minister information regarding
serious risk of injury to human health related to the safety of the device that it becomes aware of
or receives, regarding:
(a) Risks that have been communicated by any Regulatory Agency that is set out in the List of
Regulatory Agencies for the Purposes of Section 61.2 of the Medical Devices Regulations,
or by any person who is authorized to manufacture or sell a medical device within the
jurisdiction of such a Regulatory Agency, and the manner of the communication;
(b) changes that have been made to the labelling of any medical device and that have been
communicated to or requested by any Regulatory Agency that is set out in the list referred to
in paragraph (a); and
MDSAP AU P0002.007 85 | P a g e
Chapter 4 - Medical Device Adverse Events and Advisory Notices Reporting
Task 1 – Notification of Adverse Events
For greater clarity, serious risk of injury to human health is defined as a hazard associated with the
medical device that is relevant to the safety of the medical device and that, without risk mitigation,
would likely:
• be life-threatening
• result in persistent or significant disability or incapacity
• require inpatient hospitalization or prolonged hospitalization
• result in a serious health consequence such as loss of function or debilitating chronic pain
• result in death
Verify that manufacturers submit notifications of foreign risks within 72 hours after receiving or
becoming aware that a notifiable action has been taken in response to a serious risk, whichever
comes first. [CMDR 61.2(3)]
Foreign Risk Notifications can be submitted using the “Medical Device Foreign Risk Notification
Form for Industry”.
If the notification required by section 61.2 is submitted to the Minister just by the Importer, verify
that the Manufacturer has advised the Minister in writing that the report the Manufacturer and
importer would have submitted were identical and that the Manufacturer has permitted the
importer to prepare and submit reports to the Minister on the Manufacturer’s behalf [CMDR
61.3(2)]. This notification is to be done using Health Canada form “FRM-0090”.
Additional information and guidance on Foreign Risk Notification can be found in the associated
Guidance Document.
Japan (MHLW):
Marketing Authorization Holders are required to implement post market safety activities in accordance
with domestic (Japanese) regulatory requirements in addition to the QMS requirements.
The persons operating the Registered Manufacturing Sites are not required to report any adverse
event directly to a Regulatory Authority but shall report any adverse event which meets the criteria
specified by the Ordinance for Enforcement of PMD Act Article 228-20 to the Marketing Authorization
Holder [MHLW MO169: 55-3; (Old: 62.6)].
Verify that the person operating the Registered Manufacturing Site provides events which meets the
following criteria defined by the Ordinance for Enforcement of PMD Act Article 228-20.2 (see below),
to the Marketing Authorization Holder in a timely manner.
- The following malfunction events which may cause or may have caused health damage:
MDSAP AU P0002.007 86 | P a g e
Chapter 4 - Medical Device Adverse Events and Advisory Notices Reporting
Task 1 – Notification of Adverse Events
Determine whether the manufacturer has developed a process for reporting to FDA incidents involving
device-related deaths, serious injuries, and reportable malfunctions that occur within and outside the
United States if the same or similar device is marketed to the United States.
Confirm that the manufacturer has developed, maintained, and implemented written medical device
reporting (MDR) procedures for the following:
MDSAP AU P0002.007 87 | P a g e
Chapter 4 - Medical Device Adverse Events and Advisory Notices Reporting
Task 1 – Notification of Adverse Events
Verify that reports are made within 30 calendar days after the day that the manufacturer receives or
otherwise becomes aware of information, from any source, that reasonably suggests that a device that
is marketed may have caused or contributed to a death or serious injury:
If a device has malfunctioned and this device or a similar device that is marketed would be likely to
cause or contribute to a death or serious injury, if the malfunction were to recur, quarterly summary
reporting is acceptable for most device product codes.
If the manufacturer maintains MDR event files as part of the complaint file, ensure that the
manufacturer has prominently identified these records as MDR reportable events. FDA will not
consider a submitted MDR report to comply with 21 CFR 803 unless the manufacturer evaluates an
event in accordance with the quality management system requirements. Confirm that the
manufacturer has documented and maintained in the MDR event files an explanation of why the
manufacturer did not submit or could not obtain any information required by 21 CFR 803, as well as
the results of the evaluation of each event.
Compare the information submitted on the individual medical device report to the information
contained in the associated complaint and confirm the medical device report contains all information
related to the event that is reasonably known to the manufacturer.
Verify the manufacturer has submitted reports to FDA no later than 5 work days after the day that the
manufacturer becomes aware that:
MDSAP AU P0002.007 88 | P a g e
Chapter 4 - Medical Device Adverse Events and Advisory Notices Reporting
Task 2 – Notification of advisory notices
period stated in the original written request if FDA determines it is in the interest of the public
health.
Verify the manufacturer submitted supplemental reports within one month of obtaining information
that was not submitted in an initial report.
Confirm that medical device reports include the unique device identifier (UDI) that appears on the
device label or on the device package.
Medical device reports submitted to FDA must be submitted electronically via the Electronic
Submissions Gateway (ESG) using eSubmitter or the AS2 Gateway-to-Gateway using HL7 ICSR XML
software.
Links
Measurement, Analysis and Improvement
Reports of individual adverse events are a form of feedback and must be analyzed as appropriate
for trends requiring improvement or corrective action.
During the audit of the Measurement, Analysis and Improvement process, confirm that the medical
device organization has considered individual adverse events and trends of adverse events in the
analysis of data.
Australia (TGA):
Manufacturers are required to implement a post-marketing system that includes provisions for the
recall of devices – e.g. Therapeutic Goods (Medical Devices) Regulations 2002 Schedule 3 Part 1 Clause
1.4 (3A). Under the MDSAP, and in view of the written agreement between Manufacturers and the
Australian Sponsor [TG Act 41FD] (see Annex 4), proposed recalls must be reported by the
Manufacturer to the MDSAP AO, and to the TGA or Sponsor in a timely manner to ensure that a
MDSAP AU P0002.007 89 | P a g e
Chapter 4 - Medical Device Adverse Events and Advisory Notices Reporting
Task 2 – Notification of advisory notices
Sponsor can meet their reporting obligations [Therapeutic Goods (Medical Devices) Regulation 5.7 and
5.8, Therapeutic Goods Act Part 4-9 and the Uniform Recall Procedure for Therapeutic Goods (URPTG)].
Note: Further information concerning the Australian requirements for advisory notices and the
recovery of devices is available at https://www.tga.gov.au/recalls
Note: Australian Sponsors are required to provide Manufacturers with any information that will assist
the Manufacturer to comply with the obligations of a conformity assessment procedure (e.g.
information in relation to the recovery of devices) [TG(MD)R Reg 5.8].
Brazil (ANVISA):
Verify that procedures and work flows were established in order to identify when field actions (recalls
and corrections) are necessary, in accordance with the medical device organization’s post-market
surveillance system and quality system [RDC ANVISA 67/2009 - Art. 6º, RDC ANVISA 551/2021 – Art.
1º, Art. 5º].
Verify that the medical device organization keeps records regarding field actions performed, including
those that do not need to be reported to regulatory authorities [RDC ANVISA 551/2021 – Art. 4º; Art.
6º, Art. 10, Art. 11, Art. 16].
For domestic manufacturers (also applies to legal representatives in Brazil) - verify that the medical
device organization has sent to the regulatory authority the reports requested, according to Brazilian
regulation [RDC ANVISA 551/2021– Art. 10, Art. 11].
Verify that the medical device organization has performed field actions based on potential or concrete
evidence that their product does not comply with essential requirements of safety and effectiveness
[RDC ANVISA 551/2021 – Art. 4º, Art. 6º, Art. 7º, Art. 13, Art. 14, Art. 15].
For domestic manufacturers (also applies to legal representatives in Brazil) - verify that the medical
device organization has performed field actions when required by the regulatory authority [RDC
ANVISA 551/2021 – Art. 6º].
For domestic manufacturers (also applies to legal representatives in Brazil) - verify that the medical
device organization notified the regulatory authority regarding field actions, in accordance with
requirements and deadlines established per Brazilian regulation [RDC ANVISA 551/2021 – Art. 7º, Art.
8º].
For international manufacturers, verify that the legal representative in Brazil was aware about the
occurrence of field actions performed on products exported to Brazil [RDC ANVISA 67/2009 – Art. 8º].
Canada (HC):
Medical Device Regulations SOR/98-282, Section 63 – 65.1:
MDSAP AU P0002.007 90 | P a g e
Chapter 4 - Medical Device Adverse Events and Advisory Notices Reporting
Task 2 – Notification of advisory notices
Verify that the Manufacturer and the importer of a medical device, on or before undertaking a recall of
a device provide the minister with the following information [CMDR 64]:
- the name of the device and its identifier, including the identifier of any medical device that is part
of a system, test kit, medical device group, medical device family or medical device group family
- the name and address of the Manufacturer and importer, and the name and address of the
establishment where the device was manufactured, if different from that of the Manufacturer
- the reason for the recall, the nature of the defectiveness or possible defectiveness and the date
on and circumstances under which the defectiveness or possible defectiveness was discovered
- an evaluation of the risk associated with the defectiveness or possible defectiveness
- the number of affected units of the device that the Manufacturer or importer:
- manufactured in Canada,
- imported into Canada,
- sold in Canada.
- the period during which the affected units of the device were distributed in Canada by the
Manufacturer or importer
- the name of each person to whom the affected device was sold by the Manufacturer or importer
and the number of units of the device sold to each person
- a copy of any communication issued with respect to the recall
- the proposed strategy for conducting the recall, including the date for beginning the recall,
information as to how and when the Minister will be informed of the progress of the recall and
the proposed date for its completion
- the proposed action to prevent a recurrence of the problem
- the name, title and telephone number of the representative of the Manufacturer or importer to
contact for any information concerning the recall.
Verify that as soon as possible after the completion of the recall the Manufacturer and the importer
reports to the minister the results of the recall and the action taken to prevent a recurrence of the
problem [CMDR 65].
If the reports required by section 64 and 65 are submitted to the Minister just by the Importer, verify
that the Manufacturer has advised the Minister in writing that the reports the Manufacturer and
importer would have submitted were identical and that the Manufacturer has permitted the importer
to prepare and submit reports to the Minister on the Manufacturer’s behalf [CMDR 65.1].
For greater clarity and consistency with section 4.1.1 of Health Canada’s Recall Policy for Health
Products (POL-0016), AOs and auditors are advised of the following interpretations of the timelines
in sections 64 and 65 of the Medical Devices Regulations:
MDSAP AU P0002.007 91 | P a g e
Chapter 4 - Medical Device Adverse Events and Advisory Notices Reporting
Task 2 – Notification of advisory notices
Section 64 of the Medical Devices Regulations requires the manufacturer and importer of a medical
device to provide Health Canada with information concerning a recall "on or before undertaking a
recall". This is interpreted to mean that the manufacturer and importer must submit to Health Canada
as much recall information as is known within 24 hours of having made the decision to recall. This
initial notification may be made verbally or in writing. This must be followed by a written report
containing full information as required by section 64 within three business days of starting the recall.
As per section 65 of the Medical Devices Regulations, a report on the results of the recall and the action
taken to prevent a recurrence of the problem must be submitted as soon as possible after the
completion of a recall.
Japan (MHLW):
Marketing Authorization Holders are required to report advisory notices to Regulatory Authorities
[PMD Act 68-11].
Confirm that the person operating the Registered Manufacturing Site has determined and
implemented effective arrangement for communicating with the Marketing Authorization Holder in
relation to advisory notices [MHLW MO169: 29].
Note: Persons operating Registered Manufacturing Sites are not required to report any advisory notice
directly to regulatory authority, but shall communicate with the Marketing Authorization Holder, so
they can take necessary regulatory actions.
Verify that the manufacturer has a process in place to notify FDA in the event of actions concerning
device corrections and removals and to maintain records of those corrections and removals.
Verify that the written report to FDA of any correction or removal initiated to reduce a risk to health or
remedy a violation of the U.S. Food, Drug and Cosmetic Act is reported within 10 working days of
initiating the correction or removal. Confirm that the report contains the unique device identifier (UDI)
that appears on the device label or on the device package, or the device identifier, Universal Product
Code (UPC), model, catalog, or code number of the device and the manufacturing lot or serial number
of the device or other identification number.
Confirm that the manufacturer maintains records of any correction and removal not required to be
reported to FDA (e.g. corrections and removals conducted to correct a minor violation of the U.S.
Food, Drug and Cosmetic Act or no risk to health). Confirm that records of corrections and removals
not required to be reported contain the unique device identifier (UDI) that appears on the device label
MDSAP AU P0002.007 92 | P a g e
Chapter 4 - Medical Device Adverse Events and Advisory Notices Reporting
Task 2 – Notification of advisory notices
or on the device package, or the device identifier, Universal Product Code (UPC), model, catalog, or
code number of the device and the manufacturing lot or serial number of the device or other
identification number.
Links
Measurement, Analysis and Improvement
Corrections and removals are indicative that the product or process does not meet specified
requirements or planned results and the nonconformity was not detected prior to distribution.
When specified requirements or planned results are not achieved, correction and corrective action
must be taken as necessary.
During the audit of the Measurement, Analysis and Improvement process, confirm the medical
device organization has taken appropriate correction regarding devices already distributed, and
taken appropriate corrective action to prevent recurrence of the condition(s) that caused the
nonconformity.
MDSAP AU P0002.007 93 | P a g e
Chapter 5 - Design and Development
The management representative is responsible for ensuring that the requirements of the quality
management system have been effectively defined, documented, implemented, and maintained. Prior to the
audit of a process, it may be helpful to interview the management representative (or designee) to obtain an
overview of the process and a feel for management’s knowledge and understanding of the process.
Audit of the Design and Development process will follow audit of the Measurement, Analysis and Improvement
process per the MDSAP audit sequence. Information regarding product or quality system nonconformities
noted during audit of the Measurement, Analysis and Improvement process should be considered when
making decisions as to the design and development projects, including design changes resulting from
corrective actions, to be reviewed during the audit of the Design and Development process.
Review of the Design and Development process will also provide an opportunity to evaluate how the medical
device organization has utilized risk management activities to ensure design inputs are comprehensive and
meet user needs, to confirm that risk control measures that were planned have been implemented in the
design, and to verify that risk control measures are effective in controlling or reducing risk.
Additionally, review of design and development activities will assist the audit team during the audit of the
medical device organization’s Purchasing process because the auditor(s) has an opportunity to select suppliers
for review whose activities are associated with higher risk to the product or whose activities are critical to the
essential design outputs. The review of design and development activities also provides information to assist
the audit team in performing a final evaluation of the Management process at the conclusion of the audit.
Outcomes: As a result of the audit of the Design and Development process, objective evidence will show
whether the medical device organization has:
A) Defined, documented and implemented procedures to ensure medical devices are designed according
to specified requirements
B) Effectively planned the design and development of a device
Chapter 5 - Design and Development
Task 1 – Identification of devices subject to design and development procedures; technical
documentation
Australia (TGA):
When a Manufacturer applies TG(MD)R Division 3.2 and selects the Full Quality Assurance conformity
assessment procedures [TG(MR)R Schedule 3, Part1, (excluding or including clause 1.6)], quality management
system procedures for design and development must be available.
MDSAP AU P0002.007 95 | P a g e
Chapter 5 - Design and Development
Task 1 – Identification of devices subject to design and development procedures; technical
documentation
In addition, for all classes of devices, the guidance provided for the audit of technical documentation in Annex
1 is to be followed to ensure the availability of objective evidence that demonstrates compliance with the
Essential Principles of Safety and Performance.
Brazil (ANVISA):
According to Brazilian legislations, there is no exception to design control.
If design activities are outsourced, verify that the manufacturer has a complete device master record for the
device and records of the design transfer to production [RDC ANVISA 665/2022: Art. 52, Art. 63].
Canada (HC):
With respect to Class II devices that are not subject to Design and Development controls, verify that the
manufacturer has objective evidence to establish that Class II devices meet the safety and effectiveness
requirements of section 10 to 20 [CMDR 9, 10 to 20].
Japan (MHLW):
Class 1 devices are not required to comply with the requirements of MHLW MO169:30-36-2, which are
equivalent to the requirements of design and development in ISO13485 [MHLW MO169: 4.1].
Assessing conformity
Absence of design activity
The audit team may encounter situations where the medical device organization has not completed any design
projects, has no ongoing or planned design projects, and has not made any design changes (i.e., there has
been no design activity). At the minimum, verify that the medical device organization maintains a defined and
documented design change procedure. A medical device organization may also have defined and documented
other design control procedures. For that type of medical device organization — a medical device organization
with no design activity, including no design changes — assess the procedures the medical device organization
has in place. The audit team can then proceed to the audit of the next process.
In these cases, the medical device organization shall ensure that the supplier complies with the requirements of
design and development, established by Medical devices – Quality management systems – Requirements for
MDSAP AU P0002.007 96 | P a g e
Chapter 5 - Design and Development
Task 2 – Selection of a completed design and development project
regulatory purposes (ISO 13485:2016), the Quality Management System requirements of the Conformity
Assessment Procedures of the Australian Therapeutic Goods (Medical Devices) Regulations (TG(MD)R Sch3),
Brazilian Good Manufacturing Practices (RDC ANVISA 665/2022), Japanese QMS Ordinance (MHLW MO 169),
the Quality System Regulation (21 CFR Part 820), and any other specific requirements of medical device
regulatory authorities participating in the MDSAP program.
Links
Purchasing
If the medical device organization outsources design and development activities, or any portion of
the design and development, confirm that the medical device organization treats the outsourced
medical device organization as a supplier, has appropriately qualified and maintains control over
the supplier, communicates requirements to the supplier, including regulatory requirements, and
has arrangements to verify that the design and development activities satisfy those requirements.
MDSAP AU P0002.007 97 | P a g e
Chapter 5 - Design and Development
Task 3 – Design and development planning
Links
Measurement, Analysis and Improvement
At this point in the audit, the audit team will have already reviewed the Measurement, Analysis and
Improvement process. If the auditors noted corrective actions that resulted in design changes, or
noted product nonconformities that have been attributed to the design of the device, the audit
team should consider selecting those designs for review.
The audit team should be particularly mindful of how the identified quality problems from the
Measurement, Analysis and Improvement process are related to specific aspects of the design and
development of the device. For example, if the auditors review complaints related to a safety
feature of the device that is not performing as intended, the audit team should consider selecting
for review the design verification of that safety feature and determine whether appropriate risk
control methods were confirmed to be effective.
Review the design plan for the selected design and development project to understand the
design and development activities; including the design and development stages, the review,
verification, validation, and design transfer activities that are appropriate at each stage; and the
assignment of responsibilities, authorities, and interfaces between different groups involved in
design and development.
Australia (TGA):
Verify that effective planning for design and development is documented, typically as part of a Quality Plan
[TG(MD)R Sch3 P1 Cl 1.4(4)].
MDSAP AU P0002.007 98 | P a g e
Chapter 5 - Design and Development
Task 4 – Implementation of the design and development process
Canada (HC):
Verify that Manufacturers of Class IV devices maintain a quality plan that sets out the specific quality practices,
resources, and sequence of activities relevant to the device [CMDR 32].
Assessing conformity
Reviewing the design plan
Review the design plan for the selected project to understand the layout of the design and development
activities, including assigned responsibilities and interfaces.
The design plan for the selected project can be used by the audit team as a roadmap for the review of the
project.
Plans may vary depending on the type or size of the project. Some design plans may be expressed as simple
flowcharts, or for larger projects, Gantt or Program Evaluation Review Technique (PERT) charts may be used.
Plans do not have to show starting or completion dates for activities covered. However, plans must define
responsibility for implementation of the design and development activities and describe the interfaces with
different groups or activities.
Expect to see interfacing between research and development, marketing, regulatory, manufacturing, and
quality departments. The audit team might also see interfacing with purchasing, installers, and servicers. When
external institutions (e.g. universities or research and development centers) are involved in the design and
development activities, the interfaces between the medical device organization and those external institutions
must also be defined.
Design and development plans may change while the design and development process evolves; however, all
changes on the plan must be documented and approved.
Links
None
Confirm the design and development procedures address the design and development stages,
review, verification, validation, design transfer, and design changes.
MDSAP AU P0002.007 99 | P a g e
Chapter 5 - Design and Development
Task 4 – Implementation of the design and development process
Assessing conformity
Review of procedures
Design and development procedures set the structure, provide the framework, and support the medical device
organization’s Design and Development process. The purpose of auditing the procedures is to determine if the
medical device organization has that framework in place. If procedures have not been defined and
documented, or are deficient, the medical device organization’s devices may not meet user needs and intended
use.
In accomplishing this audit task, the audit team is to review the medical device organization’s procedures and
verify that the procedures address the requirements of the Medical devices – Quality management systems –
Requirements for regulatory purposes (ISO 13485:2016), the Quality Management System requirements of the
Conformity Assessment Procedures of the Australian Therapeutic Goods (Medical Devices) Regulations
(TG(MD)R Sch3), Brazilian Good Manufacturing Practices (RDC ANVISA 665/2022), Japanese QMS Ordinance
(MHLW MO 169), the Quality System Regulation (21 CFR Part 820), and specific requirements of medical device
regulatory authorities participating in the MDSAP program. For example:
- verify that the design input procedure includes a mechanism for addressing incomplete, ambiguous, or
conflicting requirements
- Verify that the output procedure ensures that essential outputs are identified
- Verify that the design review procedure ensures that each design review includes an individual who does
not have responsibility for the design stage being reviewed.
Minimum requirement
If the medical device organization has no ongoing or planned design projects, has not made any design
changes, then ensure that, at a minimum, the medical device organization maintains defined and documented
design change procedures.
Links
None
Verify that any risks and risk mitigation measures identified during the risk management
process are used as an input in the design and development process.
ANVISA: RDC ANVISA 665/2022: Art. 18, Art. 19, Art. 20, Art. 46, Art. 61
MHLW/PMDA: MO169: 6, 11, 27, 31, 55-1; [Old: 6, 11, 27, 31, 55]
Australia (TGA):
Verify that the Manufacturer has identified the relevant Essential Principles that apply to the medical device
[TG(MD)R Sch1 Essential Principles].
Verify that Manufacturer has taken into account post-production feedback as an input to monitoring and
maintaining product requirements and improving product realization processes.
Assessing conformity
Design inputs
Inputs are the physical and performance requirements of a device that are used as a basis for device design.
Inputs must be documented and approved by appropriate personnel. The audit team should review the
sources used to develop the inputs and determine that relevant aspects of the requirements for the device
were covered. These sources must include the relevant regulations where safety and performance criteria have
been defined (e.g. safety and efficacy requirements or Essential Principles of Safety and Performance).
Examples of relevant aspects include:
Organizations must take into account the current thinking of experts where published information is available
(e.g. Standards).
Design inputs may also relate to manufacturing processes particularly where validation, revalidation, the
periodic monitoring of critical process parameters, or the implementation of specified controls, is required to
assure the quality of product (e.g. sterilization, injection molding, control on the source, or inactivation of
transmissible agents in, materials of animal origin, or GMP controls on the handling, processing or
incorporation of a medicinal substance in a medical device).
Design inputs are the basis of the design verification and validation; therefore, design inputs need to be
defined and recorded as formal requirements that allow for confirmation to the design outputs.
Relevant information for design input can also come from post-production data or experience from similar
devices. Complaints, adverse events, feedback, and post-market surveillance form a feedback system that can
help drive quality improvements in new designs and changes to current designs.
Links
Device Marketing Authorization and Facility Registration
Confirm the medical device organization has considered regulatory requirements for registration,
listing, notification and licensing; and has complied with these requirements prior to marketing the
device in the applicable regulatory jurisdictions.
MHLW/PMDA: MO169: 31
FDA: 21 CFR820.30(c)]
Australia (TGA):
Confirm that design inputs include the relevant Essential Principles [TG(MD)R – Schedule 1].
Solutions adopted by the Manufacturer for the design and construction of a medical device are to conform to
safety principles that are derived from the generally acknowledged state of the art. [TG(MD)R – Sch 1 – EP2]
Safety principles are usually identified in internationally recognized standards.
Compliance with any given standard is not mandatory under Australian legislation however it is one way to
demonstrate compliance with the Essential Principles.
The TGA is to presume compliance with the relevant Essential Principles if the Manufacturer has applied, in full,
a relevant standard that is identified in a Medical Device Standards Order. (See TGA website - For example, ISO
10993).
If relevant standards have not been identified as design inputs, ensure that the Manufacturer has documented
a rationale to explain why alternatives have been applied to demonstrate compliance with the Essential
Principles [TG(MD)R Sch3 Part 1.4(5)(c)(iii)(C)].
Assessing conformity
Design inputs
Design inputs must be defined and recorded as verifiable requirements, approved by the appropriate
personnel. If the medical device organization does not have accurate and complete design inputs, the final
design may not meet user needs and intended use.
A common method for a medical device organization to confirm the design inputs for a design and
development project are complete, unambiguous, and not in conflict with each other is to perform a design
review after the initial requirements are determined.
Links
None
Verify that the design and development outputs essential for the proper functioning of the
medical device have been identified.
- device specifications
- specifications for the manufacturing process
- specifications for the sterilization process (if applicable)
- the quality assurance testing
- device labeling and packaging.
Australia (TGA):
If relevant standards have not been applied, or not been applied in full, ensure that the Manufacturer has
documented a rationale to explain why alternative methods have been applied to demonstrate compliance
with the Essential Principles [TG(MD)R Sch3 Part 1.4(5)(c)(iii)(C)].
For devices incorporating a medicinal substance, verify that documentation also identifies the data to be
derived from tests conducted in relation to the substance, and its interaction with the device [TG(MD)R Sch 3
Part 1.4(5)(c)(v)].
Assessing conformity
Design outputs
Design outputs are the work products or deliverables of a design stage. Design outputs can include
documents such as diagrams, drawings, specifications, and procedures for both products and processes. The
outputs from one stage may become inputs to the next stage. The total finished design output consists of the
specifications for the device, its packaging and labeling (including implant cards and leaflets, where applicable),
quality management system requirements, the manufacturing process, and if applicable, installation and
servicing requirements.
During this design stage, a tremendous number of records, or outputs, can be produced. Only the approved
outputs need to be retained. However, if a medical device organization chooses to retain other records, for
historical or other purposes, they may do so.
Essential outputs
Outputs that are essential for the proper functioning of the device must be identified. Typically, a medical
device organization can use a risk management tool to determine the essential outputs. To verify that this has
been done, the auditor(s) may review the medical device organization’s process for determining how the
essential outputs were identified and if it was done in accordance with their design output procedures.
The identification of essential outputs may influence other quality system activities. For example, the
establishment of manufacturing process controls and tolerances, the degree of purchasing controls and
acceptance activities applied to a supplier or the priority and depth of a failure investigation may be influenced
by whether or not the component (assembly, material, etc.) is considered an output essential for the proper
functioning of the device.
Design verification
In design verification, the medical device organization obtains objective evidence (i.e., data) that design outputs
meet design inputs. A medical device organization generates this objective evidence by conducting verification
activities such as tests, measurements, and analyses. These activities should be explicit and thorough in their
execution. A medical device organization’s verification activities should be predictive, not empiric. In other
words, acceptance criteria need to be stated in advance of the verification activity. The establishment of pre-
determined acceptance criteria should be documented in a verification protocol or similar document. During
the review of design verification activities, the auditor(s) will determine if the design verification data confirms
that design outputs met the design input requirements.
Verification techniques
Complex designs will require more and different types of verifications than simple designs. Sometimes a
medical device organization has to use its own expertise to develop (in-house) a way to verify a particular
aspect of a design. Any approach selected by a medical device organization is acceptable as long as it provides
reliable objective evidence that the output met the input.
Links
Purchasing, Production and Service Controls
During the review of a design project, the audit team should be mindful of production processes
and supplied products that are essential to the proper functioning of the device. Production
processes can include not only the manufacturing instructions, but also internal controls, such as
the type and extent of acceptance activities, equipment calibration and maintenance intervals,
environmental controls, and personnel controls. For suppliers that provide products and services
related to the essential design outputs, the degree of purchasing controls necessary is
commensurate with the effect of the supplied product on the proper functioning of the finished
device.
During the audits of the Purchasing process and Production and Service Controls process, the audit
team should consider reviewing production processes and supplied products that have the highest
risk or greatest effect on the essential design outputs.
Confirm that risk acceptability criteria are established and met throughout the design and
development process.
Verify that any residual risk is evaluated and, where appropriate, communicated to the
customer (e.g., labeling, service documents, advisory notices, etc.).
Note: In some instances, it may be necessary for the medical device organization to conduct a risk/benefit
analysis to justify a risk that cannot be mitigated to an acceptable level. Additionally, it may be necessary
to audit other processes (e.g. Production and Service Controls, Purchasing) to verify that risk
acceptability criteria are met, risk is controlled or reduced, and residual risk is communicated if
necessary.
ANVISA: RDC ANVISA 665/2022: Art. 18, Art. 19, Art. 20, Art. 61, RDC ANVISA 56/2001
Brazil (ANVISA):
Verify that the manufacturer has established and maintains a continuous process of risk management which
covers the entire life cycle of the product. Possible hazards must be identified in both normal and fault
conditions, including those arising from human factors issues. The risk associated with those hazards, shall be
calculated. Risks must be analyzed, evaluated and controlled, as necessary. Effectiveness of risk controls
implemented shall be evaluated [RDC ANVISA 56/2001, RDC ANVISA 665/2022: Art. 18, Art. 19, Art. 20].
Assessing conformity
Risk management
Each medical device organization must determine and document how much risk is acceptable. The actual use
of any medical device includes some measure of risk to users or patients. Determining an acceptable level of
risk depends on the intended use of the device, including the particular health concern of the patient
population, the training of the users involved, and the use environment. For example, pediatric patients may
have less ability to detect a device malfunction. A device used by consumers generally has less medical
oversight than a device used in a hospital setting. The goal of a risk management program is to ensure the
device is as safe as practical and the safety of the device is acceptable for the intended use.
Effective risk management usually starts in conjunction with the design and development process, proceeds
through product realization, including the selection of suppliers, and continues until the time the product is
decommissioned. Risk management should be initiated at a point early in the design and development
process. This includes defining the intended use of the device, considering risk under normal use and
reasonably foreseen misuse. Starting the risk management process after the design has progressed beyond a
point where reasonable risk mitigation features can be included in the design can lead to devices that do not
MDSAP AU P0002.007 108 | P a g e
Chapter 5 - Design and Development
Task 9 – Design verification or design validation to confirm effectiveness of risk control measures
meet customer needs and the medical device organization’s requirements for safety. Records of risk
management should demonstrate that risks that have been identified as unacceptable have been mitigated to
an acceptable level.
Mitigation of risks
There are a number of mechanisms that can be used to mitigate product risk. These risk mitigation
mechanisms, in descending order of effectiveness, include safety features inherent in the device design,
protective measures in the design (e.g. alarms), and user notifications (e.g. labeled warnings).
Links
None
ANVISA: RDC ANVISA 665/2022: Art. 18, Art. 19, Art. 20, Art. 48
Assessing conformity
Verification of risk control measures
During the review of design verification activities for the chosen design project, confirm that the identified risk
control measures are actually effective in reducing or controlling risk. For example, a design for an enteral
feeding tube may have a unique connector to prevent the potential for misconnection to other types of
devices, such as suction catheters. Design verification should show that it is difficult or impossible to connect
non-related devices to the enteral feeding tube.
Links
None
Verify that design validation testing is adjusted according to the nature and risk of the
product and element being validated.
ANVISA: RDC ANVISA 665/2022: Art. 18, Art. 19, Art. 20, Art. 49, Art. 53, Art. 54, Art. 55, Art. 56, Art. 57, Art. 58,
Art. 61
Australia (TGA):
For devices contain temperature sensitive material, environmental conditions should be considered for country
specific requirement. For example, test samples should be conditioned as per ISTA 2A to cover Australian
climate zone (extreme temperature range -29C-50C) for packaging validation.
Assessing conformity
Design validation
Design validation is performed to provide objective evidence that design specifications (outputs) conform to
user needs and intended uses. Design validation must be completed before commercial distribution of the
product. The design validation activities should be predictive, not empiric. In other words, acceptance criteria
need to be stated in advance of the validation activity. The establishment of pre- determined acceptance
criteria may be found in a validation protocol or similar document.
Design validation must be performed under defined operating conditions on initial production units, lots, or
batches, or their equivalents. Design validation shall ensure that devices conform to defined user needs and
intended uses and includes testing of production units under actual or simulated use conditions. The results of
the design validation, including identification of the design, method(s), the date, and the individual(s)
performing the validation, must be recorded.
Design validation needs to be performed for each intended use. Design validation must also confirm that user
needs and intended uses associated with the device’s packaging and labeling are met. These outputs have
human factors implications and unless they are adequately considered during design validation, they may
adversely affect the device and its use. Confirm that design validation data show that the approved design met
the predetermined user needs and intended uses. The intended uses must include the purpose of the device,
patient type (adults, pediatrics or newborn) and the environment in which the device is to be transported and
used (domestic use, hospitals, ambulances, etc.).
Links
None
ANVISA: RDC ANVISA 665/2022: Art. 53, Art. 54, Art. 55, Art. 56, Art. 57, Art. 58, Art. 61, RDC ANVISA 56/2001
Australia (TGA):
Verify that records of the validation include clinical evidence as required by the clinical evidence procedures
[TG(MD) Sch3 P1 Cl 1.4(5)(c)(vii) and TG(MD) Sch3 P8].
For more information about the sources and types of clinical evidence and how they may be used to
demonstrate compliance with the Australian EPs, auditors may refer to the clinical evidence guidelines (medical
devices)
Assessing conformity
Clinical evaluations and testing
Design validation may involve the performance of some sort of clinical evaluation, including testing under
actual or simulated use conditions. Clinical evaluations may involve full clinical studies. Clinical evaluations
may also consist of other evaluations in a clinical or non-clinical setting, provision of historical evidence that
similar designs are clinically safe, or reviews of scientific literature.
The audit team should limit their review of clinical evaluations to verifying whether clinical evaluations have
been performed as part of design validation, when necessary, and whether the medical device organization has
established acceptance criteria for the results in order to validate the device and that the results obtained meet
the defined acceptance criteria.
When applicable, review the clinical evaluations, if performed, to validate the design. The audit team should
confirm that the data from clinical evaluations demonstrates that the user needs and intended uses for the
device and its packaging and labeling were met.
Links
None
Confirm that the software was included within the risk management process.
ANVISA: RDC ANVISA 665/2022: Art. 18, Art. 19, Art. 20, Art. 53, Art. 54, Art. 55, Art. 56, Art. 57, Art. 58, Art. 61
HC: CMDR 20
Assessing conformity
Software development
Many devices are at least partially controlled by software. Some devices consist almost entirely of software. For
the device software, confirm that the software is part of the design and development plan for the device. The
life cycle requirements for medical device software must be defined, including the intended use.
Software verification
“Software verification” is a term often used to describe the testing of the software. During the review of the
software development, confirm that the medical device organization has conducted appropriate verification
activities. Verification is often accomplished by performing test cases at the unit, subsystem, and integration
levels; as well as system functional testing.
Software verification can include the testing of the software product installed on the target hardware. As with
other types of design verification, verification of software is a predictive activity. The acceptance criteria must
be determined prior to performing the testing.
The predetermined acceptance criteria are often found in a verification protocol or similar document. Confirm
that the predetermined acceptance criteria have been met by reviewing the actual results of the selected
software tests. The risk management activities for the device and software can help guide the audit team as to
which verification tests involve the essential design outputs of the device and software.
Software validation
Software validation is a “confirmation by examination and provision of objective evidence that software
specifications conform to user needs and intended uses, and that the particular requirements implemented
through software can be consistently fulfilled.” It involves checking for proper operation of the software in its
actual or simulated use environment, including integration into the final device where appropriate. Testing of
device software functionality in a simulated use environment, and user site testing are typically included as
components of an overall design validation program for a software automated device.
The audit team may encounter times when the software has been installed at user sites as part of validation,
often referred to as “beta testing”. Beta testing can be a method to confirm the device, including the software,
meets the user needs and intended uses.
Links
None
Confirm that any new risks associated with the design change have been identified and
mitigated to the extent practical.
ANVISA: RDC ANVISA 665/2022: Art. 18, Art. 19, Art. 20, Art. 49, Art. 53, Art. 54, Art. 55, Art. 56, Art. 57, Art. 58,
Art. 60, Art. 61, Brazilian Law 6360/76 - Art. 13
HC: CMDR 1, 34
MHLW/PMDA: MO169: 6, 7-2, 26, 36-1, 36-2, 55-1; [Old: 6, 26, 36]
Australia (TGA):
Verify that the Manufacturer has a process or procedure for notifying the Auditing Organization of a
substantial change to the design process or the range of products to be manufactured [TG(MD)R Sch3 Cl1.5].
Verify that the Manufacturer has a process or procedure for identifying a proposed substantial change to the
design, or the intended performance, of a Class AIMD or Class III device, and to notify the assessment body
prior to implementing the change [TG(MD)R Sch3 P1 Cl 1.6(4)].
If the Manufacturer is also a holder of a TGA Conformity Assessment Certificate, then the Manufacturer is also
required to notify the TGA of these changes.
Verify that Manufacturer has taken into account post-production feedback as an input to monitoring and
maintaining product requirements and improving product realization processes.
Brazil (ANVISA):
If the medical device evaluated is already registered/notified with ANVISA, verify that the design change was
correctly and promptly submitted to ANVISA for approval, when applicable [Brazilian Law 6360/76 - Art. 13].
Canada (HC):
Verify that the manufacturer has a process or procedure for identifying a “significant change” to a Class III or IV
medical device. Verify that information about “significant changes” is submitted in a medical device license
amendment application [CMDR 1, 34].
Japan (MHLW):
For the Marketing Authorization Holder, confirm if the Marketing Authorization Holder has submitted a new
application, a change application, or a change notification to PMDA/ a Registered Certification Body, when
applicable [PMD Act 23-2-5.1, 23-2-5.11, 23-2-5.12, 23-2-23.1, 23-2-23.6, 23-2-23.7].
For the Registered Manufacturing Site, confirm if the site has a mechanism to communicate with the Marketing
Authorization Holder about device modifications, so the Marketing Authorization Holder can take appropriate
actions. If a critical medical device modification has happened in the Registered Manufacturing Site, confirm if
the Registered Manufacturing Site has communicated with Marketing Authorization Holder about the change
[MHLW MO169: 29].
Assessing conformity
Procedures
A medical device organization may have separate change control procedures to handle the post-production
and pre-production changes, or a medical device organization may have one procedure that handles both.
Nature of change
The documentation and control of changes begins when the initial design inputs are approved and continues
for the life of the product. Design change control applies to changes to inputs or outputs as a result of design
verification or design validation, changes to labeling or packaging, changes to enhance a product’s
performance, changes of production process/es, and changes that result from product complaints. Change can
be acceptable as long as it is controlled.
Records
The control of changes is not complete until the results of the review of changes and any updates to product
specifications or changed processes are documented or amended.
Links
Measurement, Analysis and Improvement process (if a design change was made to correct a
quality problem with the device); Device Marketing Authorization and Facility Registration
During the audit of the Measurement, Analysis and Improvement process, the auditors may
encounter corrective actions or preventive actions that resulted in design changes. When
corrective action or preventive action involves changing the design, confirm that design controls
have been applied to the change, in accordance with the medical device organization’s procedures.
Confirm these design changes were effective in addressing the quality issues or potential quality
issues identified in corrective or preventive action. In addition, the design change should be
evaluated under the medical device organization’s risk management process to ensure that
changes do not introduce new hazards. Some changes may require revalidation where it is not
possible to verify that requirements have been met after the change has been implemented.
The audit team should also confirm the medical device organization has considered regulatory
requirements for registration, listing, notification and licensing; and has complied with these
requirements prior to marketing the changed device in the applicable regulatory jurisdictions.
Confirm that the participants in the reviews include representatives of functions concerned with
the design and development stage being reviewed, as well as any specialist personnel needed.
Assessing conformity
Design reviews
Design reviews typically occur at the end of each design stage or phase or after the completion of project
milestones. The number of design reviews can vary, but at a minimum, one formal review must be conducted.
Reviews should provide feedback to the design team on emerging problems, assess the progress of the design
and development project, and confirm that the design is ready to move to the next phase of development or
for transfer to the manufacturing phase.
It is not necessary to have fully convened meetings for all design reviews. For simple designs or minor
changes, desk reviews and sign-offs may be adequate. Design reviews must include an individual who does
not have direct responsibility for the design stage being reviewed and representation from manufacturing to
ensure that design and development outputs are verified as suitable for manufacturing before becoming final
production specifications.
During the review of design review activities for the selected design project, confirm that the reviews included
an individual who did not have direct responsibility for the design stage being reviewed. The audit team
should also confirm that outstanding action items are being resolved or have been resolved.
Links
None
MDSAP AU P0002.007 117 | P a g e
Chapter 5 - Design and Development
Task 15 – Impact review of design and development changes on previously made and distributed
devices
Assessing conformity
Effects on constituent parts and products already delivered
There are situations where a design change can affect constituent parts. For example, a change to a disposable
portion of an aspiration system might affect the ability of the disposable to connect to the console. When
necessary, ensure the design change does not negatively impact products in distribution.
Links
None
ANVISA: RDC ANVISA 665/2022: Art. 52, Art. 54, Art. 55, Art. 56, Art. 57, Art. 58, Art. 61
Brazil (ANVISA):
Confirm that the manufacture ensures that the design is not released for production until its approval by the
persons assigned by the manufacturer and that the person/s assigned review all records required to the design
history file in order to ensure it is complete and the final design is compatible with the approved plans, prior to
its release. Confirm that this release, including date and manual or electronic signature of the responsible is
documented [RDC ANVISA 665/2022: Art. 58, Art. 61].
Assessing conformity
Transferring the design to production
During this phase, the design is translated into production specifications. This can take place in steps or
phases. The audit team should review how the design for the selected project was transferred into production
specifications. Based on the medical device organization’s identification of essential outputs and risk
management activities, review significant elements of the manufacturing processes, including products from
suppliers and the established tolerances for processes, and compare them with the approved design outputs
contained within the design records. These activities can confirm whether or not the design was correctly
transferred.
Design transfer is a process that may be initiated not only at the end of the design and development process,
but may also be initiated immediately before validation stages and may continue as design and development
evolves. This early initiation of design transfer is helpful in order to have production processes and device
validations conducted properly and allow for corrections during the process. At the end, design and
development process is “finalized” by a “final design transfer.”
Links
Production and Service Controls, Purchasing
Verify that production processes for the device, including process validation (if required) have been
defined, documented, and implemented. Confirm that potential hazards that could be introduced
or exacerbated by the production process have been identified, and production controls have been
established. Production processes include not only the manufacturing instructions, but also
internal controls, such as the type and extent of acceptance activities, equipment calibration and
maintenance intervals, environmental controls, and personnel controls.
Confirm that the medical device organization has determined the type and extent of supplier
controls based on the relationship between the supplied products and services and product risk.
Links
None
In order to meet the Production and Service Controls requirements of Medical devices – Quality management
systems – Requirements for regulatory purposes (ISO 13485:2016), the Quality Management System
requirements of the Conformity Assessment Procedures of the Australian Therapeutic Goods (Medical Devices)
Regulations (TG(MD)R Sch3), Brazilian Good Manufacturing Practices (RDC ANVISA 665/2022), Japanese QMS
Ordinance (MHLW MO 169), the Quality System Regulation (21 CFR Part 820), and specific requirements of
medical device regulatory authorities participating in the MDSAP program, the medical device organization
must understand when deviations from device specifications could occur as a result of the production process
or environment.
The management representative is responsible for ensuring that the requirements of the quality
management system have been effectively defined, documented, implemented, and maintained. Prior to the
audit of a process, it may be helpful to interview the management representative (or designee) to obtain an
overview of the process and a feel for management’s knowledge and understanding of the process.
Audit of the Production and Service Controls process will follow audit of the Measurement, Analysis and
Improvement process and the Design and Development process per the MDSAP audit sequence. Information
the audit team has learned about device and quality management system nonconformities during audit of the
Measurement, Analysis and Improvement process, as well as higher risk elements and essential design outputs
from the design projects reviewed during audit of the Design and Development process, should be used to
make decisions as to the production processes to be reviewed during the audit of the Production and Service
Controls process.
Outcomes: As a result of the audit of the Production and Service Controls process, objective evidence will
show whether the medical device organization has:
Chapter 6 - Production and Service Controls
Task 1 – Planning of production and service process
A) Defined, documented and implemented procedures to ensure production and service processes are
planned, developed, conducted, controlled, and monitored to ensure conformity to specified
requirements
B) Developed production and service process controls commensurate with the potential effect of the
process on product risk
C) Ensured that when the results of a process cannot be verified by subsequent monitoring or
measurement, the process is validated with a high degree of assurance that the process will consistently
achieve the planned result
D) Implemented procedures for the validation of the application of computer software for production and
service processes that affect the ability of the product to conform to specified requirements, including
validation of computer software used in the quality management system
E) Maintained records for each batch of medical devices that provides information for traceability and
confirmation that the batch meets specified requirements
F) Implemented controls to protect customer property, including intellectual property, confidential health
information, and other forms of customer property that is used or incorporated into products
Confirm that the planning of product realization is consistent with the requirements of the
other processes of the quality management system and performed in consideration of the
quality objectives.
ANVISA: RDC ANVISA 665/2022: Art. 5°, Art. 6°, Art. 7°, Art. 44, Art. 52, Art. 64, Art. 65, Art. 66
Assessing conformity
Planning
In planning product realization, the medical device organization must determine as appropriate the quality
objectives and requirements for the product, the processes, documents, and resources specific to the product,
the criteria for product acceptance, and the required verification, monitoring, inspection, and test activities
specific to the product. Planning of product realization often begins in the design and development of the
product, including the translation of the design into production specifications.
The planning of product realization should be consistent with the risk control and mitigation strategies
identified by the medical device organization during risk management activities.
During the audit, be mindful of requirements for the product that relate to statutory and regulatory
requirements, requirements necessary for the product to meet specified or intended uses, and requirements for
safe and efficacious use of the product. The medical device organization must ensure their processes, and the
monitoring of processes, inspection, and test activities are planned and developed to ensure these
requirements are met.
The requirements of the rule are generally directed at labelers. Labeler is defined in 21 CFR 801.3.
Two main factors determine if a party is a labeler: (1) a labeler causes a label to be applied to a device with the
intent that the device will be commercially distributed without any intended subsequent replacement or
modification of the label, or (2) a labeler causes a label to be replaced or modified with the intent that the
device will be commercially distributed.
Manufacturers, contract manufacturers, private label distributors, and convenience kit assemblers are the most
common types of organizations that are considered labelers. Some small exceptions apply, such as adding a
name or contact information to the already existing label.
The UDI program requires labelers to work with an FDA accredited issuing agency to produce their UDIs. The
issuing agency provides a portion of the UDI to identify the labeler, as well as providing a standards compliant
format for the display of the UDI in easily readable plain text and AIDC code.
The UDI rule requires device labelers to meet two basic requirements: (1) the devices must bear a UDI in the
appropriate location, (2) and certain data elements must be entered in the Global Unique Device Identification
Database (GUDID). The GUDID is a database maintained by the UDI team at FDA that serves as a public facing
repository for UDI related device information.
Under the UDI rule, all medical devices, regardless of class (and including unclassified devices) must comply
with the requirements of the rule, unless covered by an exemption or enforcement discretion.
Quality objectives
Quality objectives are typically expressed as a measurable target or goal. The planning of product realization
should include consideration of how the production processes, the criteria for product acceptance, and the
required verification, validation, monitoring, inspection, and test activities specific to the product will achieve
the quality objectives. Confirm that the medical device organization has defined quality objectives for the
device.
Links
Management
Confirm when necessary that the quality objectives related to the product were considered for
inclusion in management review.
Reminder: Information the audit team has learned about device and quality management system
nonconformities during audit of the Measurement, Analysis and Improvement process, as well as higher risk
elements and essential design outputs from the design projects reviewed during audit of the Design and
Development process should be used to make decisions as to the production processes to be reviewed.
Links
None
ANVISA: RDC ANVISA 665/2022: Art. 30, Art. 63, Art. 62, Art. 64, Art. 65, Art. 66, Art. 84, Art. 88
Assessing conformity
Establishment of work instructions, procedures, and production processes
Production processes that may cause a deviation to a device specification and all validated processes must be
controlled and monitored. The planning of production includes the establishment of procedures and work
instructions for the control and monitoring of the production processes, including service controls when
necessary. Control and monitoring procedures may include in-process and finished device acceptance activities
as well as environmental and contamination control measures. The establishment of procedures and work
instructions to control the production of the device should provide the controls and tolerances necessary to
ensure finished devices conform to product specifications.
Links
None
Brazil (ANVISA):
Confirm that a pest control program has been established and where chemicals are used as part of the pest
control program, the company must ensure that they do not affect product quality [RDC ANVISA 665/2022: Art.
74].
Verify that the manufacturer has established and maintains housekeeping procedures and schedules for
production areas and warehouses, in conformance with production specifications [RDC ANVISA 665/2022: Art.
69].
Assessing conformity
Cleanliness requirements
The goal of establishing requirements for product cleanliness is to minimize contamination of the finished
device and the manufacturing environment. Sterile devices may require a higher level of control in terms of
minimizing the bioburden and particulate contamination in order to assure the desired sterility assurance level
is met.
Each medical device organization must evaluate the extent of cleanliness required for the proper functioning
and intended use of the finished device and implement the necessary control measures. Examples of control
measures include, but are not limited to, cleaning procedures, environmental controls (e.g. cleanrooms, or
other controlled environments), requirements for attire, and training of personnel. When necessary, confirm
the medical device organization has identified the cleanliness requirements for the finished device and the
proper controls to achieve the required level of cleanliness.
Process agents
Process agents, also known as manufacturing materials, are generally defined as materials or substances used
to facilitate the manufacturing process, which are present in or on the finished devices as a residue or impurity.
Examples of process agents include cleaning agents, mold- release agents, lubricating oils, latex proteins,
sterilant residues, etc. The medical device organization must evaluate process agents used during the
manufacturing process when the process agent could potentially have an adverse effect on the product.
During the design of the product and the development of the manufacturing process, the potential effect of
process agents should be considered.
If the audit team encounters situations where process agents are being utilized in the manufacturing of the
product, and the process agent could potentially have an adverse effect on the product, confirm that the
medical device organization has made effective arrangements to control the process agent in a manner
commensurate with the risk the agent poses to the finished device. For example, the medical device
organization may need to validate a cleaning process to ensure cutting oil is removed from an orthopedic
implant prior to packaging and sterilization.
Links
None
Task 5 – Infrastructure
Verify that the medical device organization has determined and documented the infrastructure
requirements to achieve product conformity, including buildings, workspace, process
equipment, and supporting services.
Confirm that buildings, workspaces, and supporting services allow product to meet
requirements.
Verify that there are documented and implemented requirements for maintenance of process
equipment where important for product quality, and that records of maintenance are
maintained.
HC: CMDR 14
Brazil (ANVISA):
Verify that manufacturing facilities are configured in order to provide adequate means for people flow [RDC
ANVISA 665/2022: Art. 67].
Assessing conformity
Infrastructure requirements
The medical device organization is responsible for evaluating the manufacturing facility to ensure that the
buildings, utilities, and space allow for the achievement of product conformity. The medical device
organization is responsible for ensuring adequate space to prevent mix-ups and ensure orderly handling of
products.
Equipment maintenance
The medical device organization must consider whether maintenance of production equipment may affect
product quality. Procedures, including the frequency of maintenance and the records of maintenance must be
available for these items of equipment.
Links
None
- health, cleanliness, and clothing of personnel that could have an adverse effect on product quality
- monitoring and controlling work environment conditions that can have an adverse effect on product
quality
- training or supervision of personnel who are required to work under special environmental conditions
- controlling contaminated or potentially contaminated product (including returned products) in order to
prevent contamination of other product, the work environment, or personnel
Brazil (ANVISA):
Verify that biosafety standards are used, when applicable [RDC ANVISA 665/2022: Art. 76].
Assessing conformity
Contamination control
The medical device organization is responsible for establishing and maintaining procedures to prevent
contamination of products, equipment, and personnel by substances that could adversely affect the device. If
contamination control measures are necessary to meet specified requirements, cleaning and sanitation
procedures and schedules may be required to ensure the contamination control measures are properly
functioning. The medical device organization should consider the segregation and decontamination of
returned product.
Personnel practices
Personnel practices must address personnel health, cleanliness, and attire if these could adversely affect
product quality or the work environment. In the event that maintenance or other personnel are required to
work temporarily under special environmental conditions, these individuals must be appropriately trained or
supervised by a trained individual.
Links
None
ANVISA: RDC ANVISA665/2022: Art. 103, Art. 104, Art. 105, Art. 106
Brazil (ANVISA):
Verify that analytical methods, supporting auxiliary systems for production and environmental control that can
adversely affect product quality or the quality system are validated, periodically reviewed and, when necessary,
revalidated according to documented procedures [RDC ANVISA 665/2022: Art. 103, Art. 104, Art. 105, Art. 106].
Assessing conformity
Process validation
During the planning of product realization, the medical device organization must determine which production
processes require validation and which processes can be verified. Process validation may apply to processes
that generate components, subassemblies, or finished devices. Process validation is required for processes
MDSAP AU P0002.007 130 | P a g e
Chapter 6 - Production and Service Controls
Task 8 – Process validation
where the results of the process cannot be fully verified. Processes that cannot be fully verified include
processes where clinical or destructive testing is necessary to show that the process produced the desired
result, where routine inspection and/or testing does not examine quality attributes essential to the proper
functioning of the finished device, or where routine testing has insufficient sensitivity to verify the desired
safety and efficacy of the finished product.
Examples of processes that require validation include, but are not limited to sterilization, aseptic processing,
welding, and injection molding. When applicable, confirm that the medical device organization has identified
processes which require validation, including validation requirements for any outsourced processes.
When validating processes, organizations must take into account the current thinking of experts where
published information is available (e.g. though the application of ISO standards for sterilization validation).
Links
Purchasing
The audit team may encounter situations where the medical device organization outsources
processes that require validation.
During the review of the Purchasing process, review the controls the medical device organization
has instituted over suppliers that perform validated processes. This can be particularly important
for higher risk validated processes performed by suppliers, since the finished device manufacturer
does not have immediate control over those processes.
Confirm that the validation demonstrates the ability of the process/es to consistently achieve
the planned result.
In the event changes have occurred to a previously validated process, confirm that the process
was reviewed and evaluated, and re-validation was performed where appropriate.
MHLW/PMDA: MO169: 6, 45
Australia (TGA):
Confirm that methods of validation have regard to the generally acknowledged state of the art (e.g. current
Medical Device Standard Orders - MDSO, ISO/IEC Standards, BP, EP, USP etc.) [TG Act s41CB, TG(MD)R Sch 1 P1
2(1)].
Assessing conformity
Process validation
Process validation means establishing by objective evidence (i.e. data) that a process consistently produces a
result (e.g., sterility assurance level) or product meeting predetermined specifications. Remember that the
term “product” applies to components and in-process devices as well as finished devices. Therefore, process
validation may apply to processes that generate components, in-process devices, or finished devices.
Reviewing a validation
During review of a validation study, determine when applicable whether:
- The instruments used to generate the data were properly calibrated and maintained
- Predetermined product and process specifications were established
- Sampling plans used to collect test samples are based on a statistically valid rationale
- Data demonstrates predetermined specifications were met consistently
- Process tolerance limits were challenged
- Process equipment was properly installed, adjusted, and maintained
- Process monitoring instruments were properly calibrated and maintained
- Changes to the validated process were appropriately challenged (if applicable)
- Process operators were appropriately qualified.
validation. The data from the process validation study must show the predetermined acceptance criteria have
been met.
Evidence of nonconformities
Process validation studies may also provide valuable insight into process or product nonconformities. For
example, the process validation study must demonstrate not only that the process can produce a result or
product meeting predetermined specifications but also that the process will consistently produce a result or
product meeting predetermined specifications. If process or product nonconformities related to a validated
process are encountered at a higher than anticipated rate, it may indicate the process validation study did not
confirm that the process could consistently produce a result or product meeting predetermined specifications.
Unless the medical device organization recognized this during the process validation study, they may not have
investigated the cause of the process inconsistency.
Links
None
Verify the sterilization process is validated, periodically re-validated, and records of the
validation are available.
Verify that devices sold in a sterile state are manufactured and sterilized under appropriately
controlled conditions.
Determine if the sterilization process and results are documented and traceable to each batch of
product.
ANVISA: RDC ANVISA 665/2022: Art. 83, Art. 103, Art. 104, Art. 105, Art. 106
HC: CMDR 17
Australia (TGA):
Verify that methods of sterilization validation have regard to the generally acknowledged state of the art (e.g.
Australian Medical Device Standard Orders – MDSO e.g. Medical Device Standards Order (Endotoxin
Requirements for Medical Devices) 2018) or Australian Conformity Assessment Standard Orders -
Conformity Assessment Standards Order (Quality Management Systems) 2019 that refer to the use of ISO
11135, ISO 11137 and other standards). [TG(MD)R Sch1 P1 2(1)].
Assessing conformity
Validation of sterilization processes
Sterilization processes include terminal sterilization methods (such as radiation and ethylene oxide) as well as
aseptic processing methods. Sterilization processes must be validated, with periodic revalidation as required
by established standards or requirements established by the medical device organization.
- routine monitoring and measurement of the cleaning, packaging and sterilization processes
- routine acceptance criteria of the cleaning, packaging and sterilization processes
- (re-)qualification, (re-)verification, (re-)calibration and maintenance of the cleaning, packaging and
sterilization equipment
- environmental control of production areas (cleanroom design and monitoring)
- storage of device parts, components, and packaging material
- storage of finished sterile product and management of shelf life
- handling processes for non-sterile devices for re-sterilization.
Links
None
Confirm that product risk is considered in the type and extent of product monitoring
activities.
ANVISA: RDC ANVISA 665/2022: Art. 18, Art. 19, Art. 20, Art. 64, Art. 131
Assessing conformity
Monitoring systems
The general goal of monitoring processes and product characteristics during production is to ensure that
products conform to the specified requirements defined and approved during the design and development of
the device. The medical device organization has the flexibility to determine the controls that are necessary,
commensurate with the risk to the finished device if processes or product characteristics do not meet specified
requirements. During the audit of production processes, confirm that the control measures are suitable for
detecting process or product nonconformities.
Links
None
In addition, verify that risk control measures identified by the medical device organization
for production processes are implemented, monitored and evaluated.
ANVISA: RDC ANVISA 665/2022: Art. 18, Art. 19, Art. 20, Art. 64, Art. 83, Art. 128, Art. 131
MDSAP AU P0002.007 135 | P a g e
Chapter 6 - Production and Service Controls
Task 11 – Control, operation, and monitoring of the production and service process; risk controls
Australia (TGA):
See Annex 1
Assessing conformity
Process control and monitoring
Processes that may cause a deviation to device specifications and validated processes must be controlled and
monitored. Control and monitoring procedures may include in-process and finished device acceptance
activities as well as environmental and contamination control measures.
Compare the process monitoring and acceptance procedures contained or referenced within the records of
production specifications with those available to the production personnel. Confirm that the procedures
available to the production personnel are the most current approved revisions.
While in the production area, verify that the building is of suitable design and contains sufficient space to
perform necessary operations. Also, verify that the results of control and monitoring activities demonstrate
that the process is currently operating in accordance with applicable procedures. This can be done by
comparing work instructions with what is actually being done, comparing product acceptance criteria with
acceptance activity results, reviewing control charts against specified requirements, etc.
Links
Design and Development
The design outputs for a device include documents such as diagrams, drawings, specifications,
procedures, and the production processes that are essential to the proper manufacturing of the
device. Production processes can include not only the manufacturing instructions, but also internal
controls, such as the type and extent of acceptance activities, equipment calibration and
maintenance intervals, environmental controls, and personnel controls.
During the audit of the Production and Service Controls process, consider reviewing production
processes that have the highest risk or greatest effect on the essential design outputs.
MHLW/PMDA: MO169: 22
Assessing conformity
Personnel training and qualification
Production processes must be performed by adequately trained personnel. The medical device organization
must establish procedures for identifying training needs and ensure that all personnel are trained to
adequately perform their assigned responsibilities.
This training must be documented. In addition, personnel who perform validated processes must be qualified.
It is management’s responsibility to determine what qualifications are necessary for personnel who perform
validated processes.
Links
Management
During the audit of the Production and Service Controls process, ensure that employees who are
involved in key operations that affect product realization and product quality have been trained in
their specific job tasks, as well as the quality policy and objectives.
When appropriate, review the training records for those employees whose activities have
contributed to process nonconformities.
Verify that the monitoring and measuring equipment used in production and service control
has been identified, adjusted, calibrated and maintained, and capable of producing valid results.
Assessing conformity
Maintenance and calibration
While reviewing the selected production process, make note of significant pieces of process equipment and
significant pieces of measuring or test equipment. Consider selecting process and test equipment that, if not
properly controlled, could cause devices to not meet specified requirements; or produce inaccurate results that
could lead to unrecognized nonconformities. Confirm that the production and test equipment selected for
review is suitable for its intended purpose and capable of giving valid results.
Review the maintenance, control, and calibration procedures (and records) for the equipment selected for
review. The initial frequency with which measuring and test equipment is calibrated and maintained is usually
based on the equipment manufacturer’s recommendations. As the medical device organization gains
experience with the piece of equipment, the frequency of calibration and maintenance may be adjusted, based
on a documented rationale.
Reviewing records
If production equipment or test equipment is found to be outside of its maintenance or calibration
requirements, verify that the medical device organization made an assessment of the effect of the out-of-
tolerance situation on in-process, finished, or released devices, based on risk. Equipment adjustment,
calibration, and maintenance procedures and records may provide insight into nonconformities. Review these
procedures and records to determine whether inadequate procedures or the medical device organization’s
failure to comply with adequate procedures contributed to the nonconformity. For example, determine
whether the lack of specified equipment adjustment or maintenance contributed to the production of
nonconforming product.
Links
None
Verify that the control of the monitoring and measuring devices is adequate to ensure valid
results. Confirm that monitoring and measuring devices are protected from damage or
deterioration.
MHLW/PMDA: MO169: 53
Assessing conformity
Control of monitoring and measuring devices
Organizations must maintain proper calibration, storage, and handling controls for measuring, monitoring, and
test equipment used in the development, production, installation, and servicing of product. Calibration must
be traceable to a national or international measurement standard if one is available. If calibration services are
provided by a supplier, the supplier controls are to be applied to ensure calibration is performed competently.
Proper controls will help instill confidence in results obtained from the use of the equipment.
Procedures
Organizations must define, implement, and maintain procedures for the control of monitoring and measuring
devices. The medical device organization may choose to develop general policies for the control of monitoring
and measuring devices, along with separate, more specific procedures for the actual calibration and control of
each piece of equipment.
Procedures must account for any environmental controls necessary for the equipment to produce valid results,
as well as any specific storage or handling requirements when necessary. For example, a set of calibrated
calipers may require storage in a padded case to maintain the required accuracy and precision. Confirm that
the medical device organization has the proper procedures and controls in place to preserve the proper
functioning of monitoring, measuring, and test equipment.
Links
None
Task 15 – Validation of software used for the control of the production and
service process
If the selected process is software controlled, or if software is used in production equipment or
the quality management system, verify that the software is validated for its intended use.
Assessing conformity
Validation of production and quality system software
Production process control software (and any other software used in the medical device organization’s quality
system) must be validated for its intended use according to an established protocol. If the production process
the audit team selected for review is controlled with software, review the software validation documents and
records.
- A software requirements document describing the intended use(s) and user needs associated with the
software.
- An established validation protocol or similar document describing the activities necessary to demonstrate
that the software requirements can be met.
- Records of the results of the software validation activities described in the software validation protocol or
similar document.
- Records that software changes are appropriately controlled (where applicable).
For off-the-shelf quality management system software and software-controlled production or test equipment,
it may not be possible, practical, or necessary for the medical device organization to review the software code
or the various software verification test cases that are typically performed by the software or equipment
manufacturer. However, the medical device organization must still ensure the software is capable of
functioning according to the device medical device organization’s needs. The validation to confirm the
software meets the medical device organization’s needs must be performed according to a protocol or similar
document with predetermined acceptance criteria.
If multiple software driven systems are used in the production process, be sure to assess the system(s) most
likely to have an impact on the finished device’s ability to meet specified requirements. Not all software driven
systems used in a production process will need to be audited during each audit.
Links
None
MDSAP AU P0002.007 141 | P a g e
Chapter 6 - Production and Service Controls
Task 16 – Device master file
Confirm that the medical device organization determined the extent of traceability based on
the risk posed by the device in the event the device does not meet specified requirements.
ANVISA: RDC ANVISA 665/2022: Art. 18, Art. 19, Art. 20, Art. 63, Art. 64, Art. 84, Art. 85, Art. 86, Art. 87
MHLW/PMDA: MO169: 6, 7-2, 26, 47, 48; [Old: 6, 26, 47, 48]
Australia (TGA):
Verify that the design and location of information to be provided with a medical device, including labelling and
instructions for use, comply with Essential Principle 13 and implant cards and leaflets with Essential principle
13A.
Brazil (ANVISA):
Verify that the manufacturer has established and maintains procedures to ensure integrity and to prevent
accidental mixing of labels, instructions, and packaging materials [RDC ANVISA 665/2022: Art. 85].
Confirm that the manufacturer has ensured that labels are designed, printed and, where applicable, applied so
that they remain legible and attached to the product during processing, storage, handling and use [RDC
ANVISA 665/2022: Art. 86].
Canada (HC):
Verify that the Manufacturer maintains objective evidence that devices meet the safety and effectiveness
requirements. [CMDR 9(2)].
Verify that devices sold in Canada have labeling that conforms to Canadian English and French language
requirements and contains the Manufacturer’s name and address, device identifier, control number (for Class III
MDSAP AU P0002.007 142 | P a g e
Chapter 6 - Production and Service Controls
Task 16 – Device master file
and IV devices), contents of packaging, sterility, expiry, intended use, directions for use and any special storage
conditions [CMDR 21-23].
Verify that the Manufacturer maintains distribution records in respect of a device that will permit a complete
and rapid withdrawal of the device from the market [CMDR 52-56].
Assessing conformity
Records
The required records for each type or model of device include documents such as diagrams, drawings,
specifications, and procedures associated with the device, its packaging and labeling; as well as, quality
management system and production process requirements; and if applicable, installation and servicing
requirements. Documents and records associated with production processes can include not only the
manufacturing instructions, but also internal controls, such as the type and extent of acceptance activities,
equipment calibration and maintenance intervals, environmental controls, and personnel controls.
These documents and records provide the requirements and instructions for the proper manufacturing,
labeling, packaging, and testing of the device to assure specified requirements are met during the production
of each batch of devices. For the device(s) the audit team has selected to review, confirm that the required
records have been established.
General traceability
It is the responsibility of the medical device organization to establish procedures for traceability. For devices
that are not implanted and are not life-supporting or life-sustaining, the medical device organization has the
flexibility to determine which raw materials and components are required to be traceable, commensurate with
the risk posed by the device in the event the component does not meet specified requirements.
Traceability systems commonly include elements such as written procedures describing the control numbering
system to be used, as well as the documentation of lot numbers, control numbers, or serial numbers identifying
the batch of components, subassemblies, finished devices, packaging, and labeling in order to aid their
identification in the manufacturing process.
Links
Design and Development
During the design and development of the device, the essential design outputs for the proper
functioning of the device should have been identified. Raw materials, components, and
subassemblies should have been considered for traceability if their nonconformity could result in
the finished device not meeting its specified requirements and essential functions.
ANVISA: RDC ANVISA 665/2022: Art. 39, Art. 113, Art. 114
Brazil (ANVISA):
Verify that the device history record of the product includes or refers to the following information: date of
manufacture; components used; quantity manufactured; results of inspections and tests; parameters of special
processes; quantity released for distribution; labeling; identification of the serial number or batch of
production; and final release of the product [RDC ANVISA 665/2022: Art. 40].
Verify that labeling has not been released for storage or use until a designated individual has examined the
labeling for accuracy. The approval, including the date, name, and physical or electronic signature of the
person responsible, must be documented in the device history record [RDC ANVISA 665/2022: Art. 87].
(UPC), expiration date, control number, storage instructions, handling instructions, and any additional
processing instructions [21 CFR 820.120(b)].
Confirm that labeling is stored in a manner that provides proper identification and prevents mix-ups. Verify
labeling and packaging operations are controlled to prevent labeling mix-ups [21 CFR 820.120(c) and (d)].
Verify that the label and labeling used for each production unit, lot, or batch are documented in the batch
record, as well as any control numbers used [21 CFR 820.120(e), 820.184(e)].
Assessing conformity
Verify manufacturing of the device
Verify that each batch of devices was manufactured in accordance with product and production specifications,
being mindful that in some instances, a batch can be a single device. This verification should include a review
of the purchasing controls and receiving acceptance activities applied to at least one significant component or
raw material, in-process and final finished device acceptance activities and results, environmental and
contamination control records (if applicable), and sampling plans for process and environmental controls and
monitoring.
The record for each batch of devices must include, or refer to the location of, the following information:
Links
None
Confirm that the medical device organization requires that agents or distributors of these
devices maintain distribution records and makes them available for inspection.
Verify that the medical device organization records the name and address of shipping
consignees for these devices.
Canada (HC):
Verify that the Manufacturer has identified Schedule 2 implants and provides implant registration cards with
devices or employs another suitable system approved by Health Canada [CMDR 66-68].
Verify that the Manufacturer of devices that are listed on Schedule 2 of the Medical Devices Regulations
maintains distribution records of these devices as well as any information received on implant registration
cards related to these Schedule 2 devices [CMDR 54].
Assessing conformity
Traceability of implantable, life-supporting or life-sustaining devices
Medical device organizations that produce finished devices whose failure could result in serious injury or harm
to the user must implement a traceability system. The traceability system must allow for each batch of finished
devices to be traced by a control number or similar mechanism throughout the distribution chain.
Organizations must also provide for the control and traceability of components and materials used in the
manufacture of the device, as well as documentation of the manufacturing conditions when manufacturing
conditions could cause the finished device to not meet specified requirements (e.g. cleanroom conditions).
The determination of which components and raw materials may be required to be traceable may be made by
the medical device organization using risk management tools, such as risk analysis, or by identification of the
components and processes used to fulfill the essential design outputs.
If the medical device organization manufactures or distributes a device that falls under a tracking requirement,
confirm that the medical device organization has the necessary systems in place to provide for tracking each
device to the end-user.
The medical device organization’s tracking system must be periodically reviewed and audited by the medical
device organization to confirm that the tracking system is effective. The tracking system must contain the
unique device identifier (UDI), lot number, batch number, model number, or serial number of the device or
other identifier necessary to provide for effective tracking of the devices.
Links
None
Assessing conformity
Identification
Identification is generally defined as the description of the product that distinguishes it from other product.
Organizations must define, document, and implement processes for the identification and control of product,
including components, process agents, subassemblies, finished devices, packaging, and labeling. This can be
accomplished through the use of part numbers, lot numbers, batch numbers, work order numbers, quantities,
supplier name, as well as other means. The extent of identification activities should be based on the complexity
and risk of the product.
Links
None
Verify that the medical device organization treats patient information and confidential health
information as customer property.
MHLW/PMDA: MO169: 51
Assessing conformity
Safeguarding customer property
The medical device organization is responsible for safeguarding customer property while it is under the
medical device organization’s control. If any customer property is lost, damaged, or otherwise unsuitable for
use, this must be reported to the customer and records maintained.
Links
None
MDSAP AU P0002.007 148 | P a g e
Chapter 6 - Production and Service Controls
Task 21 – Acceptance activities
Confirm that the extent of acceptance activities is commensurate with the risk posed by the
device.
Note: Acceptance activities apply to any incoming component, subassembly, or service, regardless of the
medical device organization’s financial or business arrangement with the supplier.
ANVISA: RDC ANVISA 665/2022: Art. 88, Art. 89, Art. 90, Art. 131
Brazil (ANVISA):
Verify that sampling plans are defined and based on valid statistical rationale. Each manufacturer must
establish and maintain procedures to ensure that sampling methods are suitable for their intended use and are
reviewed regularly. A review of sampling plans should consider the occurrence of nonconforming product,
quality audit reports, complaints and other indicators [RDC ANVISA 665/2022: Art. 132, Art. 133, Art.134].
Assessing conformity
Recognized acceptance activities
Organizations are expected to define, document, and implement systems and procedures for acceptance
activities to verify that products, including finished devices, in-process devices, components, packaging, and
labeling conform to specified requirements. Recognized acceptance activities include, but are not limited to,
inspections, tests, review of certificates of analysis, and supplier audits. Effective acceptance procedures and
systems directly affect the ability of a medical device organization to demonstrate that the process and product
meets specifications.
MDSAP AU P0002.007 149 | P a g e
Chapter 6 - Production and Service Controls
Task 21 – Acceptance activities
During the audit of acceptance activities for the devices selected for audit, confirm that the medical device
organization has defined processes for receiving, in-process, and final acceptance activities. Determine if the
acceptance activities have been implemented. One way to accomplish this audit task is to review a sample of
batch records and confirm that the acceptance activities have been documented and that the acceptance
activities show specified requirements have been met. Records should identify who conducted acceptance
activities.
The acceptance status of incoming, in-process, and finished devices must be identified. The identification of
acceptance status must be maintained throughout manufacturing, packaging, labeling, and where applicable,
installation and servicing to ensure that only product which has passed the required acceptance activities is
distributed, used, or installed.
Sampling
The audit team may encounter the use of sampling during acceptance activities. For example, a medical device
organization might choose to use sampling to perform receiving acceptance on a large lot of incoming
components. When used, sampling plans must be written and based on a valid statistical rationale and a risk-
based methodology.
Combination of controls
An important concept to remember is that quality cannot be inspected or tested into products. Organizations
must establish an appropriate mix of acceptance activities and purchasing controls to ensure products will
meet specified requirements. The type and extent of acceptance activities can be based in part on the amount
of purchasing controls applied to the supplier, the demonstrated capability of the supplier to provide quality
products, and the potential impact of the product on the finished device, including the risk the device poses to
the patient or user if specified requirements are not met. Organizations that conduct quality control solely in-
house must still assess the capability of suppliers to provide acceptable products.
not sufficient to identify nonconformities. Confirm that the medical device organization has taken the
appropriate action to determine the suitability of the acceptance activities.
Links
Purchasing, Design and Development
The audit team should consider reviewing the purchasing controls and requirements for suppliers
of higher risk products. The audit team should also consider reviewing the purchasing controls and
requirements for suppliers of products that undergo minimal acceptance activities at the medical
device organization, particularly if the supplied product is manufactured using a process that
requires validation. During the review of acceptance activities, if the audit team encounters
situations where records of acceptance activities for supplied product reveal products that do not
meet specified requirements, consider selecting those suppliers for review during the audit of the
medical device organization’s Purchasing process.
The establishment of the necessary purchasing controls and required acceptance activities is a
design output. The degree of the purchasing controls necessary and extent of acceptance activities
should be based on the risk posed by the product not meeting its specified requirements and
essential design outputs.
MHLW/PMDA: MO169: 47, 60-1, 60-2, 60-3, 60-4; [Old: 47, 50, 60]
Assessing conformity
Procedures
The purpose of controlling nonconforming product is to prevent the unintended use and distribution of
nonconforming product, including components, processing agents, in-process devices, and finished devices.
Confirm that the medical device organization has defined and implemented procedures for the identification,
control, segregation, evaluation, and disposition of nonconforming product.
Until a disposition can be made, the medical device organization must have a process to properly identify
nonconforming product to prevent its accidental or unauthorized use. One example is tagging and moving the
nonconforming product to a controlled enclosure away from the production area.
If nonconforming product is accepted under concession, the records of the identity of the person authorizing
the concession must be maintained.
If nonconforming product has been detected after a product has been released and put into use the medical
device organization must consider the risks associated with the device and may need to consider an advisory
notice or recall.
Links
Measurement, Analysis and Improvement
The audit team should be mindful of any instances where the acceptance of nonconforming
product has led to finished devices not meeting specified requirements. This information can often
be found in records of acceptance activities and complaint records.
During the review of the medical device organization’s corrective and preventive actions, the
auditors may have noted instances where nonconforming products were found to be the
underlying cause of quality problems and complaints. The audit team should consider reviewing
the medical device organization’s handling and evaluation of nonconforming products that were
determined to be the underlying cause of quality problems.
Ensure that the analysis of data regarding nonconforming product is considered as an input to the
medical device organization’s Measurement, Analysis and Improvement process and that corrective
or preventive actions have been implemented when necessary.
Verify that the rework process has been performed according to an approved procedure, that
the results of the rework have been documented, and that the reworked product has been re-
verified to demonstrate conformity to requirements.
Assessing conformity
Reworking nonconforming product
The audit team may encounter instances where the medical device organization has chosen to address
nonconforming product by means of reworking the component, subassembly or finished device. The medical
device organization must have suitable approved procedures in place to address nonconforming product
destined for rework. Reworked product must be re-evaluated or re-tested to ensure it meets its original
specified requirements. Rework must be documented.
Be mindful of instances where the underlying cause of quality problems, such as complaints that finished
devices do not meet specified requirements, are traced to devices that have been reworked. This can be an
indication that the rework process was not adequate to ensure the finished device meets specifications.
Additionally, rework of products manufactured using validated processes can be an indication that the process
cannot consistently produce product that meets specified requirements. If the audit team notes a pattern of
reworking products that are manufactured using a validated process, consider reviewing the process validation
to confirm that the medical device organization has data to show the process is effective, reproducible, and
stable; and that the medical device organization is operating the process within the validated parameters.
Links
None
ANVISA: RDC ANVISA 665/2022: Art. 84, Art. 107, Art. 111
HC: CMDR 14
Assessing conformity
Ensuring proper handling
The medical device organization must have a documented system that defines product handling requirements
at all stages of manufacturing to prevent mix-ups, damage, and deterioration. This can include specified
requirements for storage and shipping to ensure the preservation of the product to its destination. For
example, an in-vitro diagnostic device may need to be stored and shipped in a frozen state to maintain proper
shelf-life of the reagents. or test samples may need to be conditioned as per ISTA 2A to cover Australian
climate zone (extreme temperature range -29C-50C) for packaging validation These handling requirements
should have been considered during the planning of product realization for the device. When necessary,
confirm that the needed control measures are implemented to ensure the conformity of product to its
specified requirements.
Links
None
Verify that the medical device organization maintains documentation required by regulatory
authorities regarding maintenance of distribution records.
Brazil (ANVISA):
Verify that the manufacturer maintains distribution records which include or make reference to: the name and
address of the consignee, the identification and quantity of products shipped, the date of dispatch, and any
numerical control used for traceability [ANVISA RDC 6.3].
Canada (HC):
Verify that the Manufacturer maintains distribution records that contain sufficient information to permit
complete and rapid withdrawal of the medical device from the market [CMDR 52-53].
Verify that distribution records of a device are retained by the Manufacturer in a manner that will allow for
timely retrieval, for the longer of (a) the projected useful life of the device; and (b) two years after the date the
device was shipped [CMDR 55-56].
Assessing conformity
Distribution records
The medical device organization must maintain distribution records which include or refer to the location of
the initial consignee, the identification and quantity of devices shipped, the date shipped, and any control
numbers used.
Links
None
MHLW/PMDA: MO169: 42
Assessing conformity
Installation activities
When a device must be installed for suitable functioning, the medical device organization must establish
procedures and instructions to ensure proper installation. These instructions must be made available to
personnel performing the installation. Installation activities must be documented.
Links
None
Confirm that service records are used as a source of quality data in the Measurement, Analysis
and Improvement process.
Brazil (ANVISA):
Confirm that the manufacturer has established and maintains procedures to ensure that records of servicing
activities are kept with the following information:
Verify that the manufacturer periodically reviews the records of servicing activities. In cases where the analysis
identifies trends that pose danger or records involving death or serious injury, a corrective or preventive action
must be initiated [RDC ANVISA 665/2022: Art. 130].
Confirm that service reports are documented and include the name of the device serviced, any unique device
identifier (UDI) or universal product code (UPC), and any other device identification(s) and control number(s)
used; and the date of service [21 CFR 820.200(d)].
Assessing conformity
Procedures
When servicing is a specified requirement, the medical device organization must define and maintain
procedures, instructions, and processes for performing and verifying that servicing activities meet specified
requirements.
Servicing process
When organizations implement servicing programs, the medical device organization must ensure components
used for repair are acceptable for the intended use, inspection and test procedures are available, and test
equipment is properly maintained to ensure serviced devices will perform as intended after servicing.
Personnel performing service activities must have the appropriate training.
The audit team may observe instances where nonconformities occurred and/or complaints were received after
the servicing of the device. This can be an indication that the service activity was not properly controlled or
that service personnel do not have the proper equipment, instructions, or training to perform the required
service.
In some instances, product complaints may be initially recorded by the medical device organization as a service
report. For example, a user may report to the medical device organization that a patient blood parameter
monitoring device is not working correctly and requires service. Upon receipt of the device from the user by
the medical device organization’s service function, the service function notes the reason the monitoring device
is not working is that an essential component within the device failed prematurely. This service report should
be considered by the medical device organization to be a complaint and analyzed by the medical device
organization to determine if an adverse event report needs to be submitted to regulatory authorities.
Links
Measurement, Analysis and Improvement
During the audit of the medical device organization’s Measurement, Analysis and Improvement
process, the audit team may have already confirmed that quality data from the analysis of servicing
activities is analyzed for possible corrective or preventive action. When reviewing the medical
device organization’s service reports, the audit team should be mindful of service reports that
appear to be product complaints. Ensure that service reports that appear to be complaints have
been appropriately addressed.
In some instances, a similar quality problem for a particular device may be found in the service
reports and the complaint records. In these instances, confirm that the medical device organization
is taking appropriate corrections and/or corrective actions considering a similar quality problem is
observed in multiple data sources.
Assessing conformity
Risk control
The requirements for delivery, installation, and servicing of a particular device should have already been
evaluated and addressed by the medical device organization during design and development and planning for
product realization.
If risk control measures were identified involving the delivery, installation, and servicing for a particular device,
confirm that the necessary processes have been implemented to ensure the risk control measures are in place.
For example, a medical device organization may have identified that in order for a medical imaging device to
give accurate images, servicing must be performed by trained personnel according to specific instructions.
Risk control measures might include warnings on the imaging device that only authorized personnel should
service the device and the design of a unique tool to access the inside of the device that is only provided to
authorized service personnel.
Links
None
Links
None
Chapter 7 - Purchasing
The intent of the Purchasing process is to ensure that purchased, subcontracted, or otherwise received
products and services conform to specified requirements. The medical device organization is expected to
establish and maintain documented controls for planning and performing purchasing activities.
The controls necessary depend on the effect of the product on the quality, safety, and effectiveness of the
finished device. Effective purchasing processes incorporate purchasing requirements and specifications, the
selection of acceptable suppliers based on the capability of the suppliers to provide acceptable product, the
performance of necessary acceptance activities, and maintenance of the required quality records.
The management representative is responsible for ensuring that the requirements of the quality
management system have been effectively defined, documented, implemented, and maintained. Prior to the
audit of a process, it may be helpful to interview the management representative (or designee) to obtain an
overview of the process and a feel for management’s knowledge and understanding of the process.
The Purchasing process is integral to the other processes of the MDSAP audit sequence. As the audit is being
performed of the medical device organization’s Measurement, Analysis and Improvement process, Design and
Development process, and Production and Service Controls process, the audit team should be assessing the
affect purchased product has on the quality of the finished device. The audit team should be using information
learned about actual and potential product and process nonconformities during the audit of the Measurement,
Analysis and Improvement process, higher risk elements and essential design outputs from the design projects
reviewed during audit of the Design and Development process, in addition to significant outsourced product
and production processes identified during the audit of the Production and Service Controls process to make
decisions as to supplier evaluation files to be reviewed during the audit of the Purchasing process.
The medical device organization’s purchasing process may be reviewed in conjunction with the Measurement,
Analysis and Improvement process, the Design and Development process, and the Production and Service
Controls process, being mindful of the MSDAP process linkages. The Purchasing process should be considered
a critical process for those organizations that outsource essential activities such as design and development
and/or production to one or more suppliers.
Outcomes: As a result of the audit of the Purchasing process, objective evidence will show whether the medical
device organization has:
MHLW/PMDA: MO169: 5-2, 5-3, 5-5, 26, 37, 38, 39; [Old: 5, 26, 37, 38, 39]
Assessing conformity
Planning
In planning product realization, the medical device organization must determine as appropriate the quality
objectives and requirements for the purchased products, the processes, documents, and resources specific to
the purchased products, the criteria for purchased product acceptance, and the required verification,
monitoring, inspection, and test activities specific to the purchased products. Planning of product realization
often begins in the design and development of the product, including the translation of the design into
production specifications. The translation of the design into production specifications includes the
establishment of specified requirements for purchased product.
Quality objectives
Quality objectives are typically expressed as a measurable target or goal. The planning of product realization
should include consideration of how the purchased product, the criteria for purchased product acceptance, and
the required verification, monitoring, inspection, and test activities specific to the purchased product will
achieve the quality objectives.
Links
Design and Development, Management
During the review of a design project, confirm that the medical device organization has considered
the effect of purchased product on the essential design outputs. For suppliers that provide product
and services related to the essential design outputs, the degree of purchasing controls necessary is
commensurate with the effect of the supplied product on the proper functioning of the finished
device.
During the audit of the Purchasing process, confirm when necessary that the degree of control over
suppliers of purchased product has been made based on the risk the supplied product poses to the
ability of the finished device to meet specified requirements.
Additionally, confirm when necessary that the quality objectives related to the purchased product
were considered for inclusion in management review.
1. Indications of problems with supplied products or processes from audit of the Measurement, Analysis
and Improvement process
2. Suppliers of higher risk products or processes
3. Suppliers who provide products or services that directly impact the design outputs required for proper
functioning of the device
4. Suppliers of processes that require validation or revalidation
5. Newly approved suppliers of products or services
6. Suppliers of products or services used in the manufacturing of multiple products
7. Suppliers of components or services not covered during previous audits
Links
None
MHLW/PMDA: MO169: 37
Assessing conformity
Procedures
The medical device organization must define, document, and implement procedures to ensure that purchased
product conforms to specified requirements. These procedures commonly contain information as to the
mechanisms by which the medical device organization is going to categorize suppliers based on the risk the
supplied product has on the ability of the finished device to meet specified requirements, the criteria the
medical device organization intends to use to evaluate the suppliers, the means of determination that a
supplier is acceptable, the methods for supplier monitoring, the requirements for re-evaluating suppliers, and
the means by which a supplier might be determined to be unacceptable.
It is important to remember that the requirements for purchasing controls apply to all product received from a
supplier by the medical device organization that have an impact on product realization, whether a payment
occurs or not, and regardless of the corporate or financial affiliation between the supplier and the medical
device organization.
Links
None
Task 4 – Extent of controls applied to the supplier and the purchased product;
criteria for selection, evaluation, and re-evaluation of the supplier
Verify that the procedures assure the type and extent of control applied to the supplier and the
purchased product is dependent upon the effect of the purchased product on subsequent
product realization or the final product.
Verify that criteria for the selection, evaluation and re-evaluation of suppliers have been
established and documented.
MHLW/PMDA: MO169: 37
Assessing conformity
Extent of control
The type and extent of control applied to the supplier must take into consideration the affect the supplied
product has on the finished device. Procedures commonly contain methods to categorize suppliers, based on
the importance of the supplied product to the proper functioning of the finished device and the past history (if
applicable) of the supplier.
Be mindful of organizations that use a “one-size-fits-all” approach to managing their suppliers, as these
systems may not provide the necessary amount of evaluation and oversight over suppliers of products
essential for the proper functioning of the finished device.
Evaluation criteria
The medical device organization must define, document, and implement procedures outlining the criteria for
the selection, evaluation and re-evaluation of suppliers. The procedures for supplier evaluation and selection
typically include such items as the methods by which suppliers will be evaluated and the means and frequency
by which supplier performance will be monitored.
The evaluation of suppliers must provide a means to assess the capability of the supplier to supply products
that meet specified requirements. The medical device organization can assess a supplier’s capability to supply
quality product in a number of ways, including but not limited to performing supplier audits, first-article
inspections, supplier surveys, and reviewing the supplier’s past history in supplying a similar product or service
if applicable.
The medical device organization may also choose to consider the supplier’s conformity with quality
management system requirements through third party certifications; however, third party certification should
not be relied on exclusively in initially evaluating a supplier.
Links
None
Confirm that the degree of control applied to the supplier is commensurate with the
significance of the supplied product or service on the quality of the finished device, based on
risk.
ANVISA: RDC ANVISA 665/2022: Art. 16, Art. 17, Art. Art. 18, Art. 23
Australia (TGA):
The conformity assessment procedures require that a Manufacturer demonstrates compliance with the
Essential Principles through application of a QMS. Hence a Manufacturer must show how risk management
principles have been applied during design and construction, including purchasing, to mitigate risk. (EP 2 -
TG(MD)R Sch1 P1 2).
The conditions of marketing authorization (ARTG inclusion) require that Australian Sponsors undertake some
regulatory activities including; customer complaint handling (Act s 41FN, Reg 5.8), the management and
communication of technical files /technical documentation (Act s 41FN(3)), adverse event reporting (Act s 41FN,
Reg 5.7), conducting recalls (Part 4-9), ensuring that the name and address of the Sponsor is provided with the
device (Reg 10.2), the storage of devices (Act s 41FN,Reg 5.9) and the keeping of complaint and distribution
records (Act s 41FN,Reg 5.10). Some Sponsors also provide services for the installation and servicing of a
device on behalf of the Manufacturer.
Where a regulatory requirement for a Sponsor intersects with a regulatory requirement or a requirement of
ISO13485 for the Manufacturer, the activity is to be treated as an outsourced activity and documented in the
Manufacturer’s QMS. Verify that the Manufacturer has adequate supplier controls to mitigate risk and ensure
the Sponsor fulfils the outsourced activities included in a written agreement [TG Act 41FN] for those activities.
Other activities that may be outsourced to the Sponsor include making applications on behalf of the
Manufacturer to the TGA [TG Act s41EB], representing the Manufacturer in interactions with the TGA [TG Act
s41FN(3)], as an intermediary in recalls of products [TG(MD)R Sch 3 - Part 1:1.4(3)], in the notification of
substantial changes to a kind of medical device (TG Act s41BE) that may require a variation to an entry in the
Australian Register of Therapeutic Goods (TG Act s9D), for the provision of records [TG(MD)R Schedule 3 - Part
1:1.5, 1.9 ], or other matters that may be required to allow the Sponsor to fulfill market authorization conditions
[TG Act Part 4-5 Div 2].
The requirement of Regulation 10.2 for “ensuring that the name and address of the Sponsor is provided with
the device in such a way that the user of the device can readily identify the Sponsor” is only an obligation on
the Sponsor. This activity does not need to be included in the Manufacturer’s QMS documentation however
the arrangements for the provision of this information should be disclosed in the written agreement between
the Manufacturer and the Sponsor. In cases where an activity performed by the Sponsor also includes the
provision of information required by Essential Principle 13 (Labels and IFU) or 13A (implant cards and leaflets)
the Manufacturer must treat the Sponsor as supplier for that activity.
The Sponsor does not need to be treated as a supplier if the scope of the Manufacturer’s quality management
system includes the site and activities of the Sponsor. The oversight of the Sponsors activities should be clearly
documented in the QMS and be included in plans for internal audit.
Canada (HC):
Verify that any regulatory correspondent used by the Manufacturer is treated as a supplier and is adequately
qualified.
Assessing conformity
Supplier selection
The selection of suppliers must be based on defined criteria. An important concept to remember is that quality
cannot be inspected or tested into products. Medical device organizations that choose to conduct product
quality control solely in-house must still assess the capability of suppliers to provide acceptable product.
Some organizations require suppliers to maintain various types of certifications or registrations. While
registrations and third-party certifications may be considered in supplier evaluations, the medical device
organization should not exclusively rely on these methods to perform the initial evaluation of suppliers.
For the supplier(s) the audit team has chosen to review, confirm that the medical device organization’s
selection of the supplier was based on defined criteria commensurate with the risk posed if the supplied
product causes the finished device to not meet specified requirements.
For the supplier(s) the audit team has selected, review the medical device organization’s evaluation of the
supplier(s). Confirm that the evaluation was made according to defined criteria and is commensurate with the
effect the supplied product has on the essential design outputs.
Links
Design and Development, Production and Service Controls
The establishment of the necessary purchasing controls and required acceptance activities is a
design output. The degree of the purchasing controls necessary and extent of acceptance activities
should be based on the risk posed by the product not meeting its specified requirements and
essential design outputs.
Auditors may encounter situations where the medical device organization outsources processes
that require validation.
During the review of the Purchasing process, review the controls the medical device organization
has instituted over suppliers that perform validated processes. This typically includes confirming
that the medical device organization has reviewed the process validation data generated by the
supplier to ensure the process is effective, reproducible, and stable. This can be particularly
important for higher risk validated processes performed by suppliers, since the medical device
organization does not have immediate control over those processes.
The audit team should also consider reviewing the purchasing controls and requirements for
suppliers of products that undergo minimal acceptance activities by the medical device
organization.
MHLW/PMDA: MO169: 37
Assessing conformity
Monitoring supplier performance
The medical device organization must define and implement processes to monitor the performance of
suppliers. The monitoring of supplier performance should not be based solely on cost considerations or on-
time deliveries. The monitoring of suppliers should take into consideration the actual performance of the
supplier in terms of providing products that meet specified requirements. Examples of supplier monitoring
activities may include, but are not limited to supplier re-audits, statistical analysis of incoming acceptance
results, monitoring of complaints and nonconformities related to supplied product, independent confirmation
of certificate of conformance data, and consideration of the supplier’s responses to requests for corrective
action.
In order for the supplier to maintain a status as an acceptable supplier, the supplier must be capable of
supplying product that consistently meets the medical device organization’s specified requirements. If supplier
monitoring does not demonstrate that the supplier has the capability to provide acceptable products, the
medical device organization must have a means to undertake appropriate action, including such activities as
requesting corrective action from the supplier, and in some cases, removing the supplier from records of
acceptable suppliers.
For the supplier(s) the audit team has chosen to review, confirm that the supplier monitoring is documented
and reviewed by the appropriate individuals responsible for supplier selection. Be particularly mindful of
instances where supplied product has caused complaints and/or product nonconformities. Verify that the
medical device organization has performed the appropriate monitoring of the supplier and taken actions when
necessary, such as requesting the supplier undertake a corrective action.
Links
Production and Service Controls, Measurement, Analysis and Improvement
Organizations are expected to define, document, and implement systems and procedures for
acceptance activities to verify that supplied products conform to specified requirements. Effective
acceptance procedures and systems directly affect the ability of a medical device organization to
demonstrate that supplied products meets specifications. During the audit of the Production and
Service Controls process, confirm that the appropriate acceptance activities have been
implemented and monitored to ensure the received product meets specified requirements.
Additionally, organizations are required to determine, collect, and analyze appropriate data to
demonstrate the ability of suppliers to provide acceptable product. During the audit of the
Measurement, Analysis and Improvement process, confirm that analysis of supplier performance
data has been performed and considered for corrective or preventive action when necessary.
MHLW/PMDA: MO169: 37
FDA: 21 CFR820.50(a)]
Assessing conformity
Supplier re-evaluation intervals
Organizations must implement the appropriate combination of supplier evaluation, supplier monitoring, and
acceptance activities to provide the necessary confidence in the acceptability of supplied product. However,
supplier evaluation is not a “one-time” assessment. The medical device organization must ensure the
continued capability of the supplier to provide product that meets specified requirements. The frequency of
re-evaluation must be performed according to the medical device organization’s procedures and at intervals
consistent with the significance of the product or service on the finished device. The frequency of re-
evaluation may change based on identified quality problems with the supplied product.
For the supplier(s) the audit team has chosen to review, confirm that the re-revaluation of the supplier was
performed commensurate with the risk the supplied product poses to the ability of the finished device to meet
specifications.
Links
Measurement, Analysis and Improvement
The frequency and extent of supplier re-evaluation activities may be based, in part, on the
performance of the supplier as demonstrated by such activities as statistical monitoring of the
supplier, monitoring of complaints and nonconformities related to supplied product, and corrective
or preventive actions related to the supplier.
Confirm that the medical device organization ensures the adequacy of specified purchase
requirements prior to their communication to the supplier and that a written agreement with
the supplier is established in which suppliers has to notify the medical device organization
about changes in the product.
MHLW/PMDA: MO169: 6, 38
Brazil (ANVISA):
Confirm that purchase orders are approved by a designated person. This approval, including date and
signature, shall be documented [RDC ANVISA 665/2022: Art. 27].
Assessing conformity
Adequacy of purchasing information
Purchasing information is commonly provided to suppliers in documents such as, but not limited to,
specification sheets, drawings, contracts, purchase orders, and quality agreements. The amount of detail
required in the purchasing information must be commensurate with the effect of the supplied product on the
performance of the finished device.
finished device is borne by the medical device organization. The medical device organization is responsible for
identifying any risk control measures that are required for the supplied product. For suppliers that provide
product and services related to the essential design outputs, the degree of necessary risk control measures is
commensurate with the effect of the supplied product on the proper functioning of the finished device.
Some examples of risk control measures related to supplied product include, but are not limited to, requiring
the supplier to use quality assurance procedures approved by the medical device organization, the
establishment of inspections or testing of supplied product before shipment to the medical device
organization, requiring each incoming shipment be accompanied by a certificate of conformance, periodic
verification of the certificate of conformance by third-party laboratory analysis, implementation of acceptance
activities at the medical device organization based on the risk the supplied product poses to the ability of the
finished device to meet specifications, and the verification of validation data by the medical device organization
for validated processes performed by a supplier.
For the supplier(s) files the audit team has selected for review, confirm that risk control measures have been
identified when appropriate and the risk control measures have been implemented and are effective. If the
auditor(s) observe that supplied product has been identified as an underlying cause of complaints and
nonconformities, this can be an indication that the risk control measures are inadequate or ineffective.
Links
None
Confirm that documents and records for purchasing are consistent with traceability
requirements where applicable.
ANVISA: RDC ANVISA 665/2022: Art. 24, Art. 25, Art. 113
Assessing conformity
Documenting purchasing information
Purchasing information must describe the product to be purchased, including (when appropriate) the
requirements for approval of product, procedures, processes, and equipment, the requirements for
qualification of personnel, and quality management system requirements related to the purchased product.
Where possible, the purchasing information must contain an agreement that the supplier agrees to notify the
medical device organization of changes in products or services that may affect the quality of the finished
device. The medical device organization should approve or reject these changes, based on the impact of the
change on the essential design outputs of the finished device.
Purchasing information may be recorded in written or electronic format, but must be documented.
Traceability
It is the responsibility of the medical device organization to establish procedures for traceability. For devices
that are not implanted and are not life-supporting or life-sustaining, the medical device organization has the
flexibility to determine which raw materials and components are required to be traceable, commensurate with
the risk posed by the device in the event the component does not meet specified requirements.
Medical device organizations that produce finished devices whose failure could result in serious injury or harm
to the user, or are implanted or life-supporting or life-sustaining must implement a traceability system. The
traceability system must allow for each batch of finished devices to be traced by a control number or similar
mechanism throughout the distribution chain. Organizations must provide for the control and traceability of
components and materials used in the manufacture of the device when these could cause the finished device
to not meet specified requirements.
The determination of which components and raw materials may be required to be traceable may be made by
the medical device organization using risk management tools, such as risk analysis, or by the identification of
the components and processes used to fulfill the essential design outputs.
Links
None
Confirm that the medical device organization has implemented an appropriate combination
of controls applied to the supplier, the specification of purchase requirements, and
acceptance verification activities that are commensurate with the risk of the supplied
product upon the finished device.
ANVISA: RDC ANVISA 665/2022: Art. 22, Art. 41, Art. 42, Art. 89
Brazil (ANVISA):
Verify that the manufacturer has established and maintains procedures to ensure the retention of components,
raw materials, in-process products and returned products until inspections, tests or other specified verifications
have been performed and documented [RDC ANVISA 665/2022: Art. 91].
Assessing conformity
Establishment of acceptance activities
The medical device organization must establish an appropriate combination of supplier assessment and
receiving acceptance activities to ensure products and services, including sterilization services are acceptable
for their intended use. After a supplier has been approved, the necessary acceptance activities for the supplied
product must be implemented. The degree of acceptance activities may vary with the type and significance of
the product or service on the quality of the finished device and the extent of measures performed by the
supplier to ensure product acceptability.
Organizations are expected to define, document, and implement processes and procedures for acceptance
activities to verify that supplied products conform to specified requirements. Recognized acceptance activities
include, but are not limited to, inspections, tests, reviews of certificates of analysis, and supplier audits.
MDSAP AU P0002.007 175 | P a g e
Chapter 7 - Purchasing
Task 10 – Verification of purchased products
Effective acceptance procedures and systems directly affect the ability of a medical device organization to
demonstrate the process and product meet specifications.
It is important to remember that acceptance activities apply to any incoming component, subassembly, or
service, whether a payment occurs or not, and regardless of the medical device organization’s financial or
business arrangement with the supplier.
The medical device organization can address nonconforming product by taking action to eliminate the
detected nonconformity (e.g. sorting an incoming lot of components to remove components that do not meet
specifications), authorizing its use, release, or acceptance under concession, or by taking action to prevent its
original intended use (e.g. allowing the components to be used as training aids to show production personnel
the difference between an acceptable and unacceptable component).
For the supplied product(s) the audit team has chosen to review, confirm the records of verification activities
have been maintained. One way to perform this task is to request a sample of verification records for the
chosen product and confirm the acceptance activities have been documented, including the documentation
and appropriate disposition of nonconforming product.
Links
Production and Service Controls
The audit team may encounter instances where product has been deemed acceptable by the
successful completion of acceptance activities but the product is later shown to not meet specified
requirements (e.g. failure of the device due to nonconforming component leading to product
complaint). This can be an indication that the acceptance activities are not sufficient to identify
nonconformities; or were not appropriately conducted.
Confirm that the medical device organization has taken the appropriate action to determine the
suitability of the acceptance activities. For example, the medical device organization may need to
validate the test method used for incoming acceptance to ensure the test method is actually
capable of identifying nonconforming product.
MHLW/PMDA: MO169: 61
Assessing conformity
Collection and analysis of data
The medical device organization is responsible for assuring the supplied product meets specified requirements.
In addition to supplier evaluation, the assurance that the supplied product meets specified requirements is
accomplished with the implementation of appropriate acceptance activities and monitoring complaints and
nonconformities associated with purchased product. The data regarding acceptance activities and
nonconformities must be analyzed as appropriate to determine the need for corrective or preventive action.
Links
Measurement, Analysis and Improvement
The medical device organization must determine the appropriate acceptance activities for supplied
product, based on the essential design outputs of the device and the risk the device poses if
specified requirements are not met. Confirm as necessary that supplied product was evaluated as
to the effect on the essential design outputs. Additionally, verify that the appropriate acceptance
activities were implemented based on the potential effect the supplied product poses to the
essential design outputs.
Organizations are required to determine, collect, and analyze appropriate data to demonstrate the
ability of suppliers to provide acceptable product. During the audit of the Measurement, Analysis
and Improvement process, confirm that analysis of supplier performance data from evaluation and
monitoring supplier process activities has been performed and considered for corrective or
preventive action when necessary.
Links
None
- IMDRF/MDSAP WG/N3FINAL:2016 (2nd Ed) does not provide additional requirements for product
certification (ISO/IEC 17065:2012) or the requirements of product testing (ISO/IEC 17025:2005)
The following is explicitly excluded from the scope of IMDRF/MDSAP WG/N3FINAL:2016 (2nd Ed) due to the
lack of regulatory convergence:
- the premarket reviews (e.g. Design Dossier Examinations, Premarket Applications, Shounin Applications,
Product Registration/Notifications) typically performed by product specialist(s)
- the final decisions of safety and performance/effectiveness of a medical device made by any Regulatory
Authority.
Definitions:
Technical Documentation
Documented evidence normally an output of the quality management system (QMS), which demonstrates
compliance of a device to the regulatory requirements for products, and processes.
(Adapted from IMDRF/ MDSAP WG/ N3FINAL:2016 (2nd Ed) – Section 3.5)
Technical Expert
Clause 7.1.2 - An Auditing Organization shall have access to the necessary administrative, technical,
and scientific personnel with technical knowledge and sufficient and appropriate experience relating to
medical devices and the corresponding technologies.
Annex 1 – Audit of Product/Process related Technologies and Technical
Documentation
Clause 7.1.5 - An Auditing Organization shall be capable of carrying out all the tasks assigned to it with
the highest degree of professional integrity and the requisite technical competence in the specific field,
whether those tasks are carried out by the Auditing Organization itself or on its behalf and under its
responsibility.
Clause 9.2.4 - Stage 2 audit objectives shall specifically include evaluation of:
- the effectiveness of the Manufacturer’s QMS incorporating the applicable regulatory requirements
- product/process related technologies (e.g. injection molding, sterilization)
- adequate product technical documentation in relation to relevant regulatory requirements
- the Manufacturer’s ability to comply with these requirements.
Clause 9.3.2 - Surveillance audit objectives during the audit cycle shall specifically include evaluation of
the effectiveness of the Manufacturer’s QMS incorporating the applicable regulatory requirements and
the Manufacturer’s ability to comply with these requirements. In addition:
- new or changed product/process related technologies (e.g. injection molding, sterilization)
- new or amended product technical documentation in relation to relevant regulatory requirements.
Clause 9.4.1 - Recertification audit objectives shall specifically include evaluation of:
- the effectiveness of the Manufacturer’s QMS incorporating the applicable regulatory requirements
- product/process related technologies (e.g. injection molding, sterilization)
- adequate product technical documentation in relation to relevant regulatory requirements
- the Manufacturer’s continued fulfillment of these requirements.
ISO 13485:2016
For each medical device type or medical device family, the medical device organization shall establish
and maintain one or more files either containing or referencing documents generated to demonstrate
conformity to the requirement of this International Standard and compliance with applicable regulatory
requirements.
The content of the file(s) shall include, but is not limited to:
- general description of the medical device, intended use/purpose, and labelling, including any
instructions for use
- specifications for product
- specifications or procedures for manufacturing, packaging, storage, handling and distribution
- procedures for measuring and monitoring
- as appropriate, requirements for installation
- as appropriate, procedures for servicing.
The medical device organization shall maintain a design and development file for each medical device
type or medical device family. This file shall include or reference records generated to demonstrate
conformity to the requirements for design and development and records for design and development
changes.
The Medical Device File (ISO 13485:2016 Cl 4.2.3) and the Design and Development Files (ISO 13485:2016 Cl
7.3.10) are to contain or reference documents to demonstrate compliance with requirements of the Standard
and with applicable regulatory requirements. For compliance with the requirements of N3 (2nd Ed) these
records should contain technical documentation that includes, but not limited to:
- Outputs from the design and development process, such as: design outputs, design verification data with
acceptance criteria, design validation data with acceptance criteria, a risk management file, human factors
analysis, software validation, clinical evaluation report, electrical safety and electromagnetic compatibility,
etc.
- Specific design outputs, design verification data with acceptance criteria, design validation data with
acceptance criteria for products where a regulatory authority has specific expectations for the type of
evidence to demonstrate compliance with regulatory requirements.
- Inputs to the production and service controls process, such as: device production specifications including
appropriate drawings, composition, formulation, component specifications, and software specifications.
- Specifications for a production processes including the appropriate equipment specifications, production
methods, production procedures, and production environment specifications.
- Quality assurance procedures and specifications including acceptance criteria and the quality assurance
equipment to be used.
- Specifications for packaging and labeling, including methods and processes used for validation after
transportation and environmental conditioning.
- Procedures and methods for installation, maintenance, and servicing.
- Jurisdiction-specific statements (such as a declaration of conformity, statement on the presence of
specific substances, essential principles checklist, etc.).
The information may be a compilation of documented information or, if the documents constituting the
technical documentation are maintained separately, may be a summary that includes an explicit reference to
each of these documents.
Auditors are not expected to fully evaluate the data that substantiates the final decisions of safety and
performance/effectiveness of a medical device made by any Regulatory Authority. However, the auditor is
expected to apply the MDSAP Audit Approach for the review of Technical Documentation when auditing:
The Audit Approach requires the auditor to select design documentation and manufacturing process
documentation for review. The selection is to be based on information collected earlier in the audit, and taking
into account the risks (risk classification) associated with the device, the novelty of technology used in the
device and the associated manufacturing processes or sterilization methods, along with any changes to the
device or associated manufacturing processes that have been implemented by the Manufacturer since the last
on-site audit, including non-reported changes controlled under the QMS. A minimum of one review of a
design and development file and related medical device file should be undertaken per audit to verify that the
Manufacturer has established evidence of conformity with regulatory requirements. Additional reviews may be
undertaken if time permits or the auditor suspects that the technical documentation previously reviewed is not
a representative sample. (See tasks #2 in chapters 5 and 6).
Surveillance audits should also confirm that the Manufacturer has arrangements in place to maintain the
currency of the technical documentation for all devices. For example:
- a procedure for reviewing the currency of relevant standards and conducting gap analyses as required
- a requirement to assess design changes and the need for further technical testing
- a plan for post-market clinical trials, where necessary, or periodic literature reviews
- updating risk management documents (e.g. occurrence levels in risk analysis) based on post-market data.
The following table summarizes the tasks that an MDSAP auditor will use to review information that constitutes
the Technical Documentation.
Medical device general description, including Design and Development, task #5, 7
variants and accessories
Evidence of compliance with specified regulatory Design and Development, task #5, 7
requirements for products or processes. 5
5 For example, Australia’s - Essential Principles, Canada - Safety and Effectiveness Requirements
- the existence and the coherence of the information listed in this table
- the applicability of this information to the medical device subject to marketing authorization
- that the methods implemented throughout the Design and Development to generate this information are
sound and commensurate to the risk associated with the medical device; and
- that conclusions are substantiated.
MDSAP AU P0002.007 183 | P a g e
Annex 1 – Audit of Product/Process related Technologies and Technical
Documentation
Although the auditors are not expected to make final device safety and effectiveness decisions based on a
review of technical documentation, if an auditor suspects that device safety and effectiveness concerns exist, or
that the evidence supporting compliance with safety and effectiveness requirements is lacking, the concerns
should be explicitly described in the audit report. If an auditor suspects a public health threat, the Auditing
Organisation must submit an early awareness communication notice (“MDSAP 5-day Notice”) according to
MDSAP AU P0027.001 Post-Audit Activities and Timeline Policy.
The depth and extent of this review should be commensurate with the classification of the medical device, the
novelty of the intended use, the novelty of the technology or construction materials, and the complexity of the
design and/or technology.
Each participating regulator may have different requirements for the review of technical documentation and for
the assessment of the adequacy of that technical documentation at audit.
If inadequacies are identified, nonconformities should be raised in the normal manner, using the most specific
and relevant clause of ISO 13485, [see especially ISO 13485:2016 - §4.2.3 and §7.3.10] including those raised
against technical documentation under country specific requirements [for example, see ISO 13485:2016 -
§7.2.1.c, §7.3.3.b, §7.3.7, §4.1.1]. Refer to MDSAP AU P0037 for further guidance on the selection of appropriate
clause and the grading of nonconformities. NCs from the review of technical documentation shall be included
in the Nonconformity Grading and Exchange Form (MDSAP AU F0019.2).
Further guidance on the expectations for the evidence of compliance with regulatory requirements is provided
in the following sections.
Australia – TGA
Auditing Technical Documentation:
The assessment of product requirements for Australian Class I (supplied sterile), Class I (with a measuring
function), Class IIa and Class IIb medical devices, and Class 1-3 IVDs, is performed by the TGA on a sampling
basis prior to market authorization (aka “Application audit”). Technical documentation review is expected to be
performed in the context of audit to increase the pool of sampled devices and strengthen the sampling based
approach. Technical documentation review should take into consideration the provisions of IMDRF/MDSAP
WG/N3 – 9.3.1. This documentation shall contain sufficient detail to allow for an evaluation of the data and for
the purpose of demonstrating:
In the case of Class III, Active Implantable and Class 4 In Vitro Diagnostic medical devices that have been
subject to a Design Examination separately from the QMS audit, the on-site audit should ensure that the
technical documentation for these devices is maintained.
The technical documentation should contain, or reference, evidence of compliance with the Essential Principles
and the following requirements. An Essential Principles checklist6, although not mandatory, is often used as an
index to identify the applicable Essential Principles, any standard or validated method that has been used to
demonstrate compliance, and a reference to the document that contains the evidence of compliance.
The assessment of each set of technical documentation selected for compliance with the Essential Principles, as
a minimum, should consist of a review of:
- A detailed description of the product, including the intended use, intended user, risk classification and
assigned Global Medical Device Nomenclature (GMDN) code. For IVD medical devices, the description
should also include specimen types, a list of kit components, methodology and any instrumentation to be
used
- the inclusion of information gathered in feedback processes (e.g. complaints, adverse event reporting or
recalls for product correction) as a potential input into risk management for monitoring and maintaining
the product requirements as well as the product realization or improvement processes
- an index of the compilation of documents, or if documentation is not collated, a reference to the relevant
documentation
- a risk management file (e.g. select a particular risk and confirm that it has been managed in accordance
with the requirements of ISO 14971)
- selected report(s) of pre-clinical data and/or bench testing (including studies in animal models, testing to
support compliance with relevant standards, technical performance and safety tests for electrical safety,
6 For reference, manufacturers may choose to complete an Essential Principles Checklist as one way of indexing their
evidence of conformity to requirements. The checklist is not mandatory; however, it provides a succinct way of identifying
the relevant evidence. A sample template is available at http://www.tga.gov.au and by searching for “Essential Principles
Checklist”
mechanical safety, radiation safety etc.) identified by the Manufacturer as evidence of compliance with
relevant Essential Principles
- a selected clinical evaluation report to confirm that it is current and was prepared by an appropriately
qualified expert (See TG(MD)Regs Sch 3 Part 8)
- any other documentation required for the type of device (e.g.- special requirements for devices
incorporating medicinal substances or materials of animal origin);
- the information that accompanies a device (labelling, instructions for use, patient implant cards and
leaflets)
- the declaration of conformity, for example, to comply with TG(MD)Reg Sch 3 Part 1 Clause 1.8 (this may
be in a draft form for development devices that do not yet have marketing authorization).
Brazil – ANVISA
Brazilian regulations require that product registration / market authorization is entirely performed by ANVISA
for all medical device classes.
ANVISA expects that the Auditing Organization follows the Audit Approach for reviewing technical
documentation, including the Brazilian specific requirements defined in the document MDSAP AU P0002 –
Audit Approach. There are no additional requirements to be reviewed during an MDSAP audit.
Japan – MHLW/PMDA
The assessment of product requirements is performed prior to market authorization by the regulator or
registered certification bodies, hence technical documentation review, as assessment of conformity to the
Essential Principles of Safety and Performance of Medical Devices, is not performed in the context of MDSAP
audit.
USA – FDA
The US medical device regulations do not require a technical documentation as defined in the present
document, although most data composing the technical documentation are direct output of the Design History
File (820.30(j)) and the Device Master Record (820.181).
Overview: The control of the sterility of a medical device is the result of a series of controlled processes
including (but not limited to):
a) process validation of the cleaning, sterile barrier packaging, and sterilization processes
b) routine monitoring and measurement of the cleaning, packaging and sterilization processes
c) routine acceptance criteria of the cleaning, packaging and sterilization processes
d) (re-)qualification, (re-)verification, (re-)calibration and maintenance of the cleaning, packaging and
sterilization equipment
e) environmental control of production areas (cleanroom design and monitoring)
f) storage of device parts, components, and packaging material
g) storage of finished sterile product and management of shelf life
h) handling process of non-sterile device for re-sterilization
i) lot / batch release of terminally sterilized devices
a) Determination of criteria the supplier must meet to be selected, with regards to the control of the
sterility of the device
b) Selection and monitoring of suppliers considering the identified criteria
c) Purchasing information
d) Verification of the purchased product/service (and associated documentation)
Therefore, the audit of the control of the sterility of a medical device requires a holistic approach.
Competencies:
It is up to the Auditing Organization to determine the competencies required to achieve the audit objectives
and to assign a competent audit team. However, the AO should identify auditors and/or technical experts
having the competencies identified below. The subsequent table identifies the competencies required to audit
various aspects of sterilization.
Annex 2 - Audit of Requirements for Sterile Medical Devices
The auditing of activities and processes contributing to the sterility of a medical device may involve the
following competencies:
Microbiology:
a) Ability to assess the validation of sterilization processes and methods regardless of the availability of an
established standard (or the lack of such a standard)
b) Ability to assess the validation of environmental and microbial contamination controls
c) Ability to assess the validation of packaging activities and sterile barrier systems
d) A person deemed to have this competency would likely be educated as a medical microbiologist.
a) Ability to assess the validation of activities and processes for packaging and sterile barrier systems.
a) Ability to evaluate the adequacy of environmental and microbial contamination control programs.
Routine Sterilization:
a) Ability to assess the validation of sterilization processes and methods where an existing established
standard on the method exists other than aseptic processes
b) Ability to verify the implementation of non-standard sterilization activities and processes previously
audited by someone having the microbiology competency
c) Ability to assess the implementation of activities and processes for packaging and sterile barrier
systems previously audited by someone having the packaging and sterile barrier systems or
microbiology competency
d) Ability to assess the implementation of environmental and microbial control activities previously
assessed by someone having the microbiology or environmental and contamination control
competency.
The following table summarizes the competencies required to audit the requirements for sterile medical
devices:
Packaging and
Environmental
contamination
Sterile Barrier
Microbiology
Sterilization
Systems
Routine
control
Topic being evaluated
and
Sterilization process (re-) validation according to well-
established standards (excluding aseptic processes)
All sterilization methods used by a medical device organization should be covered throughout the certification
cycle.
Objectives for the audit of requirements for sterile medical devices should include, but not be limited to,
verification that:
- all processes that contribute to a device’s sterility are controlled through the medical device
organization’s QMS and validation has been completed, where applicable (e.g. cleaning, disinfection,
aseptic processing, sterile barrier systems, terminal sterilization, storage)
- criteria for re-validation are defined and are followed, (e.g. at defined periodicity, following significant
changes and trends)
- processes are implemented and monitored to ensure compliance to their validated parameters
- routine environmental and product cleanliness controls are implemented and monitored
- results are consistent from batch to batch
- batch records(e.g. a device history file) are maintained for each sterilization batch per an approved device
master record
- lot release is performed for each batch according to a procedure and by a designated person
- adequate control of suppliers is observed where sterilization is outsourced (process for selection of
critical suppliers defined and followed, valid agreements, supplier audits, etc.)
In the absence of significant changes with potential impact on the validated status or new (re)validation
activities since the previous audit, the audit should be focused on records review to determine that the
validated processes are followed, monitoring is performed, batch records are maintained.
While some aspects may be audited remotely (e.g. review of sterilization process validation documentation),
the audit of requirements for sterile medical devices must be conducted on-site.
The outcome of such remote review activities must serve as input to the on-site audit and be incorporated or
attached to the MDSAP audit report. The off-site assessment of the controls of the product sterility should not
prevent the on-site audit team from following audit trails, including audit trails necessitating the review of
documents that had previously been assessed remotely.
The audit of processes for validation of sterilization and sterile barrier systems performed according to well-
established standards (e.g. steam sterilization, 25 kGy gamma irradiation, Ethylene Oxide in chambers with
The audit of a validation performed according to less common standards, or using less common sterilant /
sterilization technologies / validation methods (e.g. Ethylene oxide sterilization in a bag, ethylene oxide in
chambers with parametric release, plasma sterilization, low dose gamma sterilization) should be performed by
a person having the microbiology competency. This also applies to the evaluation of aseptic process validation
or to the sterilization process validation of the microbiologic safety of devices incorporating substances, cells,
tissues of animal or human origin.
Routine implementation of sterilization processes according to previously audited validation studies may be
conducted by a person having the routine sterilization competency. This applies to all previously validated and
audited sterilization processes including processes conducted according to less common standards, or using
less common sterilant/sterilization technologies/validation methods.
If the requirements for sterile medical devices are audited separately by a competent auditor or technical
expert, this shall cover all the applicable requirements and the results of this audit shall be part of the MDSAP
audit report. This must not prevent the MDSAP audit team from following leads relative to requirements for
sterile medical devices. Any nonconformities resulting from the audit of sterile medical devices and sterilization
processes shall be graded in accordance with MDSAP policies regarding grading of nonconformities.
Brazil Must report within 72 hours in 5 calendar days from the decision
case of death, public health threat to start the field action
or counterfeiting
United States 5 calendar days if FDA has issued 10 working days of initiating the
a 5-day notice correction or removal
Clause 3.2 – an authorized representative is a natural or legal person established within a country or
jurisdiction who has received a written mandate from the manufacturer to act on their behalf for
specified tasks with regard to the latter’s obligations under that country or jurisdiction’s legislation.
Clause 3.10 – Note 1 to entry: a manufacturer is responsible for ensuring compliance with all applicable
regulatory requirements unless this responsibility is specifically imposed on another person by the
regulatory authority within that jurisdiction. In many cases written agreements are necessary to
establish the arrangements between a manufacturer and authorized representative to ensure the
representative can fulfill their legal obligations.
Clause 4.1.5 - requires manufacturers to retain responsibility for conformity to applicable regulatory
requirements for outsourced processes. The controls for these processes shall include written quality
agreements and be proportionate to the ability of the external party to the meet the requirements
identified in Clause 7.4.
Clause 4.2.5 – requires manufacturers to define and implement methods for protecting confidential
health information contained in records and for the retention and submission of any record in
accordance with regulatory requirements. Arrangements defined in agreements with an Authorized
Representative can ensure the confidentiality of information passed to a manufacturer via the
representative in the receiving and recording of information for complaint handling and the retention
of records held by the Authorized Representative.
Clause 5.2, 5.4.1, 5.5.2, 5.6.2, 7.2.1, 7.3.3, 7.3.7, 7.3.9 – written agreements with Authorized
Representatives can be a useful tool for ensuring that a manufacturer and its top management are
informed of current regulatory requirements and changes in the jurisdictions to which product is
supplied. This information may provide input to some of, and not limited to, the following areas; quality
objectives, management review inputs, definition of customer requirements, and design and
development controls.
Clause 7.2.3 – requires a manufacturer to communicate with regulatory authorities in accordance with
regulatory requirements. In some jurisdictions, the communication channel is through the authorized
representative.
Clause 7.4.1, 7.4.2 - requires the manufacturer to address the nonfulfillment of controls for outsourced
processes, with the supplier, and in compliance with regulatory requirements. In some jurisdictions, the
MDSAP AU P0002.007 195 | P a g e
Annex 4 – Requirements for Written Agreements
authorized representative is to fulfil relevant regulatory requirements with the cooperation of the
manufacturer.
Clause 7.5.9.1 - may require an authorized representative to play a part in ensuring the traceability of a
product to the extent required by the manufacturer.
Clause 8.2.2 – a written agreement with an Authorized Representative may be necessary to ensure the
timely receiving and recording of information for complaint handling.
Clause 8.2.3 - requires documented procedures for notification to regulatory authorities when
complaints meet specified reporting criteria for adverse events or issuance of advisory notices. In some
jurisdictions, an in-country authorized representative performs the notification of these events. A
written agreement between the manufacturer and the representative is necessary to establish a clear
communication channel between the manufacturer and the regulator and to ensure the maintenance of
records of reporting.
Clause 8.3.3 - requires procedures for issuing advisory notices in accordance with applicable regulatory
requirements. In some jurisdictions, an in-country representative is required to coordinate the approval
and issuing of advisory notices with the local regulatory authority, maintain distribution records that
would facilitate recall in that jurisdiction and, if necessary, to coordinate a recall under the supervision
of the local regulatory authority. A written agreement between the manufacturer and the
representative is necessary to ensure that the local representative can fulfil their legal responsibilities
and that the responsibilities are clear in the event of a recall.
Australia (TGA)
Prior to being granted market authorization, Australian Sponsors (in-country authorized representative) are
required to “certify matters” related to the device and its supply, including a commitment to enter into written
agreements with an overseas Manufacturer for matters that are specified in Regulations [TG Act - 41FD (e) and
(g)]. (Australian “legal” Manufacturers who are responsible for design, production and labelling, whether
performed by their organization or on their behalf by another organization, are also, by definition, an
Australian Sponsor).
Subsequent conditions for the market authorization include a requirement that the Sponsor continue to supply
information related to quality, safety and performance of the device through procedures and a written
agreement established with the overseas Manufacturer. This will include information that is only available from
the overseas Manufacturer of the device who is accepting responsibility for the design, production, packaging
and labelling etc. of the device (TG Act - s41BG).
Australian conformity assessment procedures also require overseas Manufacturers of medical devices supplied
in Australia to make undertakings, to provide records (information, documents and records specified in the
Conformity Assessment Procedures) and to notify the TGA or the Sponsor of specified events. These
requirements of the Conformity Assessment Procedures, and conditions for marketing authorization, place a
legal obligation on the Sponsor to participate in processes that are usually and wholly addressed by the
manufacturer’s quality management system. For example, some aspects of the ISO13485 requirements for
advisory notices (e.g. recalls) are the responsibility of the Sponsor. Hence, the manufacturer must outsource
these requirements to the Sponsor, and in doing so renders the Sponsor a supplier.
By entering into written agreements, the Sponsor and Manufacturer demonstrate their commitment to fulfil
their obligations and clarify their roles and legal responsibilities within the Australian Regulatory framework for
medical devices.
Manufacturers and Sponsors are to identify the regulatory requirements that are relevant to their
responsibilities under the legislation (e.g. ISO 13485:2016 Cl 4.1.1). The following table provides some
guidance and identifies many of the key requirements that could be identified in a written agreement between
an overseas Manufacturer and the Australian Sponsor. The parties to an agreement should incorporate, as
appropriate, the arrangements to fulfill these, or any other identified regulatory requirements, and may include
any necessary commercial arrangements.
This table is a summary of requirements, intended to raise awareness of the roles and responsibilities that may
need clarification in a written agreement. This is guidance and does not substitute for reference to
ISO13485:2016 or the relevant legislation. Sponsors and Manufacturers should refer to the Therapeutic Goods
Act, 1989 (the Act) and the Therapeutic Goods (Medical Devices) Regulations, 2002 (Regulations) to determine
all applicable requirements.
Note that some requirements and conditions apply automatically by the Act and Regulations. The TGA may
apply specified additional conditions on the manufacture and supply of a medical device at the time of market
authorization, or later. Agreements may need amendment to account for any condition that may subsequently
affect the relationship between the Sponsor and Manufacturer.
References to sections of the Act, are prefaced with “s” [e.g. s41FD]. References to a regulation of the
Regulations are prefaced with “r” [e.g. r5.8]. References to Section, Part or a clause in a Schedule of the
Regulations, are prefaced with “S”, “P” and “Cl” e.g. [S3 Cl1.8].
Application for market s41FC, Certify the matters listed in TG Provide information to the
authorization s41FD, Act s41FD including a Sponsor that would allow the
s41FH, procedure and written Sponsor to certify the matters
s41FI agreement with an overseas identified in TG Act s41FD
manufacturer to provide Provide information requested by
r5.2 information from the overseas the TGA in a notice to the Sponsor
manufacturer about compliance if the application is selected for an
with the Essential Principles and Application Audit. (See also Reg
application of an appropriate 5.3)
Conformity Assessment
Procedure, to the TGA, within If requested by the TGA, assist the
20 days of a request. Sponsor to provide a reasonable
number of samples within the
timeframe specified in the notice.
Conditions for market s41FN, Make arrangements that will Assist the Sponsor with
authorization s41FO, permit an authorized person of arrangements to permit the TGA
s41JA, the TGA to enter premises to enter the Manufacturer’s
s41MP2, outside of Australia where a premises, or those of a supplier,
s41MPA2 person deals with medical for inspection activities.
s42B devices that have market
s42BAA authorization, for purposes of If requested by the TGA, assist the
s42DD inspection, examination, Sponsor to provide a reasonable
s42DJ measurement, testing, number of samples within the
s42DL(9) sampling, image recording etc. timeframe specified in the notice.
and obtaining documentary
r5.6 evidence. (Including the Ensure advertising material
r5.7, manufacturer’s facilities or available for Australia is consistent
r5.8, those of a supplier to the with the intended purpose of the
r5.9 manufacturer) medical device and the Sponsor’s
r5.10 obligation to comply with
r5.11, Maintain procedures and Australian advertising
r8.1A agreements to ensure that requirements.
r8.1 information from the overseas
manufacturer to substantiate Ensure continued provision of
compliance with the Essential information within a timeframe
Principles and application of an that will permit a Sponsor to meet
appropriate Conformity its regulatory obligations.
Assessment Procedure, or
relevant changes to previously Ensure problem or complaint
supplied information, can be information, provided by the
manufacturer’s device, no
matter how minor;
Public notification and 41KB Follow the guidance in the Assist the Australian Sponsor to;
recall of medical Uniform Recall Procedure for meet the requirements outlined in
devices. Therapeutic Goods (URPRG) to the Uniform Recall Procedure for
take the specified steps, in the Therapeutic Goods (URPTG) for
specified manner and within the recall of devices, effect a
such reasonable period as is notification to the public of recalls
specified, to recall medical and to inform the TGA of
devices of that kind that have information relating to the
been distributed, to publish persons to whom medical devices
specified information to inform have been supplied.
the public and to notify the TGA
of information relating to the
persons to whom medical
devices have been supplied.
Application of the s41DA, Assist the manufacturer of the Comply with the relevant
conformity assessment s41JA device to determine the Class of conformity assessment
procedures and requests the device in accordance with procedures that are “obligations
for information rP3 Div the Australian classification on the manufacturer”.
3.2, rules.
S3P1 Classify a device.
Cl1.9, Facilitate the provision of the
S3P4 manufacturer’s records Apply an appropriate CA
Cl4.8, including, but not limited to; procedure to:
S3P5 records to demonstrate implement a QMS appropriate for
Cl5.8 compliance with the essential the class of the device.
principles, conformity
assessment procedures and any Demonstrate compliance with the
conditions imposed at the time relevant Essential Principles for
of, or subsequent to, the use in the Australian market.
granting of marketing
authorization that is related to Allow an authorized officer of the
the manufacturer’s activities, TGA to enter the premises of the
compliance with advertising manufacturer and whilst on those
requirements, the safety and premises to inspect the premises
efficacy of the devices for their and medical devices of any kind in
intended purpose, the accordance with the requirements
regulatory history of the devices of the legislation.
in another country, etc. when
such records are requested by On request, provide
the TGA. documentation to an authorized
person relating to devices of a
Certificates issued by
the TGA. Facilitate the provision of the Cooperate with the TGA in a
(If a manufacturer manufacturer’s records review of whether the
chooses to participate in requested by the TGA. requirements of an appropriate
the MDSAP and is CA procedure have been applied
supplying product to Ensure arrangements are in including; the application of a
Australia, the AO must place to allow the TGA to QMS and compliance with the
include the monitor the operation of, and essential principles in accordance
requirements of the carry out inspections of, the with the requirements of the
Australian jurisdiction manufacturer’s quality legislation.
within the scope of the management system.
audit. If the
manufacturer is also Obtain a Declaration of Notify the TGA and the Auditing
required to hold a TGA Conformity from the Organization of any substantial
issued CA Certificate, Manufacturer. changes to the quality
the conditions of that management system, the product
certificate must also be Where the TGA has performed range covered by the QMS or
applied.) a Design Examination ensure changes to the design of products
that changes to the design are covered by the certificate.
notified to the TGA
Comply with any additional and
Ensure that the manufacturer relevant condition applied to a
informs the Sponsor of adverse conformity assessment certificate
events and recalls that are to be when issued or subsequently
reported to the TGA amended.
The TGA formally recognizes MDSAP certificates as a “conformity assessment document” if issued in
accordance with MDSAP AU P0026 and references the regulatory requirements of the Australian jurisdiction.
The TGA uses these documents as evidence of compliance with the QMS requirements of the Australian
conformity assessment procedures. MDSAP certificates are often used when alternative EC Certification is not
available.
Note that regardless of any pathway that may have been used, or is used, for marketing authorization in
Australia, an MDSAP Auditing Organization must include the requirements of the Australian jurisdiction within
the scope of the MDSAP audit if the manufacturer is supplying product to the Australian market
See the document “Use of market authorization evidence from comparable overseas regulators / assessment
bodies for medical devices (including IVDs)”)
Part 4A of the Therapeutic Goods Act 1989 makes provision for an Australian incorporated organization to be
recognized as an Australian Conformity Assessment Bodies Body (CAB) if they satisfy assessment criteria that is
MDSAP AU P0002.007 204 | P a g e
Annex 4 – Requirements for Written Agreements
based on the EU’s MDR or IVDR Annex VII requirements. The legislation also makes provisions to recognize
the product assessments and quality management system regulatory audits performed by Australian CABs.
Australian legislation separately recognizes MDSAP Audit Reports and Certificates as evidence from a
comparable overseas regulator. See Comparable overseas regulators for medical device applications |
Therapeutic Goods Administration (TGA) [s41FDA(c) and related instruments].
The assessment processes used to recognize an MDSAP Auditing Organization may be used to support an
organization’s application to be an Australian Conformity Assessment Body if the applicant is an Australian
Corporation.
Brazil – ANVISA
There are no additional expectations for the audit of written agreements during an MDSAP audit.
There are no additional expectations for the audit of written agreements during an MDSAP audit.
Japan – MHLW/PMDA
There are no additional expectations for the audit of written agreements during an MDSAP audit.
USA – FDA
There are no additional expectations for the audit of written agreements during an MDSAP audit.
ISO 13485:2003 MHLW MO 169, Chapter 2 Note for understanding the requirements
of MHLW MO 169 Chapter 2, as amended
in 2020
Clause 1.2, paragraph 2 and 3 Article 4 Article 4 specifies the way of application of
this chapter to the organization.
ISO 13485:2003 MHLW MO 169, Chapter 2 Note for understanding the requirements
of MHLW MO 169 Chapter 2, as amended
in 2020
ISO 13485:2003 MHLW MO 169, Chapter 2 Note for understanding the requirements
of MHLW MO 169 Chapter 2, as amended
in 2020
ISO 13485:2003 MHLW MO 169, Chapter 2 Note for understanding the requirements
of MHLW MO 169 Chapter 2, as amended
in 2020
ISO 13485:2003 MHLW MO 169, Chapter 2 Note for understanding the requirements
of MHLW MO 169 Chapter 2, as amended
in 2020
ISO 13485:2003 MHLW MO 169, Chapter 2 Note for understanding the requirements
of MHLW MO 169 Chapter 2, as amended
in 2020
ISO 13485:2003 MHLW MO 169, Chapter 2 Note for understanding the requirements
of MHLW MO 169 Chapter 2, as amended
in 2020
ISO 13485:2016 MHLW MO 169, Note for understanding the requirements of MHLW
Chapter 2 MO 169 Chapter 2, as amended in 2021
Clause 1, paragraph 4-5 Article 4 Article 4.1 specifies that Class 1 medical devices are
exempted from the requirements of design and
development, Article 30 to Article 36-2.
Clause 4.1.1 Article 5-1 Roles undertaken by the organization are Marketing
Authorization Holder provided by Article 23-2.1 of PMD
Act, Registered Manufacturing Site provided by Article
23-2-3.1 and 23-2-4.1 of PMD Act, Seller of
pharmaceutical products provided by Article 24.1 of
PMD Act, Seller and Leaser of specially-controlled
medical devices provided by Article 39.1 of PMD Act,
Clause 4.2.5 Article 9 The record retention period required by the ordinance is
specified by Article 68 of MHLW MO 169.
Clause 7.5.9.2 Article 49 The requirements of Article 49.2 and Article 49.3, which
are identical to the requirements of ISO 13485:2016
Clause 8.2.2 Article 55-2 This article is identical to the requirement of ISO
13485:2016 8.2.2. However, it should be noted that the
organization is required to determine the need to notify
the information to the Marketing Authorization Holder
instead of the regulatory authorities, when the
organization is the person operating the registered
manufacturing site.
Clause 8.2.3 Article 55-3 This article is identical to the requirement of ISO
13485:2016 8.2.3. However, it should be noted that the
organization is required to notify the information to the
Marketing Authorization Holder instead of the
regulatory authorities, when the organization is the
person operating the registered manufacturing site.
Record of the notification shall also be maintained.
GHTF document N3 clause 8.2.2 requires that “the Auditing Organization shall not exclude any processes,
products, or services from the audit scope or the scope of the certificate, unless the regulations administered
by the recognizing Regulatory Authority(s) permit the exclusion”. This requirement is used to justify that an
organization participating in MDSAP must be audited for a scope of certification that includes all the
jursidictions where the medical devices are distributed, and all medical devices being distributed in these
jurisdicitions. See item 88 in the Question and Answers document. The activities/processes, products or
facilities that are eligible for exclusion from an MDSAP Program are outlined in the following table. A device
may be excluded from the scope of the MDSAP audit only if it meets the corresponding exclusion criteria from
all the jurisdicitions applicable to the audit. A jurisdiction may be excluded only if none of the medical devices
are distributed in this jurisdiction, or all medical devices distributed in this jurisdiction can be excluded.
Australia Class I medical devices (non- sterile, TG(MD)R Schedule 3 Part 6 establishes
no measuring function) are not obligations / requirements for manufacturers of
required to have a certified quality Class I medical devices (non-sterile, no measuring
management system. function) that includes process definition, adverse
event and recall reporting. By default, a certified
QMS is not required by legislation for Class I
medical devices (non-sterile, no measuring
function). However, a manufacturer may:
Brazil Class I and Class II medical devices If all devices in the scope of certification are class
are not subject to GMP Certification*. I or II, or if the audited facility’s contribution to the
scope of certification only applies to class I or
class II medical devices, the audit at that facility
* However, ANVISA Resolution RDC may disregard the requirements of the Brazilian
15/2014 still require that the regulation for registration purposes.
manufacturer of the finished device
have an effective QMS in place.
Canada Class I medical devices are not If all devices in the scope of certification are class
required to have a certified quality I or if the audited facility’s contribution to the
management system. scope of certification only applies to class I
medical devices, the audit at that facility may
disregard the requirements of the Canadian
regulation.
Japan Class I medical devices are not If all devices in the scope of certification are class
required to have a certified quality I or if the audited facility’s contribution to the
management system. scope of certification only applies to class I
medical devices, the audit at that facility may
disregard the requirements of the Japanese
regulation.
United States Some Class 1 medical devices are If all devices in the scope of certification are GMP-
“GMP-exempt”, i.e. not subject to the exempt or if the audited facility’s contribution to
US quality system regulation. the scope of certification only applies to GMP-
exempt medical devices, the audit at that facility
may disregard the requirements of the US Quality
System regulation (21 CFR 820), with the
exception of the requirements for maintaining
complaint files and recordkeeping. Additionally,
requirements still apply for compliance to Medical
Device Reporting (21 CFR 803), Medical Devices;
Reports of Corrections and Removals (21 CFR
806), and Establishment Registration and Device
Listing for Manufacturers and Initial Importers of
Devices (21 CFR 807).
Overview
Chapter 1 to Chapter 7
- Update Australian regulatory clause references following updates to the Therapeutic Goods Act
1989 and Therapeutic Goods (Medical Devices) Regulations 2002.
- Update Brazilian regulatory clause references
- Update Japanese regulatory clauses references
Task 3
Task 12
Task 15
Task 1
Task 2
Task 9
Annex 1
Annex 4
Annex 6
- Explains acceptable exclusions of medical devices or regulations from the scope of certification.
Chapter 1 to Chapter 7
- Added clause number(s) of the new MHLW MO169 in the case that the number(s) is/are different
from those for the old ordinance.
Management Process
Task 1
- Added footnote to explain the meaning of the word, “Old”, in the sections of Clause and
Regulation references for Japanese requirements – page 21
Purchasing
Task 5
- Deleted a task related to a Japanese country specific requirement, as the requirement is deleted
in the new ordinace – page 168
Annex 5
- Added new Annex that has tables showing Japan’s new and old QMS ordinance and the
relationship between ISO 13485 – page 211
- Added statement regarding the combination of the MDSAP Audit Approach and Companion
Document, formerly separate documents, into this single document – page 5
- Added statement regarding special access programs – page 7
Audit Sequence
- Clarified that order in which processes are to be audited is fixed, however the sequence of audit
tasks within a process may be arranged to allow for an efficient audit; clarified that reasonable
exceptions are allowed for following the audit sequence – pages 8-9
- Added clarifying language as to the assessment of the medical device organization’s application
of risk management principles – page 10
Terminology
- Added language for “medical device organization”, “outsourced” process, product or service,
“suppliers”, “critical suppliers” – throughout the document as appropriate.
Annexes
- Added statement regarding Stage 1 audits for re-certification audits in certain circumstances–
page 17
- Added paragraph regarding sampling during audits – page 18
Surveillance Audits
Management Process
- added text under Quality System Procedures and Instructions heading regarding expectations for
the term “documented” - page 22;
- added text under Quality Management System Planning heading regarding evidence of quality
management system planning – page 23
Task 1
- Move the matters that relate to Australian requirements for the written agreement to Annex 4 –
page 41;
- “Note” to “Assessing conformity”; added text regarding special attention should be paid to
instances where devices are being marketed to jurisdictions where marketing authorization has
not been granted – page 40;
- corrected expiry dates for Brazil for Registration and Notification – page 42
Task 2
Task 3
MDSAP AU P0002.007 223 | P a g e
Summary of Changes from Prior Revisions
- Added text within the task to emphasize the link between design changes and the need to assess
for market authorization – page 48;
- added text to the Australia country-specific requirement regarding notifying TGA of changes in
cases where the Manufacturer also holds a TGA Conformity Assessment Certificate – page 48;
- corrected a reference for Japan to PMD Act 23-2-5.12 – page 50
Task 2
Task 2
- Added statement that information from the organization’s analysis of quality data should be
used to inform the audit team’s decision as to specific products and processes to audit during
Design and Development, Production and Service Controls, and Purchasing processes – page 57
Task 7
- Corrected text for country-specific requirements for Australia, added text to the Australia
country-specific requirement regarding notifying TGA of changes in cases where the
Manufacturer also holds a TGA Conformity Assessment Certificate – page 65
Task 12
Task 14
- Task was rewritten to focus on the audit of the organization’s process for evaluating complaints
for potential individual adverse event reports – pages 75-76
Task 15
- Task was rewritten to focus on audit of the organization’s processes for evaluating quality issues
for potential advisory actions – page 77
Task 1
- Added Note for Canada that requirement to report incidents meeting the requirements of
section 59.(1) that occur outside of Canada does not apply unless the Manufacturer has
indicated, to a regulatory agency of the country in which the incident occurred, the
Manufacturer’s intention to take corrective action, or unless the regulatory agency has required
the Manufacturer to take corrective action - page Error! Bookmark not defined.;
- for United States, added allowance for quarterly summary reporting for malfunction MDRs –
page 88
Task 5
Task 7
- Under “Assessing conformity”, “Design outputs” heading, added text that design outputs can
include documents such as diagrams, drawings, specifications, and procedures for both products
and processes – page 105
Task 13
Task 1
- Under “Assessing conformity”, “Unique Device Identifier” heading, removed the phase-in dates
for device classes – page 123
Purchasing
Task 5
- added text for EP13A for patient implant cards for Australia – pages 168
ANNEXES
Annex 1
Annex 2
- Clarified requirements for grading nonconformities found during audit of sterilization processes
– page 195
Annex 3
- Quick reference guide for reporting timeframes for adverse events and advisory notices – page
192
Annex 4